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ABSTRACT 
Primary ciliary dyskinesia is a genetic disorder where patients develop lung disease 
as they are unable to clear airway infections effectively. There is currently no 
treatment for the underlying genetic defect. This thesis describes advances towards 
the development of a gene therapy targeting the airway disease in PCD patients 
with DNAH5 mutations, the most common cause of PCD. Little work has been done 
in the field so many challenges remain. DNAH5 is a large gene and the cDNA has not 
been cloned. In addition PCD models are currently inadequate. Finally, non-viral 
vectors for airway gene delivery produce sub-optimal levels of transgene expression 
and more efficient viral vectors cannot package the large DNAH5 cDNA. To address 
these issues functional DNAH5 cDNA was cloned from healthy airway cells and the 
cDNA validated by sequencing and expression studies. Lentiviral shRNA 
transduction of healthy cells was used to knock down DNAH5 in airway cells semi-
immortalised with BMI-1, a proto-oncogene that allows extended growth capacity 
of cells whilst retaining their mucociliary differentiation potential. The novel cell 
lines lacked cilia motility as is seen in patient cells. Minicircle DNA, in the context of 
airway gene delivery, was found to enhance gene expression in vitro and in vivo. A 
non-viral vector was optimised, characterised and used to deliver DNAH5 coding 
minicircle DNA to PCD models but poor transfection efficiency of DNAH5 prevented 
functional correction. Transfection of smaller genes was efficient so the vector in its 
current form could be useful for gene therapy treatment of the majority of PCD 
causing genes. Studies are needed to determine and overcome the bottlenecks in 
the efficient transfection of large transgenes to help advance PCD gene therapy.  
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1. INTRODUCTION 
1.1.  PRIMARY CILIARY DYSKINESIA 
Primary ciliary dyskinesia (PCD) refers to a family of genetic disorders affecting cilia 
motility and has an incidence of approximately 1 in 10,000 births (1). PCD, having 
ciliary dysfunction as its root cause, falls within a broader class of disorders called 
ciliopathies. 
1.1.1. HISTORY OF PCD 
In 1904 Siewert (2) was the first to describe what we now call PCD after reporting a 
patient displaying the unusual symptoms of bronchiectasis and situs inversus (a 
condition where the positions of the major structures of the thorax and abdomen 
are reversed). In 1933 Kartagener (3) described the same symptoms in four of his 
patients but also noted sinusitis. Presentation with this triad of bronchiectasis, situs 
inversus and sinusitis has since been referred to as Kartagener’s syndrome.  
The cause of Kartagener’s syndrome remained elusive until seminal discoveries in 
the mid-1970s. In 1975 Afzelius et al., (4) and Pedersen and Rebbe (5) described 
immotile spermatozoa in male patients with situs inversus. In the case of Pedersen 
and Rebbe (5) the single male patient described had situs inversus but was 
otherwise healthy. Afzelius et al., (4) described two brothers both of whom were 
suffering with chronic sinusitis and bronchitis, with only one of the brothers also 
displaying situs inversus (i.e. Kartagener’s syndrome). All the patients described had 
immotile spermatozoa. In both publications the authors found immotile 
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spermatozoa to be due to a lack of dynein arms – the structures responsible for 
powering cilia and flagella movement - in the sperm tails. 
The link between immotile cilia and Kartagener’s syndrome was further supported 
by Camner et al., (6) who showed impaired mucociliary clearance in male patients 
with Kartagener's syndrome. The following year Afzelius (7) reported that both the 
sperm tail and respiratory cilia from four patients with immotile spermatozoa 
lacked dynein arms. Impaired mucociliary clearance was also evident. Three of the 
patients reported chronic sinusitis and bronchitis. Situs inversus was also described 
in three patients although it is not made clear whether those who had situs inversus 
were the same patients who reported chronic sinusitis and bronchitis. In a number 
of patients described by Afzelius (7) and Eliasson et al., (8) Kartagener's syndrome 
was associated with impaired mucociliary clearance, immotile spermatozoa in 
males and ultra-structural abnormalities of cilia. However in these studies impaired 
mucociliary clearance, immotile spermatozoa in males and ultra-structural 
abnormalities of cilia were also found in patients without situs inversus. The authors 
correctly hypothesised that situs inversus was likely due to an importance of cilia 
motility in determining body situs and that the absence of cilia motility would lead 
to randomisation of body situs. Eliasson et al., (8) thus coined the “immotile-cilia 
syndrome” to describe a congenital disorder of cilia that causes male sterility and 
chronic respiratory infections where half of the patients would also have situs 
inversus. Immotile-cilia syndrome thus encompassed Kartagener’s syndrome.  
However, it quickly became clear that there was heterogeneity in the cilia of 
patients with immotile-cilia syndrome both with regards to cilia ultra-structure (9) 
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and motility (10, 11). Pederson and Mygind (11) and Rossman et al., (10) described 
a number of patients with Kartagener's syndrome who had asynchronous and 
dyskinetic cilia rather than immotile cilia. Rossman et al., (10) proposed renaming 
the immotile-cilia syndrome to the “dyskinetic cilia syndrome”. However, neither 
the immotile-cilia syndrome nor the dyskinetic cilia syndrome names distinguished 
between congenital (i.e. primary) and acquired (i.e. secondary) ciliary dyskinesia. In 
a letter to the editor of The Lancet, Sleigh (12) together with a number of other 
signatories proposed the name “primary ciliary dyskinesia”, in place of immotile-
cilia syndrome, to describe a congenital disorder in patients with or without situs 
inversus that is characterised by chronic sinusitis, chronic bronchitis which often 
develops into bronchiectasis and impaired mucociliary clearance. This name has 
since been adopted and so will be used hereafter. 
1.1.2. CILIA IN HEALTH AND DISEASE 
Cilia have important sensory, signalling and motility functions so it is not surprising 
that cilia dysfunction produces disorders with a myriad of symptoms affecting a 
variety of tissues and organs. Genetic diseases resulting from cilia dysfunction are 
classed as ciliopathies.  
Motile cilia were probably first described in 1677 by Leewenhoeck (13) in a letter to 
the Royal Society of London describing microorganisms found in water with a round 
upper body and “thin feet, which moved very nimbly”- most likely describing ciliate 
protozoa. In contrast primary cilia were not described until at least 200 years later. 
Zimmerman is widely credited for being one of the first to describe primary cilia in 
1898 using the name “central flagellum” and proposed a sensory function (14). 
23 
 
However, many later scientists dismissed primary cilium as a vestigial or 
rudimentary organelle. This idea was overturned only relatively recently- the 
beginning of the 21st century- with the demonstration of sensory roles for primary 
cilia of kidney tubule cells (15), the localisation of transient receptor potential ion 
channels (16) and membrane receptors involved in cellular signalling pathways (17, 
18) to the ciliary membrane and the realisation that primary cilia are involved in 
left-right patterning (19, 20) which followed the discovery that polycystic kidney 
disease mice with situs inversus had primary cilia defects (20, 21). The inv (22) and 
Oak Ridge polycystic kidney disease (ORPK) (23) mice were two such mice that were 
generated by chance in insertional mutagenesis screens.  
The INVS gene was found to be mutated in the inv mouse (22) whilst hypomorphic 
mutation of the gene Tg737, whose product was called Polaris and now called 
IFT88, produced the phenotypes seen in the ORPK mouse which resembled aspects 
of human polycystic kidney disease. IFT88 is a protein involved in intraflagellar 
transport (IFT) and shown to be vital for cilia formation and maintenance in 
Chlamydomonas (21). Pazour et al., (21) demonstrated that Tg737 was the mouse 
homolog of IFT88 and that the ORPK mouse had a ciliary defect. The authors 
correctly predicted that defects in IFT were likely to play a role in human disease 
and recently mutation of IFT88 was shown to play a role in human pathology (24). 
In addition, mutation of INVS was shown to cause nephronophthisis type 2– a 
human ciliopathy (25). A number of human ciliopathies have since been attributed 
to defects in primary cilia (26, 27). 
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Pathology resulting from dysfunction of motile cilia was described almost a century 
before primary cilia defects were shown to cause human disease. As described 
above, defects in cilia motility cause PCD in humans. 
1.1.3. PCD SYMPTOMS AND PATHOPHYSIOLOGY 
Patients with PCD exhibit symptoms involving a variety of organ systems, testament 
to the fact that motile cilia are found on numerous cell types in the body. Motile 
cilia that line the upper and lower airways, around 200 per ciliated cell, move in a 
co-ordinated waveform fashion, the metachronal wave, to sweep the periciliary 
fluid and mucus, on the apical surface of the cells, to the larynx where it is 
swallowed or expectorated; this is known as mucociliary clearance. This clearance is 
an important defence mechanism of the airways and the disruption caused by 
dysmotile cilia results in chronic respiratory infections and inflammation of the 
airways (28). The recurrent infections cause bronchiectasis and can potentially lead 
to chronic lung failure with the need for lung transplantation (29, 30). In the 
majority of PCD cases respiratory distress in the neonatal period is evident as well 
as unexplained tachypnea and neonatal pneumonia (28). 
Reduced fertility or infertility is another symptom seen in PCD patients which is 
more pronounced in male patients than female patients (31). Dysmotility of sperm 
flagella is the cause of reduced fertility in males (32) and ciliary dysmotility in the 
fallopian tubes and uterine lining contributes in females (33).  
In the brain, ependymal cells lining the brain ventricles also have motile cilia and it 
is thought that the ependymal cilia play a role in transport of cerebrospinal fluid. 
Impeded cerebrospinal fluid flow can potentially lead to hydrocephalus. Despite 
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hydrocephalus being common in animal models of PCD (34, 35) its rarity in patients 
suggests that ciliary beating is not responsible for bulk transport of cerebrospinal 
fluid in humans (36, 37). Indeed in families where hydrocephalus is seen with PCD 
not every family member with PCD develops it (38). 
Situs inversus is another symptom of PCD affecting around half of all patients. 
Around 25% of people with situs inversus are thought to have PCD (39). Patients 
with PCD tend to also have a higher incidence of congenital cardiovascular defects 
associated with heterotaxia syndromes (situs ambiguus) (40, 41). That PCD patients 
develop laterality defects suggests cilia motility has a role to play in determination 
of body situs. During gastrulation motile nodal cilia can be found at the ventral 
node of 7.5dpc mouse embryos. The nodal cilia beat in a helical manner moving 
extracellular fluid leftwards -i.e. generating a leftward nodal flow. In PCD this 
leftward nodal flow is not generated with the result being randomization of body 
situs (42). Supporting this idea, Nonaka et al., (42) showed that if nodal flow was 
disrupted in mice (which was due to a lack of nodal cilia in their Kif3B-/- knockout 
mice) randomisation of body situs was observed. Later work by Nonaka et al., (43) 
showed that use of an artificial leftward flow in iv/iv embryos, a PCD mouse model 
with immotile cilia, was able to rescue the situs inversus typically seen in half of 
iv/iv homozygotes. In addition, artificial rightward flow was able to induce situs 
inversus in wild-type and iv/iv embyros (43). In light of this evidence the importance 
of nodal flow in situs determination was widely accepted. How the rotary 
movement of nodal cilia generates a biased leftward flow as opposed to a vortical 
flow was less clear. In silico fluid dynamic simulations by Cartwright et al., (44) and 
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Browkaw (45) suggested that a linear flow could be generated by the rotatory nodal 
cilia if the axis of rotation had a posterior tilt. Experimental data by Okada et 
al., (46) and Nonaka et al., (47) confirmed these predictions.  
With high-speed video microscopy Okada et al., (46) and Nonaka et al., (47) showed 
that the rotational axis of nodal cilia was posteriorly tilted. In addition both groups 
found that the nodal cilia protruded from the posterior side of the nodal pit and 
that the basal bodies of the nodal cilia were also located in the posterior half of 
nodal cells. Finally, Nonaka et al., (47) developed a mechanical model where 
rotating wires with conical paths were used to represent the nodal cilium and 
viscous silicone fluid to represent the nodal fluid. With this model the rotating wires 
were able to generate a unidirectional leftward flow but only if titled. How leftward 
flow is translated to left-right asymmetry remains a topic of debate and two 
hypotheses have been put forward. The morphogen hypothesis states that leftward 
flow results in the accumulation of a morphogen to the left which then cements 
left-right asymmetry. The two-cilia hypothesis in contrast suggests that leftward 
nodal flow generated by motile nodal cilia is sensed by nodal primary cilia 
subsequently cementing left-right asymmetry.  
1.1.4. CILIA STRUCTURE 
Given the importance of cilia in a number of disorders including PCD, it is worth 
pausing to explore the organelle in more detail. Cilia are complex, evolutionarily-
conserved, microtubule-based hair-like appendages that are found protruding from 
most eukaryotic cells. The majority of cells assemble a single cilium but some cells 
have multiple cilia- notable examples include respiratory and ependymal cells. Cilia 
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are structurally related to the eukaryotic flagellum and as a result the names are 
often used interchangeably. In humans the tail of the spermatozoa is classed as a 
flagellum and is longer than cilia, such as those found on the ciliated airway 
epithelial cells. Cilia can be divided into sub-compartments that differ structurally 
and functionally. The sub-compartments are the basal body, transition zone, 
axoneme and ciliary tip (Figure 1.1).   
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Figure 1.1. Sub-compartments of a cilium. 
Four main sub-compartments of a cilium are shown highlighting the change in cilia 
ultrastructure where dynin arms are present in the axoneme (red arrow) but lost at 
the ciliary tip (white arrow) as are the B tubules (black arrow). 
C
ili
ar
y 
Ti
p
 
A
xo
n
e
m
e 
Tr
an
si
ti
o
n
 
Zo
n
e 
B
as
al
 B
o
d
y 
Basal Foot 
29 
 
All cilia are derived from a basal body which is a cylindrical microtubule containing 
structure that is derived from the mother centriole of the centrosome- an organelle 
that acts as a microtubule organising centre and directs spindle formation during 
mitosis. The basal body is located at the base of cilia and the cilium emerges from 
the distal end of the basal body which nucleates microtubule assembly and 
growth (48). Each basal body acts as the site of nucleation for a single cilium thus in 
multiciliated cells centriolar replication is necessary to provide sufficient quantities 
of basal bodies (49). 
Given the need for the mother centriole in both cell division (as part of the 
centrosome) and cilia formation (to form the basal body) it is widely accepted that 
disassembly of primary cilia is a prerequisite for cell division in most cells (50, 51). 
That the basal body is derived from the centrosome was first hypothesised in 1898 
by Henneguy (52) and Lenhossek (53) (the Henneguy-Lenhossek hypothesis). Whilst 
the need for cilia disassembly prior to cell division is now accepted the question of 
whether the primary cilium actively regulates cell cycle entry remains a source of 
controversy. 
Microtubules are the scaffold of the cilium and are formed from polymers of alpha 
and beta tublin protein heterodimers known as protofilaments. Typically thirteen 
protofilaments associate to form a hollow tube- the microtubule. The basal body 
consists of 9 sets of interconnected triplet microtubules termed the A, B and C 
tubules (54). The A tubule in cilia is a complete microtubule and consists of thirteen 
protofilaments whilst the B tubule consists of ten protofilaments of its own and 
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shares three protofilaments with the A tubule (55). The C tubule also consists of ten 
protofilaments and shares a further three with the B tubule (55).  
The transition zone lies between the basal body and the ciliary axoneme and marks 
the end of the triplet microtubule structure of the basal body in favour of the 
doublet structure of the axoneme. Amongst its functions the transition zone 
establishes a diffusion barrier between the cilium and the cytoplasm thus 
compartmentalising the cilia from the cell body. There is no protein synthesis 
machinery in the cilium so materials required for cilia assembly and function must 
be transported from the cytoplasm. IFT is the system utilised to transport proteins 
into and out of the cilium and the transition zone acts as the gate for IFT. IFT 
complexes carry cargo into and out of the cilium with IFT-A and IFT-B complexes 
being responsible for directing retrograde (out of the cilium) and anterograde (into 
the cilium) transport respectively (56). 
The transition zone is characterised by distinct structures such as the transition 
fibres, Y-links and the terminal and basal plates. The transition fibres, also known as 
alar sheets, radiate from the B tubule of the basal body triplet microtubules and 
anchor the basal body to the cell membrane (57). Immunolocalisation studies 
revealed that transition fibres also act as docking sites for particles involved in 
IFT (58). As the IFT system is the sole means by which proteins localise to the cilium 
the transition fibres are thus important in regulating this traffic.  
The Y-links are distal to the transition fibres and connect the outer doublet 
microtubules of the transition zone to the cilia membrane. Loss of the Y-links, as in 
CEP290 mutants, led to an abnormal protein composition of Chlamydomonas 
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reinhardtii flagella and the production of flagella of varied lengths (59), both results 
being indicative of problems with IFT. As such, the Y-links, in conjunction with the 
transition fibres, are likely to be important in the regulation of protein traffic into 
and out of cilia.  
The axoneme is distal to the transition zone and contains nine peripheral outer 
microtubule doublets with each outer doublet composed of an A and B tubule. As in 
the basal body, the A tubule of the axoneme is a complete microtubule whilst the B 
tubule appears fused with the A tubule and consists of 10 protofilaments of its own 
and shares three protofilaments with the A tubule (60, 61). Additionally the 
axoneme may contain a central pair of complete microtubules, the C1 and C2 
tubules, which form the central pair apparatus. Each central pair tubule is 
associated with unique accessory proteins that distinguish the two tubules from 
each other (62). Cilia can be classified by the arrangement of microtubules within 
their axonemes which contain either nine outer doublets only (termed 9+0 cilia) or 
a central pair of single microtubules surrounded by nine outer microtubule 
doublets (termed 9+2 cilia). Classically 9+0 cilia are classified as primary, sensory or 
non-motile cilia with the 9+2 cilia being known as motile (Figure 1.2). It is now 
evident that this view is naïve, for example the motile nodal cilia of the developing 
embryo has a 9+0 arrangement (63) (Figure 1.2) whilst the non-motile cilia of the 
vertebrate inner ear, termed kinocilia, has a 9+2 axoneme (64). In addition, sensory 
roles for motile cilia have also been reported (65-67). Perhaps what best 
differentiates motile from non-motile cilia are structures associated with the outer 
doublets. 
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In motile cilia the A microtubule is studded with dynein arm complexes, both inner 
and outer dynein arms (IDA and ODA respectively). The dynein arms are perhaps 
what best differentiates motile from non-motile cilia (Figure 1.2). These large 
protein complexes are comprised of heavy, intermediate and light chains and 
display ATPase activity (68, 69). The dynein arms attach, retract and release the 
neighbouring microtubule doublet upon ATP hydrolysis and moves toward the 
minus end of the microtubule (towards the cell) causing the doublets to slide with 
respect to one another (70).  
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Figure 1.2. Ultrastructure of 9+2 and 9+0 motile and 9+0 immotile cilia 
9+2 Motile Cilia 
9+0 Motile Cilia 
9+0 Immotile Cilia 
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Accessory structures such as the nexin links, radial spokes and the central pair 
apparatus (Figure 1.2) act to transition this sliding motion to the bending waveform 
commonly associated with respiratory cilia or Chlamydomonas flagella (71). 
Supporting this, the 9+0 motile nodal cilia of the developing embryo lack central 
pair microtubules and radial spokes and so rotates helically (46) and loss of the 
central pair produces respiratory cilia that rotate helically  (72). The dynein arms 
are thus important for force generation and thus control beat frequency whilst the 
radial spokes, nexin links and the central pair apparatus regulate beat pattern. 
Axonemal structures such as the dynein arms and radial spokes are formed from a 
number of different polypeptides and have been shown to be pre-assembled, at 
least partially, in the cytoplasm before being chaperoned into the ciliary axoneme 
via IFT (73, 74).  
Distal to the axoneme is the ciliary tip, the zone in which growth and resorption of 
the cilium takes place (48). Structurally the ciliary tip is the region where the B-
tubule, along with the associated dynein arms in motile cilia, are no longer present 
leaving singlet A-tubules and, in 9+2 motile cilia, the central pair. The loss of B-
tubules has been shown to happen simultaneously for all doublets in rat 
ependymal (75) and frog olfactory (76) cilia whereas the loss of B-tubules in 
protozoan (54, 77) and mouse renal cilia (78) is staggered. Microtubules of the 
ciliary axoneme are capped at the tip helping to regulate microtubule growth and 
resorption (79). The ciliary crown, a cluster of bristles that protrude from the cilia 
membrane at tip (80), is attached to this capping structure and forms the distal 
most structure of the ciliary tip (81). Although the molecular composition of the 
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crown is unknown it is known to bind cationic compounds demonstrating the 
presence and enrichment of anionic groups at this site (81-83). In the trachea the 
crown is in physical contact with the overlying mucus (84) and in the oviduct the 
ciliary crown is important in the cilium mediated transport of the ovum (85, 86). As 
such, it has been speculated that the ciliary crown facilitates mucus transport (87). 
1.1.5 PCD GENETICS  
The ciliary axoneme is complex and contains many proteins so it is unsurprising that 
PCD is a genetically heterogeneous disorder. A number of genes that give rise to 
PCD have been described accounting for 59-88% of patients (Table 1.1). The 
majority of PCD cases result from mutations in genes coding for ODA proteins which 
typically result in the absence of ODA from the ciliary axoneme (88, 89). The ODA 
gene DNAH11 curiously deviates from this trend in that the ODA remains present in 
the ciliary axoneme and so the cilia ultrastructure appears normal (90-94).  
Cases of PCD associated with other genetic disorders have also been described. 
Mutations in the retinitis pigmentosa guanosine triphosphatase regulator (RPGR) 
gene cause retinitis pigmentosa, a group of inherited disorders which lead to 
progressive loss of vision. RPGR has been shown to be expressed in bronchial and 
sinus epithelial cells and patients have been described where retinitis pigmentosa 
and PCD resulted from X-linked transmission of mutations in the RPGR gene (95-
97). 
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Gene ORF (bp) Patients affected (%) Protein localization Ultra-structural defect References 
AK7 2,172 Not assessed Cytoplasm Varied dynein arm defects  (98, 99) 
ARMC4 3,135 Not assessed Axoneme ODA defects  (100, 101) 
C21orf59 873 1 Cytoplasm IDA and ODA defects  (102) 
CCDC103 729 Not assessed Cytoplasm and axoneme Varied dynein arm defects  (103) 
CCDC114 1,392 3-4 Axoneme ODA defects  (104-106) 
CCDC164 2,223 Not assessed Axoneme Nexin link defects  (107) 
CCDC39 2,826 11 Axoneme IDA, nexin link and radial spoke defects  (108, 109) 
CCDC40 3,428 4 Cytoplasm and axoneme Central pair defects  (109, 110) 
CCDC65 1,455 1 Cytoplasm and axoneme IDA and nexin link defects  (102) 
DNAAF1 2,178 4-5 Cytoplasm IDA and ODA defects  (111) 
DNAAF2 2,514 Not assessed Cytoplasm IDA and ODA defects  (112) 
DNAAF3 1,767 Not assessed Cytoplasm IDA and ODA defects  (113) 
DNAH11 13,572 6-7 Axoneme None  (90-94, 114) 
DNAH5 13,875 15-28 Axoneme ODA defects  (115-118) 
DNAI1 2,100 2-10 Axoneme ODA defects  (119-122)  
DNAI2 1,818 Not assessed Axoneme ODA defects  (123) 
DNAL1 843 Not assessed Axoneme ODA defects  (124) 
HEATR2 2,568 Not assessed Cytoplasm ODA defects  (125) 
HYDIN 15,363 Not assessed Axoneme Rare central pair defects  (126, 127) 
LRRC6 1,401 3-4 Cytoplasm IDA and ODA defects  (128, 129) 
OFD1 3,039 Not assessed Cytoplasm Not assessed  (130) 
RPGR 3,459 Not assessed Cytoplasm Varied defects  (96, 97) 
RSPH1 930 4 Axoneme Central pair defects  (131-133) 
RSPH4A 2,151 2 Axoneme Central pair defects  (134-136) 
RSPH9 831 Negligible Axoneme Central pair defects  (134, 135, 137) 
TXNDC3 1,767 Not assessed Axoneme ODA defects  (138) 
ZMYND10 1,323 3-7 Cytoplasm IDA and ODA defects  (139, 140) 
Table 1.1 PCD causing genes 
Abbreviations – ORF, open reading frame; bp, base pairs; ODA, outer dynein arm; IDA, Inner dynein arm. 
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Mutations in the dynein arm genes DNAH5 and DNAI1 are the most common causes 
of PCD with mutations seen in 15-28% and 2-10% of all patients with PCD 
respectively (117-119). These figures rise to 49% for DNAH5 mutations and 14% for 
DNAI1 mutations when only patients with ODA defects are taken into account (118, 
119).  
DNAH5 encodes for a large axonemal dynein heavy chain protein that forms part of 
the ODA complex. DNAH5 is an orthologue to the γ-heavy chain in Chlamydomonas 
and was first described as a candidate PCD causing gene by using homozygosity 
mapping in one large consanguineous family (115). Further studies employing 
sequence analysis and more families identified DNAH5 as a PCD causing gene 
mutations in which lead to ODA defects, randomisation of left-right asymmetry and 
male infertility (116, 118). A genotype-phenotype correlation study found that 
mutations introducing a premature stop codon results in total absence of ODAs 
whilst splice site mutations which predict a loss of exon 75 resulted in short stubby 
ODA (141).  
1.1.6 PCD TREATMENTS  
Despite affecting many organ systems the primary aim of current therapy for PCD is 
the prevention of progressive lung damage. This approach is somewhat similar to 
the treatment for cystic fibrosis (CF) where, like PCD, lack of mucociliary clearance 
is the driver of lung pathology. Unsurprisingly then PCD treatment is informed by CF 
therapy. Ellerman and Bisgaard (142) used a disease management regimen not 
dissimilar to that used for CF on PCD patients and concluded that this approach was 
key to preventing lung deterioration and progressive lung damage. The regimen 
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included regular physiotherapy for airway clearance, monthly sputum collection 
with subsequent bacterial culture and appropriate antibiotic therapy based on 
antibiotic sensitivity cultures. Monitoring patients lung function routinely also 
helped slow disease progression (142). If a patient does reach end-stage lung 
disease then lung transplantation is also an option shown to be successful in PCD 
patients (30).  
The establishment of a PCD management service in the UK that will review patients 
and provide “individualised management plans” should improve patient prognosis 
and provide valuable data on what treatments are best for managing PCD (143). As 
it is, with current treatment regimens, almost all patients develop bronchiectasis by 
adulthood. A gene therapy treatment option that corrects the primary defect in 
PCD, administered before extensive lung damage is present, would improve the 
quality of life for patients and reduce morbidity. This goal would be aided by 
improvements in diagnosis of PCD as currently, despite symptoms in the neonatal 
period, median age at diagnosis is around 5.3 years which falls to 3.5 years when 
situs inversus is present (144).   
39 
 
1.2 GENE THERAPY 
Gene therapy is the introduction of genetic material into cells to provide a 
therapeutic benefit and has classically been thought of as the introduction of 
deoxyribonucleic acid (DNA) encoding a functional gene to replace a mutated one. 
Given that PCD results from genetic mutations it is reasonable to suspect that 
introduction of the wild-type gene into ciliated cells could rescue normal ciliary 
beating and so correct the disease phenotype.  
1.2.1 HISTORY 
In 1928 Frederick Griffith (145) showed that non-pathogenic R form of Type I 
pneumococcus became pathogenic upon mixing with heat-inactivated S form of 
Type II pneumococcus and that this mixture was capable of inducing lethal 
pneumonia infections in mice. In addition, Griffith was able to isolate the S form of 
Type II pneumococcus in these mice. As the original S form of Type II 
pneumococcus had been heat-inactivated Griffith concluded that the R form must 
have been transformed into the S form and that the pneumococcal type must also 
have been transformed from Type I to Type II. These experiments were the first to 
show that the phenotype of an organism can be changed by the introduction of 
foreign material. 
James Alloway (146) later found that filtered cell free extracts from S form of 
pneumococcus was also able to transform R form pneumococcus. Alloway 
therefore concluded that something in the cell free extract was responsible for 
transforming the pneumococcus and named this the “transforming principle”. 
Avery et al., (147) subsequently identified this transforming principle as DNA. In 
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support of the notion that DNA is heritable and sufficient for transformation 
Hershey and Chase (148) showed that only the DNA of bacteriophage was taken up 
by infected bacteria. In these experiments radiolabelled phage DNA was found to 
be transmitted to the new progeny whilst the sulphur-containing protein was not. 
As the infected bacteria produced bacteriophage progeny DNA must have 
contained all the information required to produce bacteriophage. 
The identification of DNA as the heritable material was quickly followed by studies 
showing the incorporation of foreign genetic material into mammalian cells for the 
first time (149) and the demonstration that foreign DNA could be used to impart 
onto mammalian cells a new biochemical trait (150). The latter of these studies was 
described by Szybalska and Szybalski (150) and was based on the need for cells to 
synthesise nucleic acids in order to replicate and survive in culture. Typically 
dihydrofolate reductase is utilised for de novo synthesis of nucleic acids but 
Szybalska and Szybalski added the chemotherapeutic agent aminopetrin to inhibit 
this enzyme thus forcing the cells to utilise an alternative pathway involving 
hypoxanthine-guanine phosphoribosyl transferase (HGPRT). Cells with this enzyme 
(HPGRT+) would be able to continue proliferating but those without the enzyme 
(HPGRT-) would not. Szybalska and Szybalski found that introducing DNA isolated 
from HPGRT+ cells into HPGRT- cells allowed the HPGRT- cells to proliferate despite 
aminopetrin treatment. If the transformed DNA was isolated from HPGRT- cells or 
pre-treated with DNase the proliferation phenotype was not observed thus 
providing the first evidence that gene transfer in mammalian cells could be used to 
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correct genetic defects in mammalian cells. However, this study involved the 
introduction of all the DNA content from donor cells and so was not gene specific. 
Viruses deliver genetic information into cells but it would be necessary to remove 
pathogenic genes and replace them with therapeutic genes if viruses were to be 
useful for gene therapy. However, in 1975 and with the belief that Shope papilloma 
virus encodes an arginase that could be useful in the treatment of arginase 
deficiency in man (151), Terheggen et al., (152) conducted the first direct human 
gene therapy trial using wild-type Shope papilloma virus to treat arginase 
deficiency. Unfortunately the trial was unsuccessful and sequencing later revealed 
the Shope papilloma virus does not encode an arginase. 
In order to achieve gene specific gene transfer it was vital to produce recombinant 
DNA molecules carrying the specific gene of interest and elements required for the 
efficient transcription and translation of the introduced DNA. This was made 
possible by discoveries in the 1960’s that advanced our ability of manipulate DNA 
giving rise to the field of genetic engineering. The first major breakthrough came 
when Gellert first described that DNA ends could be joined together using 
Escherichia coli (E. coli) extracts (153). The same lab then purified the enzyme 
responsible (154)- now known as DNA ligase. The second major breakthrough in 
genetic engineering came with the discovery of restriction enzymes. This discovery 
was preceded by work from Luria and Human (155) and Bertani and Weigle (156) 
who showed that bacteriophage infection was restricted in certain bacterial strains 
but not others. Arber and Dussoix (157, 158) showed that this restriction was due 
to degradation of bacteriophage DNA by the host cell. Linn and Arber (159) found 
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this degradation was initiated by restriction enzymes- so called because they 
restricted bacteriophage infection. Restriction enzymes cleave DNA at specific 
sequence motifs called restriction sites. The discoveries of DNA ligases and 
restriction enzymes allowed the cutting and pasting of different DNA sequences to 
produce recombinant DNA molecules and this technology was used by Cohen et 
al., (160) to produce the first biologically functional plasmid that afforded 
transformed E. coli antibiotic resistance.  
Maniatis et al., (161) used the discoveries of restriction enzymes and DNA ligase to 
isolate and clone the β-globin gene from rabbit genomic DNA libraries. Genomic 
DNA libraries contain untranslated intron sequences as well as protein-coding exon 
sequences. Wilson et al., (162, 163) later used reverse transcriptase- an RNA-
dependent DNA polymerase- to produce complementary DNA (cDNA) of mature 
human globin mRNAs (therefore lacking intron sequences) and inserted these into 
plasmids for sequencing and characterisation studies of the human globin 
genes (162, 163). Green et al., (164) showed β-globin expression after transfecting 
Wilsons β-globin plasmid into HeLa cells with cis- or trans-acting transcriptional 
regulatory factors from adenovirus and herepesvirus.  
The potential for gene therapy in vivo was demonstrated by Cline et al., (165) who 
showed that ex vivo gene transfer of mouse bone marrow resulted in stable gene 
expression after the modified bone marrow was transplanted into irradiated mice. 
In these studies the gene transferred conferred resistance to methotrexate, an anti-
cancer drug that inhibits dihydrofolate reductase preventing de novo synthesis of 
thymidine so affecting DNA synthesis and preventing cell growth and proliferation. 
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In the presence of methotrexate the genetically modified resistant cells had a 
selective advantage and were the majority population in the reconstituted bone 
marrow. Cline applied to the UCLA Human Subjects committee for permission to 
test the same approach of ex vivo gene transfer of bone marrow cells followed by 
bone marrow transplants of the cells in patients with β-thalassemia (a genetic 
disorder caused by mutations in the β-globin gene) with no adverse events or 
clinical benefit seen in the two patients enrolled. Despite applying to the UCLA 
Human Subjects committee for permission Cline commenced the trial without the 
board’s approval (who had concerns about the potential efficacy of the trial) and 
attracted widespread criticism for this failing and for enrolling the two patients 
from Italy and Israel, countries with no specific regulations for gene therapy trials at 
the time (166). Cline used the calcium phosphate transfection method for gene 
transfer and the lack of efficacy in the infamous clinical trial highlighted the need 
for improved gene delivery technologies particularly when corrected cells have no 
selective advantage. Both viral and non-viral vectors have been developed for gene 
therapy and the main properties of commonly used vectors have been summarised 
in Table 1.2. 
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Table 1.2. Properties of commonly used gene therapy vectors. 
Adapted from Nathwani et al., (167). AAV, adeno-associated virus; -, zero; -/+, equivocal; +, low; ++, moderate; +++, high. 
 Gammaretrovirus Lentivirus Adenovirus AAV Non-viral 
Nucleic acid RNA RNA DNA DNA RNA and DNA 
Packaging capacity ~9kb ~10kb ~30kb 4.6kb Unlimited 
Integration into host genome Yes Yes No Rarely Rarely 
Duration of transgene 
expression 
Long Long Transient Long in post-
mitotic tissues 
Transient 
Transduction of post-mitotic 
cells 
- + +++ ++ ++ 
Pre-existing host immunity No No Yes Yes No 
Immunogenicity ++ ++ +++ + - 
Safety concerns Insertional 
mutagenesis 
Insertional 
mutagenesis 
Inflammatory 
response 
Low risk of 
insertional 
mutagenesis 
- 
Germ-line transmission -/+ + - -/+ - 
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Viruses, as naturally occurring gene delivery vehicles, presented as obvious 
candidates for development. Goff and Berg (168) produced recombinant simian 
virus 40 (SV40) viruses containing λ phage sequences in place of 2kb of DNA from 
the late region of SV40 genome and this recombinant SV40 transduced cultured 
monkey cells. Mulligan et al., (169) later showed that replacing the VP1 capsid gene 
in wild-type SV40 with the rabbit β-globin cDNA produced recombinant SV40 
virions that induced β-globin expression in cultured monkey kidney cells. Further 
publications showed that non-viral genes could also be expressed from 
recombinant retrovirus (170), adenovirus (171) and AAV (172) vectors- now the 
three major classes of viral vectors. Advances have been made to improve the 
safety profile of viral vectors including the removal of pathogenic genes and 
splitting viral genomes to produce replication defective virions (173, 174). 
Additionally, using foreign envelopes to coat viruses has allowed re-targeting of 
virions to non-natural target tissues increasing their utility for gene therapy (175, 
176). 
A number of non-viral methods and vectors for gene delivery were also developed. 
These are simple containing only a few components and are generally less 
immunogenic than viral vectors. Non-viral gene delivery methods can be physical or 
chemical. Physical methods include the use of ultrasound (177) or electrical 
currents (178) to temporarily increase the permeability of target cells (sonoporation 
and electroporation respectively), direct injection of DNA into single cells (179), 
ballistic propulsion of DNA-coated particles whose momentum allows penetration 
of cells (180) and hydrodynamic gene delivery involving the rapid injection (~5-7 
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seconds) of a large volume of DNA solution (8-10% of body weight) (181-183). 
However the physical methods are typically inefficient in vivo and difficult to 
translate to man. Chemical gene delivery vectors are therefore the most widely 
studied and developed non-viral method usually employing a cationic species to 
complex with anionic nucleic acid forming complexes for gene delivery. One of the 
earliest and still widely used involve calcium phosphate co-precipitation of 
DNA (184) which was more efficient than complexes of the polycation 
diethylaminoethyl-dextran with plasmid DNA (185) which preceded the calcium 
phosphate method. Of the polycations polyethylenimine (PEI) is the most utilised in 
vitro and in vivo showing relatively high transfection efficiency (186) thought to be 
in part due to the proton-sponge effect (187) where PEI’s ability to buffer at low pH 
results in ion and water influx when inside the endosomal compartment causing 
osmotic swelling and endosomal rupture releasing the entrapped nucleic acid into 
the cytoplasm. 
Cationic lipid species formulated into liposomes have also been extensively studied 
and are now among one of the most widely used non-viral vectors. Liposomes for 
gene delivery was first described in 1980 by Fraley et al., (188) and Wong et 
al., (189) who showed efficient transfection comparable to the co-precipitation 
method whilst Schaefer-Ridder et al., (190) showed stable integration of the 
selectable thymidine kinase gene in deficient mouse cells using liposomes. Felgner 
et al., (191) later showed that cationic liposomes formulated using only DOTMA 
lipid (N-[1- (2,3-dioleyloxy)propyl]-N,N,N-trimethlylammonium chloride) resulted in 
efficient transfection superior to calcium phosphate and diethylaminoethyl-dextran 
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methods in at least COS-7 and CV1 cell lines. A number of lipids have since been 
assessed for their ability to mediate efficient transgene expression. Later, the 
addition of cationic polymers was shown to enhance liposome-mediated gene 
delivery (192). Further attempts at improving non-viral formulations have been 
made with the addition of components to improve bioavailability in vivo through 
shielding of complexes using polyethyleneglycols (193), to enhance cell-specific 
targeting using targeting moieties (194, 195), to aid endosomal escape using 
fusogenic lipids (196, 197) or pH sensitive polymers that utilise the proton-sponge 
effect (187) and to improve nuclear entry using nuclear targeting sequences (198, 
199) or nuclear localisation signal containing peptides (200-202). 
The improvements to both viral and non-viral vectors led to a flurry of clinical trials 
being initiated in the 1990s- a so called boom period for gene therapy research. The 
first FDA approved gene therapy clinical trial was a study in which two patients with 
adenosine deaminase (ADA) deficiency were treated by ex vivo gene transfer of 
their T-cells with a gamma-retroviral vector encoding the ADA gene (203). The first 
patient to be treated was Ashanti DeSilva who showed temporary improvement in 
her condition no longer necessitating relative isolation and able to attend school 
without developing more infections than her classmates or siblings. Improvements 
in the second patient were also temporary and also more modest. It is important to 
note that both patients remained on enzyme replacement therapy during the trial 
leading to some debate to the efficacy of the gene therapy given. By the end of the 
decade none of the clinical trials showed clear long-lasting efficacy of a gene 
therapy protocol and the decade ended with the tragic death of Jesse Gelsinger in 
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1999 during a clinical trial for the treatment of ornithine transcarbamylase 
deficiency at the University of Pennsylvania (204). Jesse’s death resulted from 
multi-organ failure due to the high dose of adenovirus administered inciting a 
substantial immune response. His death was the first to be attributed directly to a 
gene therapy product.  
More recently gene therapy research has experienced a revival with reports of long-
term clinical benefit in the treatment of a number of diseases including X-linked 
severe combined immunodeficiency (X-SCID) (205, 206), ADA deficiency (207, 208), 
haemophilia B (209), Leber congenital amaurosis (210), metachromatic 
leukodystrophy (211), Wiskott-Aldrich syndrome (212) and choroideremia (213). 
Gene therapy for lipoprotein lipase deficiency using an AAV vector has also been 
shown to be efficacious (214) and recently approved for clinical use by the 
European Medicines Agency (215) making it the first gene therapy medicine to be 
approved in Europe. 
1.2.2 AIRWAY GENE THERAPY 
The primary target for PCD gene therapy is to correct the airway disease which is 
the main cause of morbidity from PCD. A gene therapy approach for lung disorders 
has been a goal since the gene involved in CF was described and cloned (216), 
particularly given the accessibility of the airways for vector delivery. Proof-of-
principle studies in vitro and in CF mice using viral and non-viral vectors soon 
followed (217-220) as well as a number of human clinical trials (221-227) but 
clinically viable gene therapy treatments for lung disorders have yet to materialise. 
This lack of clinical efficacy has been in large part due to the barriers the respiratory 
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system has evolved to clear foreign particles- not surprising given the systems 
exposure to the environment. 
Mucus secreted by goblet cells and the mucous cells of submucosal glands act as 
one of the main barriers to respiratory infection. The mucus has a complex 
composition including cytokines, antioxidant proteins, lysozymes, defensins and 
importantly mucins which are large, highly charged and heavily glycosylated 
glycoproteins that form and re-form cross-links to give mucus it’s highly tangled and 
dynamic structure (228). Airway mucus traps pathogens and inhaled particles thus 
hindering their ability to reach the apical surface of airway epithelial cells, a pre-
requisite for gene transfer and infection. Mucociliary clearance, disrupted in PCD, 
then results in the removal of these particulates from the airway.  
The innate immune system is another important barrier to respiratory cell infection. 
Resident airway macrophages internalize and degrade any pathogens trapped by 
the mucus (229). In addition, airway epithelial cells can recognize pathogens 
through toll-like receptors which then initiate the immune responses of the 
respiratory epithelium (230). Adaptive immune responses can also prevent 
repeated delivery of vectors which is necessary in the context of PCD as life-long 
treatment will be necessary given that a stem cell population that can be efficiently 
targeted has not been described. 
In order to realise the promise of gene therapy for respiratory disease vectors 
capable of efficiently overcoming the extra- and intra-cellular barriers to gene 
transfer of the airway epithelium are required. In the case of PCD the vectors must 
also target ciliated cells and show low immunogenicity to avoid exacerbating the 
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characteristic inflammatory lung disease seen in PCD. The ability for repeated 
dosing without diminishing transfection/transduction efficiency is also required 
given that lifelong treatment would be necessary. These requirements are identical 
to those reported for CF gene therapy vectors and so a lot can be learnt from this 
field.  
Viral vectors 
Both viral and non-viral vectors have been investigated for CF gene therapy with 
viral vectors typically being more efficient, not surprising given that they have 
evolved to efficiently overcome the extra- and intra-cellular barriers to gene 
transfer. Viruses that naturally target the airway epithelium such as adenovirus, 
adeno-associated virus (AAV), parainfluenza virus and respiratory syncytial virus 
(RSV) have been assessed for airway gene transfer as well as lentiviral vectors which 
have been re-targeted through the use of envelope proteins from airway targeting 
viruses such as filoviruses, influenza virus, baculovirus and Sendai virus (SeV). Of 
these vectors adenovirus and AAV vectors have made it to clinical trials. 
Despite showing early promise in pre-clinical models and being well tolerated at 
low and medium doses in humans, adenovirus vectors have, in clinical trials, shown 
transient expression, variable gene transfer efficiencies and diminished expression 
following repeated delivery with neutralising antibodies against the vector and 
adenovirus-specific T-cells being reported (231-239). 
Adenoviruses are non-enveloped, double-stranded DNA viruses with numerous 
serotypes of which 2 and 5 have been assessed for respiratory gene transfer. 
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Adenovirus vectors do not integrate into the genome of the host thus negating the 
risk of insertional mutagenesis, the implications of which are unknown in the 
context of airway gene delivery given the terminally differentiated nature of the 
target cells versus the rapidly dividing nature of bone marrow cells in which 
insertional mutagenesis has been shown to lead to leukaemia (240).  
Uptake of adenovirus vectors is by endocytosis following binding of viral particles to 
the coxsackievirus and adenovirus receptor (CAR) (241, 242) which are mainly 
expressed on the basolateral surface of polarised airway epithelial cells (243) 
making them inaccessible to vectors delivered by inhalation, the favoured route for 
respiratory gene therapy, as tight junctions between adjacent cells prevents access 
to the basolateral surface. This helps explain the inefficient gene transfer observed 
in clinical trials and transduction efficiency with adenovirus vectors can be 
improved through opening of tight junctions by the use of pharmacological agents 
such as sodium caprate (244), perfluorochemicals (245) and 
lysophosphatidylcholine (LPC) (246). Whether the use of such agents in patients 
with bacterial colonisation (as is the case in CF and PCD) is wise given the potential 
risk of systemic infection remains controversial. 
AAV vectors have been the only other viral vector used in clinical trials for airway 
gene therapy. These are single-stranded DNA viruses and have not been associated 
with any human pathology. The wild-type virus integrates into human chromosome 
19 but recombinant AAV (rAAV) vectors used for gene therapy are thought to 
integrate only rarely and instead remain episomal in the nucleus upon cellular 
uptake (247). A variety of serotypes of AAV have been described for transduction of 
52 
 
airway epithelia although species-specific differences have been observed (248, 
249). In clinical trials rAAV derived from AAV2 has been commonly used and 
generally well tolerated in safety studies (224, 227). However, when utilised for CF 
gene therapy no significant improvement in lung function was observed in a well 
powered efficacy trial (226). Furthermore, virus shedding, production of 
neutralising antibodies against the vector and diminished transgene expression 
have been observed following repeated administration (226, 227). To date all CF 
clinical trials utilising AAV employed rAAV2 with an AAV2 capsid and were led by 
Targeted Genetics, Corp. using the TgAAV-CFTR vector in which CFTR expression is 
driven by a weak promoter found in the AAV long terminal repeat (LTR). The weak 
promoter activity combined with data showing that AAV2 only poorly transduces 
human airway cells could explain the lack of clinical efficacy. In the case of CF gene 
therapy the use of the weak AAV LTR promoter is necessary because AAV has a 
packaging capacity of around 4.6kb and so can carry the CFTR ORF (4.4kb) only in 
the absence of a strong exogenous promoter. The majority of PCD causing gene 
ORFs are significantly smaller than the CFTR ORF and so could be incorporated into 
rAAV vectors with a strong exogenous promoter.  
Attempts have been made to address the poor transduction of human airway 
epithelial cells by rAAV2 vectors containing AAV2 capsid proteins by pseudotyping 
rAAV2-based vectors with capsids from AAV serotypes 1 and 6 (248-250). In 
addition to using naturally occurring capsids a directed evolution approach using 
random mutagenesis of the capsid encoding cap gene (251) has been used to 
generate novel capsids and rAAV vectors with enhanced transduction of the human 
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airway epithelium in vitro (252). Whilst these advances are promising, they remain 
untested in clinical trials and do not address issues with diminished transgene 
expression following repeated administration.  
Whilst other viral vectors have not been tested in clinical airway gene delivery 
studies, pre-clinical studies testing influenza (253) and parainfluenza (254) viruses 
have shown efficient apical transduction of human airway epithelial cells with these 
viruses. More promising still, in the context of PCD gene therapy, RSV has been 
shown to specifically target ciliated cells (255, 256). However, only SeV and 
lentiviral vectors have been tested in vivo.  
SeV, otherwise known as murine parainfluenza virus type 1, is a respiratory 
pathogen that is endemic in rodents and belongs to the Paramyxoviridae family of 
viruses that includes human parainfluenza virus types 1 and 3. SeV is a single 
stranded ribonucleic acid (RNA) virus whose genome consists of a single stranded 
negative-sense RNA of around 15-16kb giving it a potentially large packaging 
capacity (257). The development of a SeV where the fusion (F) protein is provided in 
trans rather than being part of the viral genome results in viral particles capable of 
efficiently infecting airway epithelial cells but give rise to progeny that are 
incapable of further infection due to the need for the F protein in fusion of the virus 
to the cell membrane (258). This transmission defective virus was capable of 
efficiently transducing mouse airway epithelial cells in vivo (259) and importantly a 
non-natural host- the sheep airway epithelium in vivo (260). Human airway 
epithelial cells were also efficiently transduced using the SeV vector (259). 
However, gene expression was found to be transient and repeated delivery of the 
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vector in vivo resulted in diminished transgene expression thus limiting the 
suitability of SeV for PCD gene therapy (260). 
Lentiviruses are single-stranded, positive-sense RNA viruses with a genome of 
around 9.7kb, belong to the Retroviridae family and are capable of transducing non-
dividing cells making them suitable for terminally differentiated airway epithelial 
cells. Reverse transcriptase and integrase proteins expressed by lentiviruses result 
in integration of the lentiviral genome into host chromosomes thus providing stable 
and sustained transgene expression. 
Lentiviruses assessed for gene therapy include human immunodeficiency virus 
(HIV), feline immunodeficiency virus (FIV) simian immunodeficiency virus (SIV) and 
equine infectious anaemia virus (EIAV). These viruses naturally infect blood cells but 
have been re-targeted through the use of envelope proteins from other viruses- a 
process known as pseudotyping. The vesicular stomatitis virus (VSV) G glycoprotein 
(VSV-G) has been used for pseudotyping due to its broad tropism. HIV type 1 (HIV-
1) pseudotyped with VSV-G has been used successfully in clinical settings for the 
treatment of metachromatic leukodystrophy (211) and Wiskott-Aldrich 
syndrome (212) by ex vivo correction of haematopoietic stem cells followed by re-
infusion of the corrected cells into patients. 
VSV-G pseudotyped HIV-1 and FIV vectors have been assessed for airway gene 
delivery but efficient gene transfer necessitated the disruption of tight junctions 
between airway epithelial cells thus allowing virus access to the basolateral cell 
surface and also underlying basal progenitor cells (261, 262). The poor efficiency 
following delivery to the apical surface of the airway epithelium is unsurprising 
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given the VSV infects the basolateral surface of polarised cells (263)- not accessible 
in the absence of tight junction disruption. Disruption of tight junction by pre-
treatment with agents such as LPC (264) or ethyleneglycoltetraacetic acid 
(EGTA) (262) followed by VSV-G pseudotyped lentiviral gene transfer resulted in 
stable and persistent transgene expression in mice with evidence that progenitor 
populations had been transduced. In addition, a single dose was found sufficient to 
induce transgene expression that persisted for the life-time of the mice, although 
the proportion of cells expressing the introduced transgene did decline over 
time (264). Encouragingly, VSV-G pseudotyped HIV-1 introduced following pre-
treatment with LPC has been shown to efficiently transduce lungs of the 
marmoset (265)- a non-human primate- the lungs of whom are far closer related to 
that of humans.  
Despite the encouraging results with VSV-G pseudotyped lentiviral vectors, whether 
disruption of tight junctions is wise in the lungs of patients in whom bacterial 
colonisation is commonplace remains controversial given the potential risk for 
systemic disease. As such, efforts have been made to pseudotype lentiviral vectors 
with glycoproteins from organisms that naturally infect the apical surface of airway 
epithelial cells. To this end FIV has been pseudotyped with GP64, an envelope 
glycoprotein from Autographa californica that shares sequence identity with the 
influenza D GP75 glycoprotein and this novel vector has been shown, in human cell 
cultures and mice, to efficiently transduce the apical surface of airway epithelial 
cells. Transgene expression was shown to persist for over 11 months (266) and 
repeated administration did not diminish transgene expression (267). Buckley et 
56 
 
al., (268) further showed that intra-amniotic administration of GP64 pseudotpyed 
HIV resulted in efficient transduction of airway epithelia with evidence that 
progenitor/stem-cell populations had been transduced. 
Lentivirus pseudotyped with i) the glycoprotein envelope of Ebola Zaire virus (269), 
ii) hemagglutinin-neuraminidase (HN) and F proteins from SeV (270-272) and iii) HA 
from fowl plague virus (H7) together with the fowl plague virus M2 proton channel 
protein and influenza H1N1 neuraminidase (NA) (273, 274) were all shown to 
efficiently transduce mice airway epithelia with stable and persistent transgene 
expression, as seen with other lentiviral vectors described above, again indicating 
that some progenitor population had been transduced. 
Lentiviral based vectors thus fulfil most of the requirements for the ideal PCD gene 
therapy vector in that ciliated cells are transduced efficiently and repeated delivery 
is feasible without inducing a significant immune response. However, the limited 
packaging capacity of lentiviral vectors prevents DNAH5, DNAH11 and HYDIN ORFs 
(13.9kb, 13.6kb and 15.4kb respectively) from being packaged and delivered with 
lentiviral vectors. This is a particular concern considering that DNAH5 is the most 
common cause of PCD, accounting for around 1 in 4 patients and the three large 
genes together account for 21-35% of all PCD patients (Table 1.1). Alternative non-
viral vectors have been developed for airway gene transfer and have an unlimited 
packaging capacity, are well tolerated following repeated delivery and can be easily 
produced in large quantities.  
Non-viral vectors 
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Typical non-viral formulations contain a cationic component, usually a liposome or 
polymer, complexed to anionic plasmid DNA containing the transgene and 
necessary regulatory elements. The cationic and anionic components interact due 
to their opposing charges resulting in condensation of the plasmid DNA component 
and the formation of nanocomplexes with a cationic zeta potential. The 
nanocomplex interacts with the anionic cell surface and is taken up typically by 
endocytosis. The plasmid DNA cargo must then undergo endosomal escape to 
evade degradation in lysosomes and then be taken up into the nucleus where the 
transgene can be transcribed and then translated in the cytoplasm. Non-viral 
vectors are generally less efficient than viral vectors as they typically lack specific 
components to help with cell entry, endosomal escape (not a problem for viruses 
that undergo fusion), trafficking through the cytoplasm and nuclear uptake (Figure 
1.3). Viruses in contrast have developed specific strategies and proteins to 
overcome these barriers to gene transfer. Nevertheless, the advantages of low 
immunogenicity and an unlimited packaging capacity have resulted in a flurry of 
studies assessing non-viral vectors for CF airway gene delivery. 
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Figure 1.3. Schematic of non-viral gene transfer 
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A number of non-viral vector formulations have been assessed in clinical trials. The 
earliest airway gene delivery clinical trials involved the use of GL67A/DOPE 
(Genzyme lipid 67A/1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine) (275), DC-
Chol/DOPE (3β-[N- (N′,N′-
Dimethylaminoethane)carbamoyl]cholesterol/DOPE) (276, 277) or DOTAP (1,2-
Dioleoyl-3-trimethylammonium-propane) (223) liposomes complexed with plasmid 
containing CFTR cDNA. These early clinical trials were single-dose safety and 
efficacy studies with the formulations administered to patient nostrils as a 
surrogate to the lungs and in all cases the non-viral vectors were well tolerated. In 
addition, partial but transient correction of the electrophysiological defects seen in 
CF was observed so paving the way for further clinical studies (223, 275-277).  
Alton et al., (222) reported mild influenza-like symptoms that returned to normal 
30 hours following pulmonary administration of GL67A/DOPE/plasmid DNA 
formulation. In addition the inflammatory markers C-reactive protein and IL-6 were 
elevated relative to placebo following pulmonary administration of 
GL67A/DOPE/plasmid DNA vector. This elevation was transient returning to 
baseline by the time of the next measurement at day 6 and was not observed 
following nasal administration of vector. As such, the vector was considered to be 
well tolerated. With regards to efficacy vector-specific DNA was found in all active-
group patients at day 2 however no vector-specific mRNA could be detected 
despite chloride channel function being restored to around 25% of normal values in 
lungs of patients in the active group. In addition patients receiving the active drug 
showed a significant reduction in bacterial adherence ex vivo although no change in 
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mucociliary clearance was observed in vivo. This study thus showed good tolerance 
of the non-viral vector following a single administration to the lungs but efficiency 
of transfection was not sufficient to produce a clinical benefit to patients.  
Repeated administration could hypothetically produce cumulative levels of 
transgene to be expressed and so potentially result in clinical efficacy. Prior to 
commencing clinical studies the UK CF Gene Therapy Consortium assessed repeated 
delivery of GL67A/DOPE/plasmid DNA complexes in pre-clinical animal models. 
Encouragingly, repeated administration did not produce increased toxicity relative 
to a single administration in mice (278) and sheep (279). In mice, repeated 
administration (one dose per fortnight – 12 doses total) did not result in 
accumulation of vector specific DNA or mRNA but diminished expression following 
repeated delivery was reassuringly not an issue (278). These findings also held true 
following repeated administration in sheep (one dose every four weeks – 9 doses 
total) (279). Similarly, in a small human clinical trial (12 patients total - 10 in active 
group, 2 in placebo group), Hyde et al., (280) found no accumulation of vector 
specific DNA or mRNA or increase in toxicity following repeated administration of 
DC-Chol/DOPE/plasmid DNA complexes to the nostrils of CF patients (one dose 
every four weeks – 3 doses total). In this study partial Cl- ion transport correction 
was seen in some patients and importantly repeated administration did not result 
in diminished transgene expression.  
Despite the lack of accumulated vector specific DNA or mRNA following repeated 
delivery, the lack of increased toxicity and partial Cl- ion transport correction has led 
the UK CF Gene Therapy Consortium to commence a double-blind, placebo 
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controlled clinical trial sufficiently powered to detect clinical improvements to 
assess the safety and efficacy of repeated administration of GL67A/DOPE/plasmid 
DNA complexes for the respiratory treatment of CF (281). Whether this approach 
yields clinical improvements remains to be seen but it is clear that there is 
significant room for improvement of non-viral gene delivery formulations for airway 
gene transfer particularly for PCD gene therapy where the transfection efficiency 
required to correct the mucociliary clearance defect is higher than that for CF (25-
40% of cells corrected for CF (282) vs 80-100% of cells corrected for PCD (283)). As 
such, improvements to non-viral vector technologies are clearly necessary for 
airway gene transfer to provide clinical benefit particularly when correcting defects 
caused by mutations in large genes.  
In order to improve targeting and cell uptake of non-viral gene transfer agents 
techniques such as magnetofection (where plasmid DNA is coupled to magnetic 
particles making the DNA responsive to magnetic fields) and sonoporation (where 
ultrasound is used temporarily increase the permeability of target issues) have been 
assessed for the enhancement of transgene delivery using non-viral vectors but 
both techniques fared poorly in vivo (284, 285). 
Alternatively, targeting ligands have also been used to target non-viral gene 
transfer agents to airway epithelial cells. Ziady et al.,  (286) used plasmid DNA 
complexed with a covalent conjugate containing cationic poly-L-lysine and a 17 
amino acid peptide ligand to the serpin-enzyme complex receptor (expressed on 
the apical surface of airway epithelial cells) and found that the novel 
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nanocomplexes were capable of correcting the electrophysiological defect seen in 
CF mice.  
In a similar approach, Tagalakis et al., (287) developed targeted nanocomplexes 
through the use of a 7 amino acid peptide sequence identified in phage display 
studies aimed at finding sequences targeting the apical surface airway epithelial 
cells (288). The final sequence SERSMNF was found to have close homology to parts 
of receptor targeting proteins from the respiratory pathogens rhinovirus (SDRSMN) 
and Listeria monocytogenes (ERSMNF) which target ICAM-1 and E-cadherin 
receptors respectively. A short peptide sequence (P) containing the targeting 
sequence conjugated to a K16 DNA binding domain was complexed together with a 
cationic liposome (L) and anionic plasmid DNA (D) to produce small cationic 
nanocomplexes that can be nebulised (289) and efficiently transfects airway 
epithelial cells with low toxicity in mice (287) and importantly pigs (290) whose lung 
physiology is closer to that of humans. As well as containing the receptor-targeting 
sequence, which aids in cell uptake, the DOPE lipid contained within the liposome 
component of the LPD complex is known to aid in endosomal escape and plasmid 
DNA release (291). 
The polymer PEI has also been complexed with DNA and shown to aid endosomal 
escape and plasmid DNA release through a proposed “proton-sponge” effect (187) 
where unprotonated amines from PEI become protonated in the acidic 
environment of lysosomes resulting in an influx of Cl- ions and water. This influx 
results in osmotic swelling and eventual rupture of the lysosomal membrane and 
the release of its contents. PEI based complexes have been assessed for airway 
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gene delivery in studies by the UK Cystic Fibrosis Gene Therapy Consortium 
comparing a variety of non-viral gene delivery agents (292) including branched PEI 
(25kDa) and GL67A/DOPE liposome with GL67A/DOPE found to be most efficient 
and so moved forward to clinical trials. 
In addition to optimising the cationic lipid and polymer components of non-viral 
vectors for airway gene transfer the nucleic acid component has also been 
improved upon. Choice of promoter element is known to have an effect on both 
the levels and persistence of transgene expression in a tissue specific manner (293-
295). Comparing the constitutive viral promoters from cytomegalovirus (CMV), 
Rous sarcoma virus and SV40 to human polyubiquitin C (UbC) and elongation factor 
1 alpha (EF1α) gene promoters in the context of airway transgene expression Gill et 
al., (296) found the UbC and EF1α promoters provided greater persistence of 
transgene expression whilst the viral promoters provided higher initial levels of 
transgene expression. Addition of human CMV enhancer sequences to the UbC and 
EF1α promoters was shown to increase the initial levels of transgene expression 
whilst complete removal of CpG motifs resulted in further enhancement to 
transgene expression and persistence (297). CpG motifs induce an immune 
response in vertebrates (298-301) via toll-like receptor 9 (302) and so in addition to 
enhancing transgene expression and persistence their removal reduced the 
neutrophil count and levels of the inflammatory cytokines interleukin-12 (IL-12), 
tumor necrosis factor α (TNFα) and interferon γ (IFNγ) in bronchoalveolar lavage 
fluid (BALF) of transfected mice (297).  
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The use of CpG-free sequences reduces the inflammatory response to airway gene 
delivery by non-viral vectors (297, 303), an important advance given that airway 
inflammation is a characteristic of PCD that should not be exacerbated by gene 
delivery formulations. A number of studies have also implicated CpG motifs in 
transgene silencing (297, 304-306) but this remains controversial (307). Assessing 
an alternative hypothesis Lu et al., (308) found that the plasmid backbone 
sequence, typically rich in CpG motifs, when placed within the 3’ untranslated 
region of a eukaryotic expression cassette yielded persistent transgene expression 
as did vectors devoid of a bacterial backbone (minicircle DNA). The group went on 
to show that the size of the backbone and not its sequence was responsible for 
producing a potent negative effect on transgene persistence (308). In the context of 
gene therapy, minicircles have been shown to exhibit sustained transgene 
expression to plasmids in a variety of organ systems in vivo including the liver (309, 
310), heart (311, 312) and skeletal muscle (312) but minicircles have not been 
assessed in the context of airway gene delivery. 
1.2.3 PCD GENE THERAPY 
Research into gene therapy for CF has advanced airway gene delivery. Ciliated cells 
of the airway epithelium are the target cells for PCD gene therapy and also thought 
to be the target for CF gene therapy, although this remains controversial (313). As 
such, many of the advances in CF gene therapy are applicable to PCD but the latter 
has additional challenges associated. Genetic heterogeneity dictates that no single 
gene therapy product is likely to treat all forms of PCD. Chhin et al., (314) 
established proof-of-principle that gene therapy could be used to correct the cilia 
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motility and cilia ultrastructural defect in airway epithelial cells of a PCD patient 
with DNAI1 mutations. Cells were corrected ex vivo using a lentiviral vector to 
transduce de-differentiated human airway epithelial cells which were then re-
differentiated to ciliated cells using Jorissen’s culture method (315). This method 
produces spheres of ciliated cells rather than the mucociliary pseudostratified 
airway epithelium seen in vivo so measurement of mucociliary clearance was not 
possible.  
Using de-differentiated airway tissue followed by lentiviral gene transfer and re-
differentiation of airway cells with an air-liquid interface (ALI) culture system that 
generates a pseudostratified mucociliary airway epithelium Ostrowski et al., (283) 
showed recovery of cilia motility in cells from their Dnaic1 conditional knock-out 
mouse (316). PCD pathology (mucus accumulation, infection and inflammation) was 
evident in the nasal cavity but not the trachea of Dnaic1 conditional knock-out 
mice (316). Gene transfer was shown to be less efficient in the nasal cavity of PCD 
mice than in control animals whilst no significant difference in transduction 
efficiency was seen in the trachea where PCD pathology was not evident (283) 
highlighting a need for administration of a gene therapy treatment before 
significant disease pathology develops. To this end, intra-amniotic or neonatal 
administration of vector may offer the dual benefits of transducing an undamaged 
lung as well as enhanced transduction relative to adult lung gene transfer (268). 
Until recently the levels of correction required to restore mucociliary clearance in 
PCD was unknown. Using the conditional Dnaic1 mouse model Ostrowski et 
al., (283) used varying doses of tamoxifen to titrate Dnaic1 expression and found 
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around 20% of normal Dnaic1 expression restored mucociliary transport to 33-66% 
of the wild-type clearance rate. Whether this will be sufficient to prevent PCD 
pathology or reduce its severity remains to be seen but the group also showed that 
around 40% of normal Dnaic1 expression completely restored normal rates of 
mucociliary transport (283). Whether this finding holds true for PCD caused by 
DNAH5 mutations has not been assessed but given both DNAI1 and DNAH5 
mutations produce the same ultra-structural defect (absence of ODA) it is likely that 
the levels of correction required for both are similar. 
For PCD gene therapy targeting patients with DNAH5 gene mutations non-viral 
vectors are required due to the size of the transgene and the need for repeated 
administration. The ideal vector needs to also transfect the apical surface of the 
airway epithelium and likely needs to transfect at least 40% of ciliated cells if not 
more. These conditions rule out the use of established viral vectors such as 
lentiviruses which are unable to package the DNAH5 transgene or adenoviruses 
which are highly immunogenic and so do not allow repeat administration.  
In order to assess PCD gene therapy targeting patients with DNAH5 gene mutations 
suitable models are required and discussed below.  
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1.3 PCD DISEASE MODELS 
To better understand disease mechanisms and assess potential therapies it is 
important to have appropriate models of disease on which to experiment. Models 
can be broadly categorised as being in vitro, ex vivo or in vivo with examples 
including cell lines, tissues obtained from patients or animal models and 
experiments performed on patients or animal models respectively. With regards to 
genetic disease human patients and their tissues are natural models. Several breeds 
of dog have also been identified suffering from PCD (108, 317-320) and are also 
natural models. Experimenting on human participants and large animal models 
presents significant ethical and economical barriers particularly with regards to 
their use at the early stages of drug development. The alternative is to use tissue 
samples obtained from human and animal models but the rarity of PCD and a lack 
of genotyping of human patients limit the ability of researchers to obtain suitable 
ex vivo samples. These limitations necessitate the use of gene technologies to 
produce suitable models of disease. 
1.3.1 TECHNOLOGIES FOR DISEASE MODELLING 
Gene technologies used for production of disease models employ either post-
transcriptional modification of gene expression (e.g. RNAi; antisense silencing) or 
alteration of chromosomal DNA (e.g. homology recombination; ZFN; TALENs; 
CRISPR/Cas). 
Antisense Silencing 
Antisense compounds are single-stranded molecules that function by 
complimentary base pairing with mRNA to modulate gene expression by i) blocking 
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assembly of the translational machinery, ii) promoting RNase H degradation of the 
RNA or iii) blocking splice acceptor sequences thereby inducing exon skipping. The 
use of antisense oligonucleotides to inhibit gene expression was first shown to be 
effective by Zamecnik and Stephenson (321, 322) who found that a 13-mer 
oligonucleotide sequence complimentary to 13 nucleotides of the 3’- and 5’- 
terminal repeat sequences of Rous sarcoma virus inhibited virus replication and 
transformation by inhibiting viral RNA translation. These studies utilised unmodified 
DNA oligonucleotides and since then a number of more potent single-stranded 
antisense molecules have been developed (323). 
RNA Interference 
RNA interference (RNAi) describes a physiological mechanism by which RNA is able 
to specifically and potently inhibit gene expression post-transcriptionally. That the 
introduction of exogenous sense-strand RNA could inhibit endogenous transgene 
expression was first described in 1990 by Napoli et al., (324) and van der Krol et 
al., (325) in two back-to-back papers in the journal Plant Cell. Both groups 
attempted to over-express chalcone synthase, a pigmentation enzyme, in petunia 
by introducing a cloned chalcone synthase gene and unexpectedly observed a 
reduction in endogenous chalcone synthase expression. This phenomenon was 
termed co-suppression (324) . Further study showed that introduction of a 
truncated gene sequence also induced co-suppression in tomato plants (326) and 
von Blokland et al., (327) showed that the mechanism occurred post-
transcriptionally and resulted in an increased turnover of mRNA. Co-suppression 
was also described in non-plant species including the fungus Neurospora 
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crassa (328) (termed quelling by Romano and Macino), the fruit fly Drosophila 
Melanogaster (329) and the nematode worm Caenorhabditis elegans (330).  
Guo and Kemphues (330) showed that in Caenorhabditis elegans sense RNA was 
able to inhibit par-1 expression, as did antisense RNA, but silencing mediated by 
sense RNA relied on homology to the coding region of par-1 and so involved a 
different mechanism of gene silencing to antisense RNA. The mechanism by which 
sense RNA could inhibit gene expression which was termed “RNA-mediated 
interference” by Mello’s group in 1997 (331). A year later the mechanism for RNAi 
was described by Fire et al., (332) with Andrew Fire and Craig Mello receiving the 
2006 Nobel Prize in Physiology and Medicine for their discovery. Fire et al., (332) 
injected either sense, antisense or both sense and antisense RNA into 
Caenorhabditis elegans in order to inhibit expression of the unc-22 gene which 
when reduced was known to produce twitching movements in the worm. 
Introduction of either sense and/or antisense RNA did not result in twitching but 
introduction of even a small amount of double-stranded RNA (dsRNA) produced a 
potent and specific inhibition in unc-22 and resulted in twitching.  
RNAi is an evolutionary conserved pathway and has been found to restrict viral 
infection in plants (333-335), invertebrates (336-339) and more recently 
mammals (340, 341). The mechanism of RNAi (Figure 1.4) involves first the cleavage 
of double stranded RNA into small 21-23 nucleotide double stranded small-
interfering RNA (siRNA) molecules that have 2-nucleotide 3’ overhangs. This 
cleavage is performed by Dicer (342), a protein within the RNase III family of 
nucleases. The antisense strand of the siRNA is then loaded into a multi-protein 
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complex, the RNA-induced silencing complex (RISC) (343) and guides the specific 
degradation of target mRNA via complimentary base-pairing. The antisense strand 
is therefore also known as the guide strand. 
Introduction of siRNA into cells and organisms has been a valuable way of inducing 
specific gene silencing without triggering an IFN response in mammalian cells (344). 
As such, RNAi has been a useful tool for investigating the function of individual 
genes. However, the transient nature of siRNA makes its use for the generation of 
stable disease models unfeasible.  
In addition to siRNA, RNAi can be induced by short-hairpin RNAs (shRNAs) (345). 
shRNAs are based on endogenous small non-coding micro RNA (miRNA) sequences 
that also make use of the RNAi machinery to effect gene regulation (Figure 1.4). 
miRNAs are initially long primary transcripts called pri-miRNA that undergo nuclear 
processing by the RNase III family Drosha enzyme (346) into short ~70-nucleotide 
stem-loop precursors called pre-miRNA. The pre-miRNAs are then exported from 
the nucleus into the cytoplasm where they are processed into ~22 nucleotide 
products by Dicer, incorporated into RISC and go on to mediate targeted gene 
silencing either through translational repression or mRNA degradation (347). In 
contrast to siRNA, miRNAs typically contain mismatches to their target sequences. 
Paddison et al., (345) aimed to re-target miRNA and found that introducing 
sequences that have perfect homology to the target mRNA sequence into miRNA 
stems i.e. shRNAs resulted in potent inhibition of transgene expression.  
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Figure 1.4. RNAi Mechanism 
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Expression of shRNA in cells can be achieved through the use of plasmid or viral 
vectors the latter of which can result in integration of the shRNA producing 
sequence into the host genome. Following transcription of the introduced shRNA 
producing sequence, the single stranded transcribed RNA is able to form hairpin 
structures mimicking endogenous pri-miRNA. These products are cleaved into pre-
shRNA by Drosha and exported into the cytoplasm where Dicer processes the pre-
shRNA into functional siRNA that is incorporated into RISC and produces potent and 
specific RNAi. The ability to integrate shRNA-encoding DNA sequences into cells has 
allowed the generation of animal models of disease in which shRNA expression is 
controlled by an inducible promoter thus allowing temporal control of gene 
silencing (348). In addition, shRNA-encoding lentiviral vectors have been used to 
produce stable shRNA expressing cell lines (349, 350) opening the door to the 
production of in vitro cell models of disease. 
Chromosomal DNA alterations 
The most common method of mutating chromosomal DNA to produce disease 
models is the use of a chemical mutagen such as ethylmethanesulfonate. This 
approach introduces random mutations and thus is most applicable to forward 
genetic screens where a specific phenotype is sought. If mutation of a specific gene 
is desired approaches utilising homology directed repair (HDR) or non-homologous 
end joining (NHEJ) are most suitable. 
HDR and NHEJ are DNA repair mechanism with the former utilising a donor 
template (typically the sister chromatid) to repair double-stranded breaks whilst 
the latter simply joins non-homologous ends together following a double-stranded 
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break (351). NHEJ produces frame-shift mutations (insertions or deletions) which 
can lead to loss of protein or the production of a truncated protein. HDR is more 
accurate at restoring the wild-type sequence and can be used to introduce specific 
mutations. zinc-finger nucleases (ZFN) (352, 353), transcription activator-like 
effector nucleases (TALENs) (354-356) and clustered regularly interspaced short 
palindromic repeats/Cas9 (CRISPR/Cas9) (357-360) systems have been developed to 
induce double-stranded breaks at specific DNA locations to utilise NHEJ and HDR 
mechanisms for genetic engineering. Of these methods CRISPR/Cas9 has been 
shown to be the most efficient as well as being the easiest to manipulate (360). 
1.3.2 PCD DISEASE MODELS 
In Vitro Models 
The only cell models for PCD currently described are tissues or cells derived directly 
from patients and animal models. Ciliated cells obtained through brushings or 
biopsies of the airway or brain epithelium can be directly manipulated for 
experimentation e.g. to look at cilia beat frequency (CBF), cilia beat pattern (CBP) 
and cilia ultrastructure. Alternatively, cells can be expanded in culture and 
subsequently differentiated to produce ciliated cells and/or a ciliated 
epithelium (361-363). For recapitulating the airway epithelium culturing on an ALI is 
best as the resulting epithelium displays the variety of cell types found in vivo (i.e. 
basal cells, mucus-producing goblet cells, non-ciliated columnar cells and ciliated 
columnar cells) and so would also display the barriers to gene transfer likely to be 
encountered in vivo. However, a major drawback of using primary cells to model 
PCD is their limited growth and differentiation capacity. Also, given that PCD is rare 
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and the specific gene defects rarer still, obtaining suitable samples for the purposes 
of developing gene therapy treatments is fraught with difficulty.  
In Vivo Models 
A variety of organisms have been used as model systems to study PCD including 
Chlamydomonas, zebrafish and mice. Chlamydomonas are single cell algae that 
have been used as a model organism for the study of flagella formation and 
function for some time due to its speedy life cycle, ease of growth and 
maintenance, existence of well-established protocols for the production and 
isolation of flagella mutants (364) and the sequencing of the Chlamydomonas 
genome (365). Proteomic studies suggest that over 650 proteins make up the ciliary 
axoneme of Chlamydomonas reinhardtii (the most widely used species) with 52% of 
the proteins conserved in humans (366) making findings in Chlamydomonas 
informative on the formation and function of human motile cilia and flagella. 
Indeed mutations in the IC78 dynein intermediate chain gene of Chlamydomonas 
was known to cause a PCD phenotype of immotile flagella with missing ODA (367) 
and this finding led to the identification of the human ortholog of IC78 (DNAI1) as a 
PCD causing gene in humans (120). 
Most genetic studies with Chlamydomonas invoke forward genetic screening 
typically through the use of ultraviolet (UV) radiation to generate random 
mutations followed by selecting for immotile clones when flagella formation and 
function is being assessed (364). Although possible, knockdown of specific genes 
and so reverse genetic studies, is somewhat inefficient and unreliable in 
Chlamydomonas (368, 369). In contrast zebrafish are highly amenable to gene 
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knockdown through the use of anti-sense morpholinos injected into the yolks of 1-8 
cell stage embryos. Given the ease at which zebrafish can be maintained and 
manipulated in large numbers Austin-Tse et al., (102) used a morpholino screen to 
identify C21orf59 and CCDC65 as candidate PCD causing genes which they then 
verified in humans. In zebrafish motile cilia can be found in the olfactory placode, 
pronephric duct and Kupffer’s vesicles with ciliary dyskinesia, kidney cysts, body 
axis curvature, left-right asymmetry defects and hydrocephalus phenotypes used to 
identify ciliopathy mutants. Morpholino use in zebrafish for reverse genetics studies 
have been useful for validating human genetic studies when identifying PCD causing 
genes (103, 113, 370). In addition to gene-targeted morpholinos, random chemical 
mutagenesis has also been used to produce zebrafish PCD models (371). 
Whilst Chlamydomonas and zebrafish offer inexpensive and easy to manipulate in 
vivo systems both are non-mammalian and have no lungs –the organ of most 
interest with regards to human PCD pathology and treatment. To this end, 
mammalian mouse models have been used to complement Chlamydomonas and 
zebrafish models for the study of PCD. The majority of PCD mouse models to date 
have been derived through chemical mutagenesis screens. These screens are 
phenotype driven and those looking for situs abnormalities resulted in the isolation 
of the iv/iv mouse (372), one of the earliest PCD mouse models. The iv/iv mouse 
resulted from a E2271K missense mutation in the lrd gene (now known as 
Dnahc11) (373) with confirmation that Dnahc11 was involved coming in later 
studies where targeted mutations in the gene resulted in iv/iv phenotypes (374). 
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Dnahc11 is the mouse homolog of human DNAH11- a known PCD causing gene (90-
94, 114). 
Further PCD mouse models have been unexpectedly produced following chemical 
mutagenesis and screening for congenital heart disease with a notable one, with 
respect to this thesis, being the Dnahc5 mouse model –the mouse ortholog of 
human DNAH5 (375). This model recapitulated the phenotype observed in patients 
with DNAH5 mutations such as missing ODA, randomised organ situs and 
hydrocephalus. Another Dnahc5 mouse model was produced by Ibañez-Tallon et 
al., (35) whilst utilising an insertional mutagenesis approach attempting to target an 
unrelated gene. The resultant transgenic mice again displayed immotile cilia with 
missing ODA, randomised organ situs and hydrocephalus. However, with the 
exception of the Dnahc11 mouse model (93), PCD mouse models produced by 
targeted deletions or random chemical mutagenesis of ciliary genes usually result in 
severe developmental defects including cardiac abnormalities and severe 
hydrocephalus that causes high levels of neonatal death with most mice surviving 
no more than 2-4 weeks in the case of the Dnahc5 mouse model (375). This severity 
raises animal welfare concerns and makes such models difficult to work with when 
assessing efficacy of airway gene delivery approaches given that mortality results 
from hydrocephalus and cardiac abnormalities. A conditional knockout mouse in 
which Dnaic1 (the mouse homolog of human DNAI1) can be removed following 
administration of tamoxifen is able to ameliorate the lethality observed with non-
conditional PCD knockouts/mutants with conditional knockout mice surviving >11 
months following knockout of Dnaic1 (316). In the case of the Dnaic1 mouse model 
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exons 17 and 18 of Dnaic1 were flanked with loxP sites and homozygous progeny 
were mated with CreER expressing mice -those expressing a tamoxifen-inducible 
Cre recombinase. Administration of tamoxifen to 8-12 week old 
Dnaic1flox/flox/CreER+/- resulted in absent ODA, impaired mucociliary clearance and 
chronic rhinosinusitis. Although the phenotypes took at least 2-3 months to 
manifest the lack hydrocephalus development and a more pronounced respiratory 
pathology makes these mice a better model of human PCD and of greater interest 
for studying respiratory gene therapy approaches for PCD. However it is important 
to note that pulmonary infections were not observed in these mice despite a lack of 
mucociliary clearance and the fact that mice were not housed in pathogen-free 
conditions. This contrasts with human PCD where chronic respiratory infections are 
a major feature. Nevertheless, conditional knockout alleles present the best way of 
producing mouse models of PCD to date and should be applicable to producing 
viable Dnahc5 mouse models without hydrocephalus and severe cardiac 
abnormalities. 
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1.4 SUMMARY AND AIMS 
PCD is a ciliopathy affecting cilia motility. In the airways PCD patients suffer 
significant lung damage resulting from chronic airway infections due to a lack of 
mucociliary clearance. Current treatment options do not address the primary defect 
although proof-of-principle studies have shown that correcting the genetic defect 
restores ciliary function in cases where PCD results from mutations in DNAI1. 
However, the most common cause of PCD is mutation of DNAH5, a gene with a 
14kb ORF and so not amenable to delivery by the viral vectors used to correct 
DNAI1-null cells. Non-viral vectors have been optimised for airway gene delivery 
and are capable of delivering large DNA constructs but suitable and easily accessible 
models for assessing the efficacy of PCD are lacking. 
Moving towards gene therapy for PCD the aims of this thesis are; 
1. To clone wild-type DNAH5 cDNA into mammalian expression systems and 
assess transgene expression. 
2. To assess the potential advantages of minicircle DNA in the context of 
airway gene delivery 
3. To produce an in vitro model of PCD caused by loss of DNAH5. 
4. To attempt gene therapy correction of PCD caused by loss of DNAH5. 
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2. MATERIALS AND METHODS 
2.1. MATERIALS 
Unless stated otherwise tissue culture reagents were supplied by Gibco, Life 
Technologies; general chemicals were supplied by Sigma-Aldrich; restriction 
enzymes were FastDigest brand of restriction enzymes and supplied by Thermo 
Scientific; western blot reagents were supplied by Novex, Life Technologies. 
2.1.1 EQUIPMENT 
Name Supplier 
ABI PRISM 7000 Sequence Detection 
System 
Applied Biosystems, Life Technologies 
Bio-Plex 100 Bio-Rad 
FLUOstar Optima BMG Labtech 
Hitachi H7000 TEM Hitachi 
MotionPro X4 High-speed Motion Camera DEL Imaging Systems 
NanoDrop ND-1000 Spectrophotometer Thermo Scientific 
NanoZoomer Digital Pathology System Hamamatsu Photonics 
Nikon Digital Sight DS-QiMc Nikon 
 Nikon Eclipse Ti-U Inverted Microscope Nikon 
Philips CM120 BioTwin TEM Philips 
Zetasizer Nano ZS Malvern 
2.1.2 KITS AND REAGENTS 
Name Supplier 
10X PCR Buffer Applied Biosystems, Life Technologies 
5X Protein Assay Dye Reagent Bio-Rad 
5X Reporter Lysis Buffer Promega 
6x DNA Loading Dye Thermo Scientific 
BEBM Basal Medium Lonza 
Buffer TE Qiagen 
CellTiter 96 AQueous One Solution Assay Promega 
Cytokine Mouse 10-Plex Panel Novex, Life Technologies 
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Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
dNTP’s Promega 
Eagle’s Minimal Essential Medium (MEM) Sigma-Aldrich 
EndoFree Plasmid Giga Kit Qiagen 
EndoFree Plasmid Maxi Kit Qiagen 
Foetal Bovine Serum (FBS) Sigma-Aldrich 
GENECLEAN SPIN KIT MP Biomedicals 
Glycerol Sigma-Aldrich 
HiFi HotStart DNA Polymerase with dNTPs Kapa Biosystems 
Lysogeny broth (LB) Agar Sigma-Aldrich 
LB Broth Sigma-Aldrich 
Luciferase Assay System Promega 
Magnesium Chloride (MgCl2; 25mM) Applied Biosystems, Life Technologies 
MuLV Reverse Transcriptase Applied Biosystems, Life Technologies 
PicoGreen Invitrogen, Life Technologies 
Pierce ECL Western Blotting Substrate Thermo Scientific 
Plasmid Maxi Kit Qiagen 
Platinum qPCR SuperMix-UDG with ROX Invitrogen, Life Technologies 
PureCol, bovine collagen Nutacon 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
Random Primers Applied Biosystems, Life Technologies 
RNase Inhibitor Applied Biosystems, Life Technologies 
SingleQuot Kit Suppl. & Growth Factors Lonza 
SOC Media Invitrogen, Life Technologies 
T4 DNA Ligase and Buffer Promega 
T4 DNA Polymerase Promega 
Taq ReadyMix Kapa Biosystems 
TOPO XL PCR Cloning Kit Invitrogen, Life Technologies 
TURBO DNA-free Kit Ambion, Life Technologies 
ULS DNA labelling Kit (Cy5) Kreatech 
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2.1.3 E.COLI CELLS 
Strain Supplier Genotype 
Stbl3 Invitrogen,  
Life Technologies 
F– mcrB mrr hsdS20 (rB–, mB–) recA13 supE44 
ara-14 galK2 lacY1 proA2 rpsL20 (StrR ) xyl-5 λ– 
leu mtl-1 
TOP10 Invitrogen,  
Life Technologies 
F– mcrA Δ (mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ (ara leu) 7697 galU 
galK rpsL (StrR) endA1 nupG 
ZYCY10P3S2T System Biosciences Cp8.araE ΔendA bla.lacY A177C 3BAD.I-SceI 
2BAD.ΦC31 4BAD.Φ31 4BAD.Φ31 
2.1.4 EUKARYOTIC CELLS 
Name Growth Media Supplier/Reference 
16HBE14o- MEM with 10% FBS and 2mM L-glutamine Prof. Dieter Gruenert (376) 
HEK293T DMEM with 10% FBS ATCC 
NHBE BEGM or ALI media Lonza 
2.1.5 PLASMIDS 
Name Promoter Transgene Supplier/Reference 
pCI CMV  None, contains MCS Promega 
pCI-Luc CMV  Firefly luciferase  (377) 
pCMV-dR8.74 CMV Gag, pol, rev and tat Prof. Didier Trono 
pCpGfree-LacZ hEF1α, CMV enhancer LacZ Invivogen 
pEGFP-N1 CMV EGFP Clontech 
pGIPZ CMV GFP, PAC and shRNA Open Biosystems 
pGL4.10 None Firefly luciferase Promega 
pHRsincpptSEClaI SFFV GFP Dr. Joao Matelo 
pMC.BESPX.MCS2 None None, contains MCS System Biosciences 
pMD.G2 CMV VSV-G Prof. Didier Trono 
pNL1.3 None Secreted NanoLuc Promega 
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2.1.6 LIPOSOMES AND PEPTIDES 
Name Composition Supplier 
DHDTMA:DOPE 50% DHDTMA and 50% DOPE (molar amounts) Avanti Polar Lipids 
K16E K16GACSERSMNFCG ChinaPeptides Co. 
K8E K8GACSERSMNFCG ChinaPeptides Co. 
R16E R16GACSERSMNFCG ChinaPeptides Co. 
2.1.7 PRIMARY ANTIBODIES 
Name Supplier Catalogue # 
Anit-MUC5AC Invitrogen, Life Technologies 18-2261 
Anti-Acetylated α-tubulin Sigma-Aldrich T6793 
Anti-BMI-1 Invitrogen, Life Technologies 37-5400 
Anti-DNAH5 Sigma-Aldrich HPA037470 
Anti-GAPDH Ambion, Life Technologies AM4300 
Anti-HSP90β Invitrogen, Life Technologies 37-9400 
Anti-MUC5B Dallas Swallow, UCL  (378) 
Anti-Occludin Invitrogen, Life Technologies 71-1500 
Anti-p16INK4 Pharmingen, BD Biosciences 551153 
Anti-p63 Invitrogen, Life Technologies 37-9500 
 
Secondary antibodies for immunofluorescence were anti-IgG antibodies conjugated 
with AlexaFluor dyes (Invitrogen, Life Technoloies). Secondary antibodies for 
Western blots were horseradish peroxidase conjugated (HRP-conjugated) anti-IgG 
antibodies (Dako, Agilent Technologies). AlexaFluor dye conjugated Phalloidin toxin 
(Invitrogen, Life Technoloies) was used to stain filamentous actin (F-actin). 
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2.1.8 RECIPES 
Solution Composition 
2.5% 
Glutaraldehyde 
50mM sodium cacodylate,4mM HCl, 0.02% (w/v) CaCl2 and 2.5% 
(v/v) glutaraldehyde 
6X Crystal Violet 
Loading Dye 
30% (v/v) glycerol, 20mM ethylenediaminetetraacetic acid (EDTA), 
100 µg/mL crystal violet 
ALI media 500 mL contains 50% (v/v) BEBM, 50% (v/v) DMEM, 1x SingleQuot 
Kit Suppl. & Growth Factors. 100 U/mL penicillin, 100 mg/mL 
streptomycin and 1nM retinoic acid (added at each feed) 
Innoue 
Transformation 
Buffer 
10mM PIPES, 15mM CaCl2.2H2O and 55mM MnCl2.4H2O; adjusted to 
pH6.7 
Minicircle 
Induction Media 
LB broth with 0.02% (w/v) L-arabinose and 40mM NaOH 
Super optimal 
broth (SOB) 
2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10mM NaCl, 2.5mM KCl 
and 10mM MgCl2 
Terrific Broth 
(TB) 
12 g/L tryptone, 34 g/L yeast extract, 0.4% (v/v) glycerol, 2.31 g/L 
KH2PO4 and 12.54 g/L K2HPO4 
Tris-acetate-
EDTA buffer 
(TAE) 
4.84 g/L Tris base, 0.114% (v/v) glacial acetic acid and 0.2% (v/v) 
0.5M EDTA at pH8.0 
  
85 
 
2.2. METHODS 
2.2.1. GROWTH AND MAINTENANCE OF E. COLI 
E. coli were streaked or spread on solid LB agar plates and incubated at 37oC 
overnight (15-17 hours). Alternatively, LB broth was inoculated with E. coli and 
incubated overnight at 37oC with shaking at 250rpm in a vessel capable of holding 
at least five times the volume of inoculated LB broth used. LB broth or solid LB agar 
containing 100µg/mL or 50µg/mL of ampicillin or kanamycin respectively was used 
for antibiotic selection where appropriate. 
2.2.2. LONG TERM STORAGE OF E. COLI 
A single colony of E. coli, grown overnight at 37oC on solid LB agar plates, was 
inoculated into 5mL of LB broth and grown overnight at 37oC with shaking at 
250rpm. 650µL of this culture was added to a cryovial with 150µL of sterile 80% 
(v/v) glycerol, mixed well and stored at -80oC. 
2.2.3. PRODUCTION OF CHEMICALLY COMPETENT E. COLI 
The Inoue method (379) was used to produce chemically competent E. coli. A single 
colony of Stbl3, TOP10 or ZYCY10P3S2T strains of E. coli was used to inoculate 25mL 
of SOB media and incubated for 8 hours at 37oC with shaking at 250rpm. This 
culture was then used to inoculate 250mL of SOB and incubated at room 
temperature with shaking at 200rpm to an OD600 of 0.5-0.6. The culture was then 
chilled in an ice-water bath for 10 minutes and centrifuged at 2500 x g for 10 
minutes at 4oC. The cells were gently re-suspended in 80mL of ice-cold Inoue 
transformation buffer and then centrifuged at 2500 x g for 10 minutes at 4oC. The 
cells were gently re-suspended in 20mL of ice-cold Inoue transformation buffer, 
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1.5mL of dimethyl sulfoxide (DMSO) was added and gently mixed by swirling and 
cells kept in an ice-water bath whilst 50µL aliquots, suitable for single use, were 
dispensed into 1.5mL microfuge tubes, snap frozen in liquid nitrogen and stored at -
80oC. 
2.2.4. TRANSFORMATION OF CHEMICALLY COMPETENT E. COLI 
50µL aliquots of chemically competent E. coli were thawed on ice for 5 minutes. 1-
100ng of DNA in a maximum volume of 5µL was added to competent E.coli and 
incubated on ice for 30 minutes. The cells were then heat shocked by incubation at 
42oC for 45 seconds and then immediately placed on ice for 2 minutes. 250µL of 
super optimal broth with catabolite repression (SOC) media was added to the cells 
and incubated for 1 hour at 37oC with shaking at 250rpm. The culture was then 
spread on a solid LB agar plate with an appropriate antibiotic and incubated 
overnight at 37oC. 
2.2.5. PLASMID DNA EXTRACTION 
Transformed E. coli were grown on solid LB agar plates with an appropriate 
antibiotic and incubated overnight at 37oC. A single colony was inoculated into 5mL 
of LB broth with an appropriate antibiotic and incubated overnight at 37oC with 
shaking at 250rpm. Plasmid DNA was extracted by an alkaline lysis method and 
purified using the QIAPrep Spin Miniprep kit (≤20µg plasmid DNA). This uses a 
chaotropic salt solution to reversibly bind DNA to a silica-gel membrane and DNA is 
then eluted in low-salt conditions. If larger quantities of plasmid DNA were required 
the 5mL LB broth culture was used to inoculate larger volumes of LB broth and 
plasmid DNA extracted using Plasmid Maxi kit (≤500µg plasmid DNA). For 
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preparation of endotoxin-free plasmid DNA EndoFree Plasmid Maxi kit (≤500µg 
plasmid DNA) or EndoFree Plasmid Giga kit (≤10mg plasmid DNA) was used. These 
utilise an anion-exchange system using a silica-based resin with a high density of 
diethylaminoethyl groups which reversibly binds DNA over a wide range of salt 
concentrations allowing efficient removal of impurities. DNA is then eluted with a 
high-salt buffer and alcohol precipitation then performed to purify and concentrate 
the DNA. Plasmid DNA concentration was quantified by measuring the OD260 using a 
NanoDrop ND-1000 spectrophotometer and the 260/280 ratio was used to assess 
purity of the extracted DNA with a ratio of 1.8-2.0 considered sufficiently pure for 
use in further experiments. 
2.2.6. MINICIRCLE DNA EXTRACTION 
Transformed ZYCY10P3S2T E. coli strain containing a minicircle producer plasmid 
was grown on solid LB agar plates with 50µg/mL kanamycin and incubated 
overnight at 37oC. A single colony was inoculated into 5mL of LB broth with 
50µg/mL kanamycin and incubated for 8 hours at 37oC with shaking at 250rpm. 
100µL of this starter culture was used to inoculate 400mL of TB broth and 
incubated with 50µg/mL kanamycin at 37oC with shaking at 250rpm to an OD600 of 
4-6. 400mL of minicircle induction media was added to the culture and incubated at 
30oC with shaking at 250rpm for 6h. Minicircle DNA extraction and purification from 
E.coli was then performed as for plasmid DNA. Minicircle DNA concentration was 
quantified by measuring the OD260 using a NanoDrop ND-1000 spectrophotometer 
with the same criteria of purity used for plasmid DNA (method 2.2.5). 
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2.2.7. TOTAL RNA EXTRACTION 
Harvested cells were pelleted at 378 x g for 5 minutes and total RNA was extracted 
using RNeasy Minit Kit. This uses a chaotropic guanidine-thiocyanate containing 
buffer together with ethanol to bind RNA to reversibly bind RNA to a silica-based 
membrane and RNA is then eluted in low-salt conditions with RNase-free water. 
RNA concentration was quantified by measuring the OD260 using a NanoDrop ND-
1000 spectrophotometer and the 260/280 ratio was used to assess purity of the 
extracted DNA with a ratio of 1.9-2.1 considered sufficiently pure for use in further 
experiments. Potential DNA contaminants were removed by DNase digestion using 
TURBO DNase. 
2.2.8. REVERSE TRANSCRIPTION 
Up to 2µg of DNase digested purified total RNA was added to 0.8µL of a 
deoxyribonucleotide triphosphate (dNTP) mix containing 25mM of each dNTP, 2µL 
of 50µM random hexamers and topped up to 12µL with DNase/RNase-free water. 
This mix was incubated at 70oC for 10 minutes and placed on ice. A reverse 
transcription enzyme mix consisting of 2µL GeneAmp PCR Gold Buffer, 4µL 25mM 
MgCl2, 1µL 50U/µL murine leukemia virus (MuLV) reverse transcriptase and 1µL 
20U/µL RNase Inhibitor was added and the mix incubated for 1 hour at 42oC 
followed by 85oC for 5 minutes. For no RT controls MuLV reverse transcriptase was 
replaced with DNase/RNase-free water. 
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2.2.9. RESTRICTION ENZYME DIGEST 
DNA was digested with appropriate restriction endonucleases using the appropriate 
reaction buffer and at the appropriate reaction temperature as per the 
manufacturer’s instructions. 
2.2.10. FILLING OF 5’ SINGLE STRANDED DNA OVERHANGS 
5’ overhangs following restriction enzyme digest of 1-4µg of plasmid DNA were 
filled using the large Klenow fragment of DNA Polymerase I (1U/µg of DNA) in 1x 
DNA Polymerase I buffer (supplied by the manufacturer) and 40µM each of 
deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), 
deoxyguanosine triphosphate (dGTP) and deoxythymidine triphosphate (dTTP). This 
reaction mixture was incubated at room temperature for 10 minutes and the 
reaction stopped by incubation for a further 10 minutes at 75oC. 
2.2.11. REMOVAL OF 3’ SINGLE STRANDED DNA OVERHANGS 
3’ overhangs following restriction enzyme digest of 1-4µg of plasmid DNA were 
removed using the large Klenow fragment of DNA Polymerase I (1U/µg of DNA) in 
1x DNA Polymerase I buffer (supplied by the manufacturer) with no dNTPs. This 
reaction mixture was incubated at room temperature for 10 minutes and the 
reaction stopped by incubation for a further 10 minutes at 75oC. 
2.2.12. POLYMERASE CHAIN REACTION (PCR) 
PCR was performed in a total volume of 25µL using 1-100ng of template DNA, 
0.4µM each of forward and reverse primers and 12.5µL of 2X Taq ReadyMix with 
dye (a pre-prepared mixture which at 1X contains 1U Taq polymerase, Tris-HCl, KCl, 
0.2mM each dNTP, 1.5mM MgCl2 and two inert tracking dyes enabling direct 
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loading of PCR products onto agarose gels). The PCR cycling conditions were 95oC 
for 3 minutes followed by 30-35 cycles of 95oC for 30 seconds, primer Tm -5
oC for 30 
seconds and 72oC for 1 minute/kb which was followed by a final extension step of 
72oC for 1 minute/kb. 
2.2.13. HIGH FIDELITY PCR 
PCR was performed in a total volume of 50µL using 100ng template DNA, 0.3µM 
each of forward and reverse primers, 0.3mM dNTP mix, 10µL of 5X PCR Buffer 
containing 2mM MgCl2 (HiFi Fidelity Buffer) and 1U of a proofreading DNA 
polymerase (HiFi HotStart DNA Polymerase). The PCR cycling conditions were 95oC 
for 3 minutes followed by 20 cycles of 98oC for 20 seconds, 65oC for 15 seconds and 
72oC for 1 minute/kb which was followed by a final extension step of 72oC for 1 
minute/kb. 
2.2.14. QUANTITATIVE REVERSE TRANSCRIPTION PCR (qRT-PCR) 
10-100ng of cDNA was mixed in a 25µL reaction with 12.5µL of Platinum 
Quantitative PCR SuperMix-UDG w/ROX (a 2X master-mix which at 1X contains hot-
start Taq DNA polymerase, Tris-HCl, KCl, 3mM MgCl2, 200µM each of dGTP, dATP 
and dCTP, 400µM deoxyuridine Triphosphate (dUTP), uracil DNA glycosylase and 
1µM ROX reference dye) and 1.25µL TaqMan Gene Expression Assay primer/probe 
set and real-time quantitative PCR performed using an ABI PRISM 7000 Sequence 
Detection System. The PCR reaction cycles used were 50oC for 2 minutes, 95oC for 
10 minutes, 40 cycles of 95oC for 15 seconds and 60OC for 1 minute. Fluorescence 
data was collected at the end of each 60oC reaction and relative expression levels 
calculated using the delta-delta Ct (2- ΔΔCt) method (380). 
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2.2.15. ETHIDIUM BROMIDE AGAROSE GEL ELECTROPHORESIS 
0.5-2% (w/v) of agarose was dissolved in TAE buffer by heating, allowed to cool to 
around 50oC and 1µg/mL ethidium bromide added. The solution was then poured 
into an appropriately sized casting tray and allowed to set at room temperature. 6X 
DNA loading dye was added to DNA samples to a final concentration of 1X and the 
DNA fragments separated by electrophoresis in TAE at 80-120V for 60-90 minutes. 
DNA bands were visualised by exposure of the gel to UV light using the UVIdoc 
system. 
2.2.16. CRYSTAL VIOLET AGAROSE GEL ELECTROPHORESIS 
0.5-2% (w/v) of agarose was dissolved in TAE buffer by heating, allowed to cool to 
around 50oC and 1.6µg/mL crystal violet added. The solution was then poured into 
an appropriately sized casting tray and allowed to set at room temperature. 6X 
crystal violet loading dye was added to DNA samples to a final concentration of 1X 
and the DNA fragments separated by electrophoresis in TAE at 80-120V for 60-90 
minutes. DNA bands could be seen under visible light. 
2.2.17. PURIFICATION OF DNA FRAGMENTS (<10KB) 
DNA fragments following PCR, restriction enzyme digestion, 5’ overhang filling and 
3’ overhang removal reactions that were not subsequently separated by gel 
electrophoresis were purified with using the QIAquick PCR Purification kit. DNA 
fragments separated by gel electrophoresis were excised using a scalpel and 
purified using the QIAquick Gel Extraction kit. Both kits use a chaotropic salt 
solution to reversibly bind DNA to a silica-gel membrane and DNA is then eluted in 
low-salt conditions. 
92 
 
2.2.18. PURIFICATION OF DNA FRAGMENTS (≥10KB) 
DNA fragments following PCR, restriction enzyme digestion, 5’ overhang filling and 
3’ overhang removal reactions and fragments excised following crystal violet gel 
electrophoresis were purified using the GENECLEAN SPIN kit. This uses a chaotropic 
salt solution to reversibly bind DNA to silica beads and DNA is then eluted in low-
salt conditions. 
2.2.19. LIGATION OF DNA FRAGMENTS 
25-100ng of plasmid backbone was ligated with an insert using T4 DNA ligase and 
T4 DNA ligase buffer in a final volume of 20µL. Ligation reactions were performed at 
16oC for 18 hours. Ligations where the fragments were flanked with compatible 
overhangs (sticky ends) were performed at a backbone: insert ratio of 1:4. Ligations 
where the fragments were flanked with no overhangs (blunt ends), or one sticky 
and one blunt end, were performed at a backbone: insert ratio of 1:6. 
Subsequently, 5µL of ligation product was transformed into competent E. coli. 
2.2.20. TOPO CLONING 
Single 3’ A overhangs were added to gel purified PCR products, from high fidelity 
PCR, by incubation of PCR products at 72oC for 30 minutes with 1U Taq DNA 
Polymerase, Standard Taq Buffer (10mM Tris-HCL, 50mM KCl and 1.5mM MgCl2) 
and 0.2mM dATP. PCR products were then purified from the reaction solution and 
cloned into a pCR2.1-TOPO TA vector (fragments <3kb) or pCR-XL-TOPO vector 
(fragments ≥3kb) by incubation for 5-30 minutes at 22oC of 4µL purified DNA 
product, 1µL salt solution (1.2M NaCl and 0.06M MgCl2) and 1µL TOPO vector. 2-
5µL of the reaction solution was the used to transform chemically competent E.coli 
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and plasmid extracted from the resultant colonies was sequenced by the UCL DNA 
Sequencing Service to verify the fidelity of the PCR reaction. 
2.2.21. SITE-DIRECTED MUTAGENESIS 
For single base pair mutagenesis mutagenic primers were designed using the 
QuickChange Primer Design Program 
(http://www.genomics.agilent.com/primerDesignProgram.jsp) and mutagenesis 
performed using QuickChange II XL Site-Directed Mutagenesis kit. 
For multiple base-pair mutagenesis mutagenic primers were designed using the 
QuickChange Primer Design Program and the mutagenic primers were used in a 
high fidelity PCR reaction with 10ng of plasmid DNA as template. A 10µL aliquot of 
the PCR product was electrophoresed on an ethidium bromide agarose gel to verify 
the success of the PCR reaction. The remaining PCR product was purified and used 
in a sequence and ligation-independent cloning reaction (381) to obtain a 
circularised and mutated plasmid that was transformed into chemically competent 
E. coli. DNA sequencing was performed by the UCL DNA Sequencing Service to 
verify the success of site-directed mutagenesis. 
2.2.22. SEQUENCE- AND LIGATION-INDEPENDENT CLONING (SLIC) 
PCR products flanked with a 15-20bp sequence homologous to the ends of the PCR 
product (for multi base pair site-directed mutagenesis) or the ends of a restriction 
enzyme linearized plasmid backbone were purified and single-strand 5’ overhangs 
were generated using the 3’-5’ exonuclease activity of T4 DNA Polymerase in 20µL 
“chew-back” reactions containing 1µg of linearized backbone or PCR product, 0.5U 
T4 DNA Polymerase and 2µL of 10X T4 DNA Ligase Buffer (300mM Tris-HCl (pH 7.8 
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at 25°C), 100mM MgCl2, 100mM DTT and 10mM ATP) and incubated for 30 minutes 
at room temperature after which 2µL of 10mM dCTP was added to halt the 
exonuclease activity of T4 DNA Polymerase and the mixture placed on ice. An 
assembly reaction consisting of 100ng of chewed-back linearized backbone added 
to an equimolar amount of chewed-back PCR product insert and topped up to 15µL 
with 1X T4 DNA Ligase Buffer was incubated at 37oC for 30 minutes and then placed 
on ice. For multi base pair site-directed mutagenesis the assembly reaction 
consisted of 100ng of chewed-back PCR amplified plasmid in 1X T4 DNA Ligase 
Buffer to a final volume of 15µL. 5µL of the assembly reaction was transformed into 
chemically competent E. coli and plasmid extracted from the resultant colonies was 
sequenced by the UCL DNA Sequencing Service to verify the fidelity of the PCR 
reaction. 
2.2.23. COLLAGEN COATING 
Tissue culture plates, flasks and transwells were coated for at least 1 hour at room 
temperature with 1% (v/v) of a 3mg/mL bovine collagen solution (PureCol; 95% 
Type I and ~5% Type III collagen) in phosphate buffered saline (PBS), then washed 
once with 0.22µM filter sterilized distilled water and either seeded with cells 
immediately or allowed to air-dry overnight in a sterile hood and stored at room 
temperature until use. 
2.2.24. SUBMERGED CELL CULTURE 
16HBE14o- cells are an SV40 Large T-Antigen transformed human bronchial 
epithelial cell line derived by Dr Dieter Gruenert (376). 16HBE14o- cells were 
cultured in Minimum Essential Media (MEM) based growth media. HEK293T cells 
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were cultured in Dulbecco's Modified Eagle Medium (DMEM) based growth media. 
Primary normal human bronchial epithelial (NHBE) and nasal epithelial cells and 
BMI-1 transduced NHBE cells were grown on collagen-coated plastic in bronchial 
epithelial growth media (BEGM). All cells were grown at 37oC and 5% CO2. 
Transduction was completed by adding concentrated BMI-1 coding VSV-G 
pseudotyped lentivirus to NHBE cells in submerged culture. Concentrated BMI-1 
coding lentivirus was provided by Dr Tristan McKay. 
2.2.25. ALI CULTURE 
NHBE cells in BEGM were seeded onto collagen-coated Transwell Permeable 
Supports (0.4µm pore size, polyester membrane) at a seeding density of 900,000 
cells/cm2 and BEGM was added to the basolateral compartment and the cells 
incubated at 37oC and 5% CO2 for 48 hours. The apical and basolateral fluid was 
then removed and ALI media added to the basolateral compartment. The cells were 
then incubated at 37oC and 5% CO2 with apical fluid being removed and the ALI 
media from the basolateral compartment replaced every 2-3 days. 
2.2.26. LONG TERM STORAGE OF EUKARYOTIC CELLS 
1-4 x106 cells were pelleted by centrifugation at 378 x g for 5 minutes and re-
suspended in 1mL freezing medium (90% FBS and 10% DMSO) and incubated 
overnight at -80oC in a Mr Frosty Freezing container filled with isopropanol to allow 
slow freezing. Cells were then transferred to liquid nitrogen. 
Frozen cells were revived by quick thawing in a 37oC water-bath and the cells 
transferred to 10mL of pre-warmed complete growth media. The cells were 
pelleted at 378 x g for 5 minutes to remove the DMSO and re-suspended in 15mL 
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complete growth media, placed into a 75cm2 tissue culture flask and incubated at 
37oC and 5% CO2. 
2.2.27. PREPARATION OF NANOCOMPLEXES 
All complexes were prepared in water, OptiMEM or Buffer TE (10mM Tris.Cl pH 8.0 
and 1mM EDTA). LPD complexes were prepared at a 0.75:4:1 weight ratio of 
liposome:pepide:DNA with the liposome and peptide components being mixed 
together first then the DNA component being added and mixed well. PD complexes 
were prepared at a 4:1 weight ratio of peptide:DNA, LD (0.75:1) complexes were 
prepared at a 0.75:1 weight ratio of liposome:DNA and LD (4:1) complexes were 
prepared at a 4:1 weight ratio of liposome:DNA. Following addition of the different 
components all formulations were incubated at room temperature for 30 minutes 
to allow self-assembly of nanocomplexes. Complexes were typically prepared to a 
DNA concentration of 10ng/µL or 333.3ng/µL for in vitro and in vivo applications 
respectively. An example of a LPD formulation for in vitro and in vivo use is given in 
Appendix A. 
2.2.28. TRANSFECTION OF SUBMERGED CULTURES 
Cells were seeded so as to reach 70-80% confluency following 24 hours at 37oC and 
5% CO2. For experiments where luciferase activity would be assessed cells were 
seeded in black plates with clear bottoms. The following day complexes were 
prepared in OptiMEM and the desired amount of DNA formed in complexes was 
added to cells in complete growth media. Cells were then incubated at 37oC and 5% 
CO2 for varying amounts of time depending on the assay to be performed.  
97 
 
2.2.29. TRANSFECTION OF ALI CULTURES 
Once well ciliated (>4 weeks at ALI) the apical surface of cells were washed twice 
with bronchial epithelial basal media (BEBM). Varying amounts of DNA formulated 
into LPD complexes in OptiMEM were added to the apical, basolateral or both 
compartments and incubated at 37oC and 5% CO2 for 2 hours. Complexes were then 
aspirated from the cells and ALI media added to the basolateral compartment. Cells 
were then incubated at 37oC and 5% CO2 for varying amounts of time depending on 
the assay to be performed. 
2.2.30. TRANSFECTION OF CELLS IN SUSPENSION (REVERSE TRANSFECTION) 
LPD complexes were prepared in OptiMEM at varying concentrations of DNA and 
cells then detached from flasks using Trypsin-EDTA which was subsequently diluted 
in PBS to significantly slow Trypsin activity. Cells were then centrifuged at 378 x g 
for 5 minutes and the solution aspirated. After 30 minutes of incubation to allow 
self-assembly complexes were added to cells and incubated at room temperature 
for 30 minutes after which the cells were again centrifuged at 378 x g, complexes 
aspirated, cells re-suspended in complete media, seeded onto plates and/or 
transwells and incubated at 37oC and 5% CO2. 
2.2.31. IN VIVO TRANSFECTIONS 
Complexes were prepared in water and 50µL of complexes delivered via the 
oropharyngeal route to CD1 mice. Mice were anaesthetised with gaseous isoflurane 
and nostrils pinched closed using tweezers so as to ensure that breathing takes 
place through the mouth. Whilst the nostrils were held closed 50µL of complex 
solution was pipetted to the rear of the oral cavity and gripping of the nostrils 
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maintained until all the solution had been inhaled. This oropharyngeal route of 
delivery is less invasive than intratracheal instillation that provides direct 
application of vector to the lung. Oropharyngeal delivery is also preferred to 
nebulisation as it uses less material and allows more control over dosage. 
2.2.32. LUCIFERASE ASSAY FOR IN VITRO TRANSFECTIONS 
Cells were washed with 1x PBS 24 hours following transfection and lysed with 20 µL 
1X Reporter Lysis Buffer for 20 minutes at 4oC then -80oC for at least 30 minutes 
followed by thawing at room temperature. Luciferase activity was assessed using 
the Luciferase Assay System and luminescence detected with a FLUOstar Optima 
plate reader. The results were standardised for protein content using the Bradford 
protein assay and expressed as relative luminescence units per milligram of protein 
(RLU/mg of protein). 
2.2.33. LUCIFERASE ASSAY FOR IN VIVO TRANSFECTIONS 
At least 24 hours following transfection mice were euthanized with 100µL of 
pentobarbital sodium (Euthatal) administered intraperitoneally. The chest cavity 
was exposed post-mortem and the heart perfused with 5mL of PBS after-which the 
lungs were dissected and stored at -80oC for a minimum of 24 hours. Lungs were 
weighed, placed in 2mL tubes containing 1.4mm ceramic beads and 4µL of Reporter 
Gene Assay Lysis Buffer added per milligram of tissue. The mixture was then frozen 
at -80oC for 20 minutes, left to thaw at room temperature for 10 minutes and then 
placed on ice for a further 10 minutes. Tissue homogenisation was then performed 
using a Percellys 24 tissue homogeniser at a 3D motion speed of 5700rpm for 30 
seconds which was performed twice with a 30 second delay between the two steps. 
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Samples were then centrifuged at 14,196 x g for 10 minutes at 4oC to pellet the 
ceramic beads and tissue debris. The supernatant was transferred into autoclaved 
microfuge tubes and assayed for luciferase activity using the Luciferase Assay 
System and luminescence detected with a FLUOstar Optima plate reader. The 
results were standardised for protein content using the Bradford protein assay and 
expressed as RLU/mg of protein. 
2.2.34. BRADFORD PROTEIN ASSAY 
Following luciferase assay 20µL of cell lysate-luciferase assay system solution was 
added to 180µL Bio-Rad Protein Assay Reagent in new clear 96-well plates and 
incubated at room temperature for 10 minutes. Absorbance at 590nm was then 
read using a FLUOstar Optima plate reader and the protein content of the cell 
lysate was calculated using a standard curve generated with known concentrations 
of bovine serum albumin (BSA).  
For in vivo samples supernatant obtained following tissue homogenisation was 
diluted 100X in water and 20µL mixed with 180µL Bio-Rad Protein Assay Reagent 
with later steps performed as for in vitro samples. 
2.2.35. BALF COLLECTION AND LUMINEX ASSAY 
24 hours following transfection mice were euthanized with 100µL of pentobarbital 
sodium (Euthatal) administered intraperitoneally. The chest cavity was exposed 
post-mortem, the trachea cannulated and the lungs lavaged ten times with 500µL 
of ice-cold PBS (total of 5mL PBS). Each aliquot of PBS was instilled slowly over 15 
seconds and incubated in situ for 30 seconds prior to gentle removal over 15 
seconds. The lavage fluid was kept on ice throughout and, upon completion, 
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centrifuged at 300 x g for 5 minutes at 4°C. The presence of inflammatory cytokines 
in BALF was assessed and quantified using the Cytokine Mouse 10-Plex Panel 
(Invitrogen) following the manufacturer’s instructions. This is a multiplexed 
fluorescence based assay where specific antibodies are conjugated to dyed beads 
with differing intensities so allowing the detection of a number of different analytes 
from a single sample. Plates were read using a Bio-Plex 100 reader (Bio-Rad) and 
results analysed with Bio-Plex Manager software (v 4.1.1; Bio-Rad) 
2.2.36. HISTOLOGY 
24 hours following transfection mice were euthanized with 100µL of pentobarbital 
sodium (Euthatal) administered intraperitoneally. The chest cavity was exposed 
post-mortem and inflation-fixed by intratracheal instillation of 4% (w/v) 
paraformaldehyde in PBS at a pressure of 20 cm 4% paraformaldehyde. The lungs 
were then dissected and immersed in fixative overnight at 4oC and then immersed 
in a 15% (w/v) sucrose solution in PBS overnight at 4oC. The tissue was then 
dehydrated in alcohol and embedded in paraffin wax. 5µm thick sections were cut 
and dried onto microscope slides. Samples were then de-waxed, rehydrated, 
stained with haematoxylin, counter-stained with eosin, dehydrated and cleared 
using a Tissue-Tek DRS 2000 multiple slide stainer (Sakura). Briefly, de-waxing was 
performed by immersing the slides in xylene twice for 3 minutes. Samples were 
then rehydrated in graded alcohol by immersing twice for 2 minutes in 100% 
ethanol followed by &0% ethanol for 2 minutes, 30% ethanol for two minutes and 
dH2O for 1 minute. Tissues were haematoxylin stained for 5 minutes before being 
rinsed with tap water for 20 seconds, decoloured in acid alcohol (2% HCl in alcohol) 
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for 6 seconds, rinsed again with tap water for 2.5 minutes, counterstained with 
eosin for 4 minutes and rinsed a final time with tap water for 15 seconds. Stained 
samples were then dehydrated in graded alcohol by immersing in 70% ethanol for 
30 seconds followed by 100% ethanol once for 45 seconds and again for 30 
seconds. The tissue was cleared by immersing in xylene twice for 2 minutes and 
mounted. Images were then taken using a NanoZoomer Digital Pathology System 
(Hamamatsu Photonics) and processed with NDP.scan software (v2.3; Hamamatsu 
Photonics).  
2.2.37. FLOW CYTOMETRY 
Cells grown on 96-well plates were detached using 50 µL Trypsin-EDTA and re-
suspended with 150 µL PBS. Cells were then acquired with a BD FACSArray flow 
cytometer and analysis was performed with FlowJo software v. 8.8.3. Cells grown in 
larger plates or flasks were detached using an appropriate volume of trypsin and re-
suspended in PBS. Cells were transferred to 5mL FACS tubes and cells acquired 
using CyAn ADP Analyser and analysis was performed with FlowJo software v. 8.8.3. 
2.2.38. CELL VIABILITY ASSAY 
24 hours following transfection in 96-well plate’s cell viability was assessed using 
the CellTiter 96 Aqueous One Solution Assay. Following transfection complete 
media was aspirated and replaced with 100µL of fresh complete media and 20µL 
CellTiter 96 Aqueous One Solution. The cells were then incubated at 37oC and 5% 
CO2 for 2 hours and absorbance at 490nm was then read using a FLUOstar Optima 
plate reader. Absorbance values of background corrected treated cells were 
normalised to values for untreated cells -set as 100% viable cells.  
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2.2.39. TRANSMISSION ELECTRON MICROSCOPY (TEM) FOR COMPLEXES 
Complexes were prepared in water at a DNA concentration of 333ng/µL and a 5 µL 
aliquot was applied onto a 300-mesh copper grid coated with a Formvar carbon 
support film (Agar Scientific) then, after a few seconds, dried by blotting with filter 
paper. The sample was then negatively stained with 1% (w/v) uranyl acetate for a 
few seconds, before blotting with filter paper and air dried. Imaging was carried out 
with a Philips CM120 BioTwin Transmission Electron Microscope and operated at an 
accelerating voltage of 120 kV. 
Processing of complexes for TEM was performed by Dr. Aristides Tagalakis and 
imaging by Mr. David McCarthy. 
2.2.40. TEM FOR CILIA ULTRASTRUCTURE 
Ciliated cells cultured at an ALI were scraped and cells washed off with 200µL 
warmed BEBM. Cells were fixed by addition of 2mL of 2.5% glutaraldehyde and 
stored at 4oC for at least 24 hours prior to further processing by the PCD diagnostic 
service team at the Royal Brompton & Harefield NHS Foundation Trust, UK. 
Glutaraldehyde Fixed samples were centrifuged at 378 x g for 5 minutes, post-fixed 
in 1% (w/v) osmium tetroxide and incubated for 1 hour at room temperature. After 
incubation the samples were centrifuged at 378 x g for 5 minutes, washed with 
distilled water, centrifuged at 378 x g for another 5 minutes and embedded in 2% 
(w/v) agar. Next the sample was dehydrated by incubating 2x 20 minutes in 70%, 
90% and 100% methanol at room temperature. The sample was then infiltrated 
with Araldite to provide blocks suitable for ultra-thin section cutting. This 
infiltration was done by first incubating, at room temperature, the dehydrated 
103 
 
samples for 2 x 30 minutes in propylene oxide, 20 minutes in a 1:1 mixture of 
propylene oxide and Araldite, 30 minutes in a 1:4 mixture of propylene oxide and 
Araldite and then 2x 3 hours in Araldite at 30oC. Samples were then hardened by 
baking for 72 hours at 60oC. Once cooled survey sections of around 1μm thickness 
were stained with 1% (w/v) toluidine blue for a few seconds and examined by light 
microscopy to select the area with the most cilia cut transversely. Ultra-thin 
sections of this area (~80–100nm thick) were stained with 2% (w/v) uranyl acetate 
in methanol for 5 minutes followed by lead citrate for 2 minutes. Cilia were then 
viewed with a Hitachi H7000 transmission electron microscope. Assessment of cilia 
ultrastructure was undertaken blinded by Dr Amelia Shoemark who is part of the 
PCD diagnostic service team at the Royal Brompton & Harefield NHS Foundation 
Trust, UK. 
2.2.41. HYDRODYNAMIC SIZE AND ZETA POTENTIAL MEASUREMENTS 
Complexes were prepared in water and diluted in 1mL dH2O to a final 
concentration of 5µg/mL DNA and then analysed for hydrodynamic size and zeta 
potential using a Malvern Nano ZS. Liposome alone and a liposome-peptide mixture 
(LP; liposome: peptide ratio of 1:5.3) were also diluted in 1mL dH2O to a final 
concentration of 5µg/mL of liposome before being analysed as above. The data was 
collected and processed by the manufacturer’s software, DTS version 5.03. 
2.2.42. GEL RETARDATION ASSAY 
Complexes were prepared in water and either left untreated or treated with 
20U/mL heparan sulphate for 1 hour at room temperature. 250ng of plasmid DNA 
complexed into particles (or plasmid DNA alone as a control) were loaded onto a 
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1% agarose gel, made in TAE buffer and stained with 1µg/mL ethidium bromide and 
electrophoresed at a voltage of 100 V for 1 hour with TAE as the running buffer.  
2.2.43. PICOGREEN FLUORESCENCE ASSAY 
Plasmid DNA was mixed with 0.67% (v/v) PicoGreen reagent in TE buffer and 
incubated for 5 minutes at room temperature. The stained plasmid DNA was 
formulated into complexes at a DNA concentration of 10ng/µL in TE buffer. Varying 
concentrations of heparan sulphate (0-10 U/mL) diluted in TE buffer were mixed 
with the complexes and incubated for 1 hour at room temperature and 
fluorescence analysed at excitation and emission wavelengths of 485nm and 520nm 
respectively using the FLUOstar Optima plate reader. Values were collected as 
relative fluorescence units (RFU) and these were normalised to naked plasmid DNA 
stained with PicoGreen and treated with the varying concentrations of heparan 
sulphate. 
2.2.44. LENTIVIRUS PRODUCTION 
1.5 x107 HEK293T cells were seeded in 175cm2 flasks so as to reach 70-80% 
confluency following 24 hours at 37oC and 5% CO2. For each flask 40µL of vector 
plasmid (containing the gene/shRNA to be integrated into target cells), 30µL of 
pCMV-dR8.74 plasmid (containing gag, pol, rev and tat elements from HIV-1) and 
10µL of pMD.G2 plasmid (containing VSV-G) were added to 5mL OptiMEM and 
filtered through a 0.22µm filter. Separately 1µL of 10mM PEI was added to 5mL 
OptiMEM and filtered through a 0.22µm filter and the two solutions thoroughly 
mixed and incubated for 20 minutes at room temperature to allow complex 
formation. Cells were then washed with OptiMEM and incubated with the 
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complexes for 4 hours at 37oC and 5% CO2. The complexes were then removed and 
replaced with pre-warmed complete media. Lentivirus was harvested at 48 and 72 
hours following transfection. The virus containing supernatant was centrifuged at 
2,688 x g for 10 minutes, filtered through a 0.22µm filter and centrifuged at 98,000 
x g for 2 hours to pellet lentiviral particles. Viral pellets were re-suspended in PBS, 
incubated on ice for 1 hour, centrifuged at 1,344 x g and aliquots stored at -80oC.  
2.2.45. LENTIVIRUS TITRATION (FLOW CYTOMETRY METHOD) 
All lentivirus titrations were performed with HEK293T cells. 50,000 cells were 
seeded per well of a 12 well plate and incubated overnight to allow cell adherence. 
The following morning 30µL of lentivirus preparation was diluted 1:50 into 1,470µL 
of complete media. A 10-fold dilution series was prepared to a final dilution of 
1:5,000,000. Complete media was then aspirated from HEK293T cells, replaced with 
diluted virus, the cells incubated for 72 hours at 37oC and 5% CO2 and green 
fluorescent protein (GFP) expression assayed by flow cytometry. The dilution at 
which 5-30% of cells were GFP positive was used to calculate virus titre. Above this 
range the probability that each GFP positive cell was transduced twice significantly 
increases thereby risking an underestimation of the true virus titre (382). The 
formula used to calculate virus titre, expressed in Transducing units per millilitre 
(TU/mL), was; 
    ⁄  
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2.2.46. WESTERN BLOTTING 
Pelleted cells were lysed with Cell Extraction Buffer Protein content of cell lysate 
was assessed using the Pierce BCA Protein Assay Kit 20-50µg of cell lysate was then 
mixed with an appropriate volume of NuPage LDS Sample Buffer and boiled at 90oC 
for 15 minutes. Samples were then loaded onto NuPage Novex 4-12% Bis-Tris Gels 
(protein of interest <160kDa) or NuPage Novex 3-8% Tris-Acetate Gels (protein of 
interest >160kDa) with an appropriate protein ladder used (SeeBluePlus2 Pre-
Stained Standard for 4-12% gels and HiMark Pre-Stained Protein Standard for 3-8% 
gels). Samples were electrophoresed through the gel at 175V for 1-2 hours with 1X 
NuPage MES SDS Running Buffer for Bis-Tris gels and 1X NuPage Tris-Acetate SDS 
Running Buffer for Tris-Acetate gels. Protein was transferred onto an Immobilon-P 
polyvinylidene fluoride (PVDF) membrane using an X-Cell II Blot Module at 25V for 
2-4 hours and a solution of 1x NuPage Transfer Buffer and 20% methanol was used 
as the transfer buffer. The membrane was then blocked with 4% (w/v) BSA in PBST 
(PBS with 0.05% (v/v) Tween-20) for 1 hour at room temperature. The membrane 
was then washed with PBST thrice for 5 minutes at room temperature and primary 
antibody, diluted in 1% (w/v) BSA in PBST, added and incubated with the 
membrane at 4oC overnight. The membrane was then washed with PBST thrice for 
5 minutes at room temperature and HRP-conjugated secondary antibody, diluted in 
1% (w/v) BSA in PBST, added and incubated with the membrane for 1 hour at room 
temperature. The membrane was then washed with PBST thrice for 5 minutes at 
room temperature and bands visualised by using the Pierce ECL Western Blotting 
Substrate and UVIchemi chemiluminescence imaging system. 
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2.2.47. IMMUNOFLUORESCENCE STAINING AND CONFOCAL MICROSCOPY 
Cells were fixed with 4% PFA for 10 minutes at room temperature and washed 
thrice with PBS. Cells were permeabilised by incubating with PBS-Triton (PBS 0.1% 
(v/v) Triton-X100) for 10 minutes at room temperature and then washed thrice for 
5 minutes with PBS. Cells were then blocked with 4% (w/v) BSA in PBS-Triton for 1 
hour at room temperature and washed thrice for 5 minutes with PBS before 
incubation at room temperature for 2 hours with primary antibody diluted in 1% 
(w/v) BSA in PBS-Triton and where stated with 4',6-diamidino-2-phenylindole (DAPI; 
0.5µg/mL) and/or Alex Fluor conjugated Phalloidin (4U/mL) also included. Cells 
were then washed thrice for 5 minutes with PBS and incubated for 1 hour at room 
temperature with Alexa Fluor conjugated secondary antibodies diluted in 1% (w/v) 
BSA in PBS-Triton. Cells were then washed thrice for 5 minutes with PBS and rinsed 
once with dH2O then mounted onto microscope slides with VECTASHIELD Mounting 
Medium and No. 0 coverslips. Images were then obtained using an Inverted Zeiss 
LSM 710 Confocal microscope with the appropriate excitation lasers selected for 
the dyes used.  
2.2.48. HIGH-SPEED VIDEO MICROSCOPY 
High-speed video was recorded using a MotionPro X4 high-speed motion camera 
attached to a Nikon Eclipse Ti-U inverted microscope built with an environmental 
chamber. Videos were recorded at a frame rate of 500fps using Motion Studio 
software (IDT Vision, v2.11) with cells maintained at 37oC. Cilia beat-frequency was 
assessed using CiliaFA software (383). 
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Whilst on transwells cells grown at an ALI were washed twice apically with 100µL 
BEBM and incubated at 37oC and 5% CO2 for 30 minutes to allow the cells to 
equilibrate before video recording was started.  
Cells were also scraped off transwells using a metal spatula and suspended in 300µL 
of BEBM by washing the scraped transwells twice with 150µL BEBM. 100µL of this 
suspension was dropped onto a microscope slide, a cover-slip placed on top of the 
cells and high-speed videos recorded.  
2.2.49. FLUORESCENCE MICROSCOPY 
Bright-field and fluorescence images were captured with a Nikon Digital Sight DS-
QiMC video camera attached to a Nikon Eclipse Ti-U inverted microscope. Videos 
and images were processed using NIS Elements AR software (Nikon, v4.00.12). 
2.2.50. STATISTICS 
Parametric tests; Student’s t-test was used when comparing two groups whilst one-
way analysis of variance analysis (ANOVA) followed by Bonferroni post-test analysis 
was used when comparing three or more groups. Where ANOVA showed that 
significant differences existed between the study groups but Bonferroni post-test 
analysis was unable to identify which means significantly differed then Tukey’s 
post-test analyses was used. Non-parametric tests were used when normal 
distribution could not be assumed (animal studies). Kruskal-Wallis test followed by 
Dunn’s post-test analysis was used when comparing three or more groups. Fisher’s 
exact test was used when analysing contingency tables. Differences were 
considered significant when p<0.05. Where means or medians are displayed n 
values were three or more.  
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3. LPD OPTIMISATION AND CHARACTERISATION 
3.1. INTRODUCTION 
Gene therapy targeted to the airway epithelium has been an objective for CF 
researchers for over two decades and a number of vectors have been developed in 
order to achieve efficient gene transfer. The ideal vector needs to be efficient in 
vivo, non-immunogenic given the potential need for repeated delivery, capable of 
withstanding nebulisation, simple to manufacture in large quantities and, to be 
suitable for PCD gene therapy, particularly when focussing on correcting DNAH5 
mutations, a large packaging capacity is required.  
The Hart laboratory has developed a variety of synthetic receptor-targeted 
lipopolyplex vectors for gene delivery. These vectors contain lipid and peptide 
components that self-assemble into nanocomplexes upon mixing with DNA. An 
LED-1 vector (287) (hereafter referred to as LPD) was shown to give efficient in vivo 
transfection targeted to the airway epithelium, retained transfection activity 
following nebulisation and repeated delivery, targeted the tracheal and bronchial 
epithelium as opposed to the lower airways and transfected ciliated cells (287, 289, 
290) making the vector a good candidate for use in PCD gene therapy. The LPD 
vector is formulated with a liposome (L), made up of DHDTMA (1-Propanaminium, 
N,N,N-trimethyl-2,3-bis (11Z-hexadecenyloxy)-iodide ) and DOPE lipids, a dual 
functioning DNA-condensing and receptor-targeted peptide (P), with the sequence 
K16GACSERSMNFCG (K16E) and DNA (D) formulated at an L:P:D weight ratio of 
0.75:4:1.  
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Lipopolyplexes that combine both liposomes and polymers have gained popularity 
due in large part to the higher transfection efficiencies observed when compared to 
their respective liposome-DNA or polymer-DNA (lipoplexes and polyplexes 
respectively) counterparts (384-388) though whether this holds true for the LPD 
nanocomplex described above has not been investigated nor have the biophysical 
properties for this nanocomplex been assessed in detail. 
3.2. AIMS 
In this chapter the peptide component of the LPD vector was optimised and its 
ability to transfect primary airway epithelial cells was assessed as well as its ability 
to transfect the DNAH5 transgene in mammalian cells. The biophysical properties of 
the LPD vector was also investigated and related to the transfection capabilities of 
the LPD lipopolyplex. 
3.3. RESULTS 
3.3.1. VECTOR OPTIMISATION 
Tagalakis et al., (287) had previously optimised the liposome component of the LPD 
vector whilst the optimal targeting sequence for airway epithelial cells was found to 
be SERSMNF following phage display studies (288). This peptide sequence showed 
close homology to parts of the receptor targeting proteins of rhinovirus- a 
respiratory pathogen (288). However the effect on transfection efficiency of 
altering the lysine-based DNA binding domain of the targeting peptide had not 
previously been assessed.  
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Gene delivery vectors must balance the need for efficient DNA condensation, which 
help protect the DNA, with intracellular release of DNA so that it escapes 
degradation in lysosomes and is available to the transcription machinery. Both 
arginine and lysine-containing peptides have been used in vector complexes and 
these amino acids are also utilised in natural systems for DNA condensing. 
Protamines, proteins that condense DNA in sperm heads, are rich in arginine whilst 
histones, proteins that condense DNA in somatic cells, use both lysine and arginine 
for DNA condensation. Both amino acids have been shown to condense DNA 
differently with lysine-based peptides less able to densely pack DNA than arginine-
based peptides (389, 390). Although efficient DNA condensation is important in the 
formation of small nanoparticles for gene delivery, very strong packaging of DNA 
can lead to inefficient intracellular release of DNA and so inefficient gene 
expression downstream. Poor transfection efficiencies were achieved as a result 
with long poly-L-lysine polymers (180 residues) over shorter ones (19-36 residues) 
because the former had a lower tendency to dissociate from bound DNA (391). 
In comparing polyplexes formulated using either lysine or arginine peptides of 
varying lengths (K9, R9, K12, R12, K16, R16) Mann et al., (390) showed that 
condensation of plasmid DNA was different for lysine and arginine-based polyplexes 
and the types of particles formed, including linear rods or spheres, was dependent 
on both length and chemical composition of the peptides. Polyplexes formed from 
arginine-based peptides were superior with regards to transfection efficiency to 
those formed from lysine-based peptides and 16-mer peptides showed higher 
levels of transgene expression than 12- and 9-mer peptides. The superiority of 
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polyplexes formed from arginine-based peptides was down to greater intracellular 
release of plasmid DNA whilst poor cellular uptake and plasmid DNA release 
hampered the transfection efficiency of polyplexes based on short 9-mer and 12-
mer peptides (390).  
3.3.1.1.  Optimising peptide component of LPD vector 
Given the superiority of arginine homopeptides in polyplexes the effect of altering 
the DNA binding domain of the K16E peptide (K16) on transfection efficiency of LPD 
lipopolyplexes was determined. Whilst retaining the targeting sequence, the DNA 
binding domain was altered to assess if shorter strings of lysine residues (K8E) or the 
use of arginine (R16E) in place of lysine could enhance the transfection efficiency of 
LPD vectors. Use of 8 lysine residues instead of 16 in the DNA binding domain 
resulted in a significant drop in luciferase expression with activity falling from 
2.32±0.14x108 RLU/mg of protein with K16E to 4.50±0.16x10
7 RLU/mg of protein 
with K8E (Figure 3.1; p<0.001; one-way ANOVA with Bonferroni post-test analysis). 
There was a smaller fall in transfection efficiency when R16E was used instead of 
K16E with luciferase activity falling to 1.36±0.14x10
8 (Figure 3.1; p<0.001; one-way 
ANOVA with Bonferroni post-test analysis). Given the data the K16E peptide was 
considered optimal and therefore used in further experiments. 
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Figure 3.1. Optimising peptide component of LPD vector 
Luciferase transfections of 16HBE14o- cells using LPD complexes formulated with 
K16E, R16E and K8E targeting peptides. ***P<0.001; one-way ANOVA with Bonferroni 
post-test analysis used to assess significance. Values are background subtracted 
and displayed as mean ±SEM. 
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3.3.1.2. Synergy in transfection with LPD lipopolyplex 
The LPD lipopolyplex contains three components making it more complex than 
binary peptide-DNA or liposome-DNA complexes. Being simpler to formulate the 
binary complexes are potentially more attractive if they displayed similar or greater 
levels of transgene expression than the LPD complex. However, lipopolyplexes have 
previously displayed a synergistic increase in transfection efficiency compared to 
their lipoplex and polyplex counterparts (384-388) and whether this finding held 
true with the LPD lipopolyplex was assessed. Transfected luciferase activity using 
the LPD complex was 3.5-fold higher than that achieved with the LD (4:1) complex - 
an optimised-for-transfection lipoplex (Figure 3.2; p<0.001; one-way ANOVA with 
Bonferroni post-test analysis), 15.9-fold greater than the LD (0.75:1) complex 
(Figure 3.2; p<0.001; one-way ANOVA with Bonferroni post-test analysis) and 
1030.5-fold higher than with the PD complex (Figure 3.2; p<0.001; one-way ANOVA 
with Bonferroni post-test analysis). Moreover, LD (4:1) complexes, but not LD 
(0.75:1) complexes, gave significantly higher levels of luciferase activity than PD 
complexes (Figure 3.2; p<0.001; one-way ANOVA with Bonferroni post-test 
analysis). Therefore, the ternary combination of liposome, peptide and DNA in LPD 
complexes gave greater transgene expression compared to binary PD and LD 
complexes (Figure 3.2). Moreover having the liposome and peptide together 
provided a synergistic and not simply and additive increase in transgene expression 
as observed in other studies (384-388). 
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Figure 3.2. Synergy in transfection efficiency of LPD vector 
Luciferase transfections of 16HBE14o- cells comparing transfection efficiency of 
ternary LPD complexes with binary LD and PD formulations. ***P<0.001; one-way 
ANOVA with Bonferroni post-test analysis used to assess significance. Values are 
background subtracted and displayed as mean ±SEM. 
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3.3.1.3. LPD vs L2K 
To place the transfection capabilities of the LPD vector into perspective it was 
compared to the commercial reagent Lipofectamine 2000 (L2K). 16HBE14o- cells 
were transfected with either pEGFP-N1, to assess the percentage of cells each 
reagent would transfect, or pCILuc, to assess the level of transgene activity. L2K, at 
all the ratios tested, transfected a higher percentage of cells (Figure 3.3a; p<0.001; 
one-way ANOVA with Bonferroni post-test analysis) although luciferase activity was 
highest in the cells transfected with LPD (Figure 3.3b; p<0.05; one-way ANOVA with 
Bonferroni post-test analysis). Also, cells transfected with L2K showed a lower 
percentage of viable cells and so greater cell toxicity than the LPD particles (Figure 
3.3c; p<0.001; one-way ANOVA with Bonferroni post-test analysis). This toxicity was 
also apparent under light microscopy (Figure 3.3d). Cells transfected with the LPD 
particles showed no observable difference to the OptiMEM control with both 
showing cells in a compact cobblestone appearance. In contrast, cells transfected 
using L2K were predominantly spherical at all the three different ratios used. 
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Figure 3.3. Transfections of 16HBE14o- cells using LPD and L2K 
Following transfections with either LPD or L2K formulations cells were assayed for 
(a) the percentage of cells transfected, (b) luciferase transgene activity and (c and 
d) cell viability. *P<0.05; ***P<0.001; one-way ANOVA with Bonferroni post-test 
analysis used to assess significance. Scale bars are 100µm. Values are background 
subtracted and displayed as mean ±SEM. 
d 
OptiMEM LPD 
L2K (2:1) L2K (3:1) 
L2K (4:1) 
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Cell lines are generally easier to transfect than primary cells (392) most likely due to 
differences in endocytosis, cell metabolism, cell division and the numbers and types 
of receptors present on the cell surface. The ability of the LPD nanocomplex to 
transfect primary human airway epithelial cells, the target for PCD gene therapy, 
has not been previously assessed and was investigated here in transfection 
experiments with basal cells obtained from nasal brushings of healthy volunteers 
(V1-V4). Transfection efficiency of the LPD nanocomplex was again compared to 
L2K (4:1) which was found to be optimal for transfection of human nasal airway 
epithelial cells. The mean percentage of cells transfected varied between the 
volunteers and ranged from 21-23% with the LPD particles and from 13-21% when 
using L2K (Figure 3.4a). The percentage of transfected cells was significantly higher 
when using the LPD particles on cells from volunteers 2 and 3 (V2 and V3 
respectively; p<0.01; Student’s t-test). In all instances luciferase activity was 
significantly higher when using the LPD particles (Figure 3.4b; p<0.01; Student’s t-
test), even in volunteers 1 and 4 (V1 and V4 respectively) where there was no 
significant difference in the percentage of cells transfected. However, the LPD 
particles were more toxic to the primary cells than L2K (Figure 3.4c; p<0.001; 
Student’s t-test). 
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Figure 3.4. Transfection of nasal epithelial cells using LPD and L2K 
Following transfection of nasal epithelial cells with either LPD or L2K formulations 
cells were assayed for (a) the percentage of cells transfected, (b) luciferase 
transgene activity and (c) cell viability. **P<0.15; ***P<0.001; Student’s t-test used 
to assess significance. Values are background subtracted and displayed as mean 
±SEM. 
a 
b 
c 
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3.3.2. VECTOR CHARACTERISATION 
Whilst it was shown that the LPD vector provides efficient gene delivery to airway 
epithelial cells, the functional significance of the three different components in the 
formation and function of the LPD vector has not been previously assessed. 
Detailed structural and functional studies were performed to answer these 
questions in an attempt to better understand why the LPD lipopolyplex displayed a 
synergistic enhancement in transfection when compared to binary LD and PD 
complexes (Figure 3.2). It was anticipated that this information will help in the 
rational design of more efficient vector systems. 
3.3.2.1. Cellular uptake of Cy5-labelled plasmid DNA 
One of the first steps in the process of transfection and an important barrier to 
transfection is vector binding and uptake. Differences in uptake could explain the 
differences in transgene expression seen when comparing LPD, PD and LD 
complexes (Figure 3.2). To address this, 16HBE14o- cells were transfected for 6 
hours with Cy5-labelled pCI-Luc plasmid using LPD, PD and LD complexes. Cellular 
uptake of Cy5-labelled plasmid was then assessed using flow cytometry. With LD 
(0.75:1) complexes 2.5 ±0.1% of cells showed uptake of plasmid DNA compared to 
25.2 ±0.9% with LD (4:1) complexes (Figure 3.5a; p<0.001; one-way ANOVA with 
Bonferroni post-test analysis). In both cases LD complexes showed significantly 
lower levels of plasmid uptake when compared to PD and LPD complexes that 
showed uptake of plasmid in 50.5 ±5.0% and 53.4 ±3.1% of cells respectively (Figure 
3.5a; p<0.001; one-way ANOVA with Bonferroni post-test analysis). There were no 
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significant differences between PD and LPD complexes with regards to the 
percentage of cells that had taken up the Cy5 labelled plasmid.  
Next, the mean fluorescence intensity (MFI) of Cy5 labelled plasmid was assessed to 
determine if there were any differences in the number of plasmid molecules taken 
up by transfected cells which may help explain the differences in transgene 
expression. There was no significant difference in MFI when comparing the two LD 
complexes (MFI of 56.7 ±4.8 and 126.8 ±3.1 for LD (0.75:1) and LD (4:1), 
respectively; Figure 3.5b). LD complexes showed a significantly lower MFI when 
compared to LPD and PD complexes which gave MFI levels of 1080 ±33.2 and 1472 
±54.2, respectively (Figure 3.5b; p<0.001; one-way ANOVA with Bonferroni post-
test analysis). Whilst there was no significant difference between LPD and PD 
complexes in regards to percentage of transfected cells (Figure 3.5a), the latter did 
show significantly higher levels of Cy5 labelled plasmid within each transfected cell 
so suggesting greater plasmid uptake with PD complexes (Figure 3.5b; p<0.001; 
one-way ANOVA with Bonferroni post-test analysis).  
Confocal microscopy images of transfected cells corroborated the flow cytometry 
findings and showed that uptake of Cy5 labelled plasmid was greatest when cells 
were transfected with PD and LPD complexes and lowest when using the LD 
(0.75:1) complex (Figure 3.5c). In order to explain the differences in vector and 
plasmid uptake the biophysical properties of the different vectors was assessed.   
124 
 
 
 
 
  
a 
b 
125 
 
 
 
  
c 
LPD 
LD (0.75:1) LD (4:1) 
PD 
OptiMEM 
Figure 3.5. Cellular uptake of LPD, LD and PD complexes 
16HBE14o- cells were transfected with Cy5-labelled pCI-Luc complexed into LPD, LD 
and PD complexes and flow cytometry used to assess the (a) percentage of Cy5 
positive cells and (b) their MFI. (c) Laser scanning confocal microscopy was used to 
assess uptake of Cy5-labelled pCI-Luc (magenta). Nuclear (blue) and F-actin staining 
(green) was used to show cell boundaries. NS, not significant; ***P<0.001; one-way 
ANOVA with Bonferroni post-test analysis used to assess significance. Scale bars are 
15µm. Values are background subtracted and displayed as mean ±SEM. 
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3.3.2.2. Morphology, size and charge characterisation  
The morphology, size and zeta potential of gene delivery vectors influences cellular 
uptake of the vectors and potentially transfection efficiency. Given the differences 
observed in cellular uptake of plasmid DNA the morphology, size and zeta potential 
of LPD, PD and LD complexes was assessed to see if differences in these properties 
could explain the differences observed in the cellular uptake studies described 
above. 
TEM revealed that the LPD complexes formed a heterogeneous population of 
roughly spherical particles with sizes around 100-200 nm in diameter (Figure 3.6a). 
PD complexes were also roughly spherical though particle sizes were smaller with 
the majority falling within 30-60 nm in diameter and a few particles with sizes of 
around 100 nm (Figure 3.6b). In contrast to LPD and PD complexes LD mixtures 
appeared as aggregated material (Figure 3.6c and d). At both the 0.75:1 and 4:1 
liposome: DNA ratios multi-lamellar structures were observed (Figure 3.6c and d) 
while at the 4:1 weight ratio more rounded particles were apparent (Figure 3.6d).  
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Figure 3.6. Morphology of LPD, LD and PD complexes 
TEM micrographs of (a) LPD, (b) PD, (c) LD (0.75:1) and (d) LD (4:1) complexes. Scale 
bars are 500nm. 
a b 
c d 
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The average hydrodynamic size of particles, also known as the z-average size, was 
obtained using dynamic light scattering (DLS). DLS involves the use of a laser beam 
illuminating a sample and the intensity of the scattered light being detected and its 
decay measured over time. The decay in intensity of scattered light is related to the 
size of the particles which can be calculated using the Stokes-Einstein 
equation (393). It is important to note that the hydrodynamic diameter obtained 
using this method is the hydrodynamic diameter of a sphere that diffuses at the 
same speed as the particle being measured. 
Zeta potential refers to the potential difference between the dispersion media and 
the fluid layer surrounding and electrically interacting with the dispersed particles. 
As such, the zeta potential describes the electrokinetic potential of a particle in a 
given solution and is related to the surface charge of the particle. To obtain the zeta 
potential an electric field is applied to particles in solution and their velocity 
measured to give the electrophoretic mobility of the particles (394). Zeta potential 
is then calculated from the electrophoretic mobility. 
DLS (Table 3.1) of the four described complexes showed that the mean 
hydrodynamic size of the PD complexes was smallest at 44.6 ± 0.1 nm, followed by 
LPD at 58.0 ± 0.2 nm, LD (0.75:1) at 116.1 ± 1.1 nm and 280.3 ± 1.0 nm for LD at the 
4:1 ratio. Zeta potential measurements (Table 3.1) for these particles were found to 
be +67.2 ± 2.1 mV, +32.5 ± 0.5 mV and +31.0 ± 0.6 mV for LPD, LD (4:1) and PD 
complexes, respectively. When formulated at the lower ratio of 0.75:1 LD 
complexes showed a negative zeta potential of -20.8 ± 0.2 mV suggesting that the 
DNA was not neutralized or condensed at all. The liposome used in this study had a 
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smaller hydrodynamic size, at 82.1 ± 1.1nm, than both LD complexes, as well as a 
higher zeta potential at +60.1 ± 0.9 mV. A mixture of liposome and peptide (LP) 
showed a similar hydrodynamic size to liposome alone (Table 3.1) suggesting no 
interaction between liposome and peptide. A higher zeta potential for the LP 
mixture compared to liposome alone was also observed (Table 3.1) and was likely 
due to the charge contribution from the cationic peptide. However, it was not 
possible to obtain a zeta potential value for the peptide alone so the charge 
contribution from the peptide could not be determined. 
 
Table 3.1. Hydrodynamic size and zeta potential of LPD, LD and PD complexes 
Nanocomplex Hydrodynamic size (nm) Zeta potential (mV) 
LPD 58.0 ± 0.2 +67.2 ± 2.1mV 
LD (0.75:1) 116.1 ± 1.1 -20.8 ± 0.2mV 
LD (4:1) 280.3 ± 1.0 +32.5 ± 0.5mV 
PD 44.6 ± 0.1 +31.0 ± 0.6mV 
yt 
 
Liposome 82.1 ± 1.1 +60.1 ± 0.9mV 
LP 86.6 ± 0.5 +74.9 ± 1.7 mV 
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3.3.2.3. DNA condensation and packaging properties of LPD, PD and LD 
complexes 
Differences in the morphology, size and zeta potential of LPD, PD and LD complexes 
indicate differences in DNA condensation and packaging so the DNA packaging and 
release properties of the different complexes were assessed using the gel 
retardation assay and the fluorescence quenching assay which utilise ethidium 
bromide and PicoGreen respectively. Nanocomplexes are too large to travel 
through the pores of a 1% agarose gel so mobility of DNA, when condensed and 
packaged into nanocomplexes, is retarded and this can be observed by 
electrophoresing complexed DNA alongside naked DNA on an ethidium bromide 
stained agarose gel. Ethidium bromide and PicoGreen fluorescence can also be used 
to assess DNA condensation and packaging of DNA as these compounds upon 
intercalating with DNA have an intensified fluorescence profile that can be detected 
and measured. Well condensed and packaged DNA molecules become inaccessible 
to ethidium bromide and PicoGreen resulting in quenching of fluorescence. In 
addition to packaging, DNA release can be assessed by using a highly anionic 
species, such as heparan sulphate, that will compete with DNA to interact with 
cationic species within nanocomplexes thereby releasing the DNA.  
The gel retardation assay was used to assess mobility and condensation of plasmid 
DNA complexed into LD, PD and LPD complexes (Figure 3.7a). There was no 
difference in DNA mobility between untreated and heparan sulphate treated naked 
plasmid DNA when run on an agarose gel showing that heparan sulphate itself does 
not retard plasmid mobility. At the liposome/DNA ratio used in the LPD complexes 
(0.75:1) some smearing of plasmid DNA was observed but a significant amount of 
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plasmid was not retarded indicating that at this low ratio there was little 
condensation of the plasmid. In contrast, LD complexes formulated at a 4:1 ratio 
completely retarded mobility of the plasmid DNA which was retained in the wells 
with strong ethidium bromide staining. It is important to note that complete 
dissociation of the LD (4:1) complexes could not be achieved even with 20 U/mL 
heparan sulphate with the majority of the DNA remaining within the wells. 
However, the intensity of the ethidium bromide staining of plasmid DNA increased 
suggesting that the heparan sulphate exposed the plasmid DNA, but was unable to 
effectively induce dissociation of the LD complex. 
LPD and PD complexes also showed retarded plasmid mobility but with greater 
ethidium bromide exclusion than the LD (4:1) complexes as suggested by the faint 
staining in the wells compared to the LD (4:1) complexes. In contrast to the LD (4:1) 
complexes, heparan sulphate treatment liberated plasmid DNA from LPD and PD 
samples indicating that organisation and packaging of plasmid DNA is similar in LPD 
and PD complexes and dissimilar in LPD and LD (4:1) complexes. Taken together the 
data indicated that LPD and PD complexes condensed and packaged plasmid DNA 
more efficiently than LD complexes.  
The observed differences in plasmid DNA condensation were further supported by 
quenching experiments using the PicoGreen assay (Figure 3.7b). When normalised 
to free plasmid, 30.5±1.2% of PicoGreen labelled plasmid was quenched in LD (4:1) 
complexes which contrasted with the 73.5±0.1% and 75.9±0.04% quenching of 
fluorescence seen when using LPD and PD complexes respectively. LD complexes 
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formulated at a 0.75:1 liposome: DNA ratio did not show noticeable quenching of 
PicoGreen labelled plasmid.  
The addition of varying amounts of heparan sulphate to all four complexes revealed 
that LD (4:1) complexes were very sensitive to the lowest heparan sulphate 
concentration used in this study with the RFU values, expressed as a percentage 
relative to free DNA, having increased from 69.5±1.2% in the absence of heparan 
sulphate to 76.1±0.3% in the presence of 0.1 U/mL heparan sulphate. In contrast, 
LPD and PD complexes were more stable to heparan sulphate challenge and only 
showed a significant increase in fluorescence with the addition of 0.5 U/mL or more 
of heparan sulphate. At a heparan sulphate concentration of 5 U/mL the RFU values 
of the complexes followed the order of LD (0.75:1) >LD (4:1) > LPD > PD, with the 
values being 100.6 ±0.5%, 96.3 ±0.7%, 77.8 ±0.1% and 72.1 ±0.2% RFU, respectively. 
The difference in the amount of quenching of plasmid DNA with LPD and PD 
complexes was 2.4% in the absence of heparan sulphate (73.5% of fluorescence 
quenched for LPD and 75.9% for PD; Figure 3.7b; p<0.001; Student’s t-test) which 
increased to 5.7% in the presence of 5 U/mL heparan sulphate (22.2% of 
fluorescence quenched for LPD and 27.9% for PD; Figure 3.7b; p<0.001; Student’s t-
test), with PD complexes showing greater quenching in both cases. Intracellular 
release of plasmid DNA may therefore be more efficient with the LPD complexes 
than with the PD complexes.  
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Figure 3.7. DNA packaging and release with LPD, LD and PD complexes 
 (a) Gel shift assay showing 250ng naked pCI-Luc, LD (0.75:1), LD (4:1), PD and LPD 
complexes incubated for 1 hour at room temperature in the presence or absence 
of 20U/mL heparan sulphate. (b) PicoGreen fluorescence quenching was used to 
assess the stability of the different complexes to heparan sulphate challenge as 
well as assess the quenching capabilities of the different complexes in the absence 
of heparan sulphate. The level of PicoGreen fluorescence was measured as RFU 
with naked PicoGreen labelled pCI-Luc plasmid set as 100% RFU. Values are mean 
±SEM. 
a 
Heparan sulphate      -      +      -       +      -      +      -      +       -     + 
b 
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3.3.2.4. Endosomal escape 
Differences in the biophyisical properties between LPD, PD and LD complexes could 
help explain the differences in vector uptake described above (Figure 3.5a-c) and 
the differences in uptake of plasmid DNA could also explain differences in 
transgene expression when comparing LPD and LD complexes. However, it was 
clear that LPD and PD complexes had similar biophysical properties and displayed 
similar uptake levels, yet the differences in transgene expression were substantial. 
As such, an explanation for this disparity must lie in the vectors abilities to 
overcome intracellular barriers to gene transfer. 
For efficient transgene expression it is vital that complexes taken up into the cell 
are able to escape the endosome to avoid degradation later in lysosomes. The 
DOPE lipid used to produce the liposomes utilised in the LPD and LD complexes has 
been shown to aid in endosomal escape by fusing with the lipid bilayer of the 
endosome. Hypothesising that the major difference between the LPD and PD 
complexes was that the latter had no mechanism by which to avoid lysosomal 
degradation the DOPE lipid in DHDTMA:DOPE liposome (LE) was replaced with the 
non-fusogenic DOPC lipid (1,2-Dioleoyl-sn -glycero-3-phosphocholine) to form 
DHDTMA:DOPC liposomes (Lc). These were then used to formulate LPD and LD 
complexes, along with PD complexes and transgene expression assessed following 
luciferase gene transfection. 
When using LE liposome the same trend in transfection efficiency seen previously 
(Figure 3.2) was observed again with transgene expression being greatest with 
LEPD> LED (4:1)> LED (0.75:1)= PD (Figure 3.8). When the Lc liposome was used 
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transfection with LcPD and LcD complexes were not better than transfections with 
PD complexes so highlighting i) the importance of the DOPE lipid in the functionality 
of the LPD and LD complexes and ii) that endosomal escape is the main barrier to 
efficient transgene expression with PD complexes.  
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Figure 3.8. Function of DOPE lipid in LPD and LD complexes 
16HBE14o- cells were transfected with pCI-Luc formulated into LPD, LD and PD 
complexes. Either the DHDTMA:DOPE (LE) or DHDTMA:DOPC (LC) liposomes were 
used in the formation of LPD and LD complexes. ***P<0.001; one-way ANOVA with 
Bonferroni post-test analysis used to assess significance. Values are background 
subtracted and displayed as mean ±SEM. 
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3.3.3. DNAH5 CLONING AND CHARACTERISATION 
To assess gene therapy for PCD caused by DNAH5 mutations the wild-type gene 
must first be cloned. The DNAH5 cDNA was cloned from ciliated NHBE cells grown 
at an ALI. The strategy used (Figure 3.9) involved cloning of the DNAH5 cDNA as 
three overlapping segments which were TOPO cloned into pCR-XL-TOPO plasmid. 
The primers used to clone the overlapping fragments were; 
5’ Fragment 
Forward Primer; 5’ – CTACAGGTACCATGTTTAGGATTGGGAGGA– 3’ 
Reverse Primer; 5’ – GCAGGGCATAAGATTCCTCAATAGGTCCTACTTG– 3’ 
Middle Fragment 
Forward Primer; 5’ – CCTGGATGGTTGTCATTGGACGCCACTG– 3’ 
Reverse Primer; 5’ – CCTGAGGAGTACGAATGACACGAGAGATCTTGAC– 3’ 
3’ Fragment 
Forward Primer; 5’ – GATCTTTCTCGGGTCTGGCAGGGAATGCTG– 3’ 
Reverse Primer; 5’ – CCCACGTCGACTTACTTGACATCACACAGAAGG– 3’ 
DNAH5 cDNA was flanked with KpnI and SalI sites (bold; Figure 3.9; grey and yellow 
bars respectively) whilst naturally occurring AfeI and SexAI sites (Figure 3.9; green 
and orange bars respectively) were utilised to allow reconstruction of the full-
length DNAH5 cDNA in later steps. Sequencing of three segments revealed several 
mutations which deviated from the expected DNAH5 cDNA sequence (NCBI 
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Reference Sequence: NM_001369.2). The majority of these were either silent 
mutations or known single nucleotide polymorphisms (SNP’s) that do not cause 
disease. However, two missense mutations were also found which were of concern 
as their effects on the DNAH5 protein, if any, were unknown. These were corrected 
using site-directed mutagenesis and the three segments then reconstructed into 
the full-length DNAH5 cDNA in the pMK-Polylinker plasmid which was designed to 
contain a KpnI-AfeI-SexAI-SalI cloning cassette. The full-length DNAH5 cDNA was 
then cloned into the mammalian expression plasmid pCI using KpnI and SalI to 
produce the plasmid pCI.DNAH5.  
  
139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
AAAAAAA 
Figure 3.9. pCI.DNAH5 cloning strategy.  
(a) NHBE cells were grown at an ALI to induce ciliogenesis and (b) DNAH5 mRNA 
isolated and (c) reverse transcribed and three overlapping sections amplified by 
PCR and (d) sub-cloned into the pCI expression plasmid after assembly in cloning 
plasmids. 
a 
b 
c 
d 
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To determine if the cloned DNAH5 cDNA provided expression of wild-type DNAH5 
mRNA and protein the human embryonic kidney cell line HEK293T was transfected 
with pCI.DNAH5 using the LPD nanocomplex with DNAH5 mRNA and protein 
expression assessed using reverse transcription-PCR (RT-PCR), immunofluorescence 
and Western blot. DNAH5 mRNA was not detected in untransfected cells whilst a 
637bp region of the DNAH5 mRNA was amplified using cDNA obtained by extracting 
total RNA from pCI.DNAH5 transfected cells (Figure 3.10a). A lack of potential 
plasmid or genomic DNA contamination was demonstrated in PCR reactions where 
no reverse transcriptase was added to the cDNA reaction. GAPDH was also 
amplified in the same reaction as an internal control using primers designed to 
produce a 447bp product so allowing separation of DNAH5 derived and GAPDH 
derived PCR products. At the protein level immunostaining with an anti-DNAH5 
antibody was positive only in pCI.DNAH5 transfected cells (Figure 3.10b). The 
Western blot technique was used to assess if the protein expressed from the 
pCI.DNAH5 plasmid was of the correct size and so confirming its identity as DNAH5. 
To this end 250µg of total protein was run on a 3-8% tris-acetate gel and protein 
transferred to a PVDF membrane as described in material and methods. An anti-
DNAH5 antibody was then used to blot for the DNAH5 protein and a protein greater 
than 460kDa in size (estimated weight for DNAH5 is 529kDa) was only detectable in 
transfected pCI.DNAH5 transfected cells. A number of other non-specific bands, 
most likely due to the amount of protein loaded, were seen in both untransfected 
and transfected cells. The data thus confirmed that the cloned DNAH5 cDNA in 
pCI.DNAH5 gave wild-type DNAH5 mRNA and protein expression.   
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Figure 3.10. Transfection of large plasmid using LPD 
Following transfection of HEK293T cells with pCI.DNAH5 (a) total RNA was 
extracted and RT-PCR performed to assess DNAH5 expression at the mRNA level. 
(b) Immunostaining and (c) a Western blot was performed to assess DNAH5 
protein expression. Scale bars are 10µm. 
DNAH5 
HSP90β 
460kDa 
a 
OptiMEM  pCI.DNAH5 
Reverse Transcriptase       +           -           +         - 
DNAH5 
GAPDH 
b 
OptiMEM 
pCI.DNAH5 
DNAH5 DAPI Merge 
c 
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Plasmid size has been shown to affect transfection efficiency (395) so to enable 
quantification of the percentage of cells transfected with the pCI.DNAH5 plasmid an 
enhanced green fluorescent protein (eGFP)-DNAH5 fusion construct was produced. 
The eGFP cDNA from pEGFP-N1 plasmid was amplified by PCR using the primers; 
Forward Primer; 5’ –GAGAATTCACGCGTGGTACCGCCACCATGGTGAGCAAG– 3’ 
Reverse Primer; 5’ –CTCCCAATCCTAAACATGTGATGCTTGTACAGCTCGTCCATGCC– 3’ 
The 5’ ends of both primers contain over 15bp homology to the ends of KpnI 
digested pCI.DNAH5 (underlined) whilst the 3’ ends of both primers were 
homologous to pEGFP-N1 plasmid (italic). The above primers amplified the 
GCCACCATGG Kozak sequence and eGFP cDNA sequence of pEGFP-N1 with the stop 
codon absent. In addition, the sequence CATCAC (2x His; bold) was introduced as a 
spacer following the eGFP cDNA sequence and preceding the DNAH5 cDNA 
sequence. The PCR product consisting of 5’ and 3’ ends that had 15bp homology to 
the 5’ and 3’ ends of KpnI digested pCI.DNAH5 was gel purified and cloned into KpnI 
digested pCI.DNAH5 using SLIC as described in Materials and Methods (Chapter 
2.2.22; p93) to produce the plasmid pCI.eGFP.DNAH5. The eGFP transgene from 
pEGFP-N1 was also sub-cloned into the pCI vector using SalI-NotI restriction sites to 
both isolate eGFP and sub-clone it into pCI to give the plasmid pCI.eGFP. This was 
produced to provide a small eGFP expression plasmid contained within the same 
backbone as the larger eGFP-DNAH5 fusion transgene so allowing direct 
comparison of transfection efficiency when transfecting large and small transgenes. 
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16HBE14o- cells were transfected with the pCI.eGFP and pCI.eGFP.DNAH5 plasmids 
and expression of eGFP and the eGFP-DNAH5 fusion protein was assayed using flow 
cytometry. Transfection of the pEGFP-N1 plasmid was used as a positive control. 
When a total of 250ng/well of each plasmid was transfected (at a concentration of 
1.25ng/µL) the large pCI.eGFP.DNAH5 plasmid transfected a lower proportion of 
cells compared to the smaller pCI.eGFP (0.75 ±0.11% for pCI.eGFP.DNAH5 and 8.82 
±0.40% for pCI.eGFP; Figure 3.11a; p<0.001; one-way ANOVA with Bonferroni post-
test analysis). The size difference between the two plasmids (4.7kb for pCI.eGFP 
and 18.6kb for pCI.eGFP.DNAH5) means that when 250ng of each was transfected 
the number of plasmid molecules and so transgene cassettes, transfected was 
around four times lower when using pCI.eGFP.DNAH5 over pCI.eGFP. Taking this 
into account equimolar amounts of pCI.eGFP.DNAH5 was transfected 
(977.5ng/well; concentration of 4.89ng/µL) but this failed to significantly improve 
the proportion of cells expressing the eGFP-DNAH5 fusion protein (Figure 3.11a). It 
is also of note that the MFI and so the amount of transgene expressed, was ~12-
fold higher when transfecting the small pCI.eGFP plasmid (Figure 3.11b; p<0.001; 
one-way ANOVA with Bonferroni post-test analysis). As such, both the percentage 
of cells transfected and the amount of transgene expressed is reduced when 
transfecting the large DNAH5 containing plasmid. 
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Figure 3.11. Transfection efficiency of large plasmids using LPD 
16HBE14o- cells were transfected with the small pCI.eGFP plasmid and larger 
pCI.eGFP.DNAH5 and assayed by flow cytometry for (a) the percentage of cells 
transfected and (b) the MFI of transfected cells. ***P<0.001; one-way ANOVA with 
Bonferroni post-test analysis used to assess significance. Values are background 
subtracted and displayed as mean ±SEM. 
a b 
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To provide some insight into the causes of the low transfection efficiency when 
transfecting the large pCI.eGFP.DNAH5 plasmid the biophysical properties of LPD 
vectors containing the small pCI.eGFP and large pCI.eGFP.DNAH5 plasmid was 
assessed. No differences in LPD particle morphology could be seen with pCI.eGFP 
(Figure 3.12a) and pCI.eGFP.DNAH5 (Figure 3.12b) containing LPD complexes with 
both plasmids producing predominantly spherical nanocomplexes. LPD particles 
formed with pCI.eGFP.DNAH5 plasmid appeared larger than those formed with the 
pCI.eGFP plasmid by TEM (Figure 3.12a and b) and indeed quantification by DLS 
confirmed this observation. LPD nanocomplexes formed with the pCI.eGFP.DNAH5 
plasmid were 136.0 ±1.9nm compared to 108.9 ±1.3nm for those formed with the 
pCI.eGFP plasmid (Figure 3.12c; p<0.001; Student’s t-test). No significant 
differences in the zeta potential of the two nanocomplexes was observed. Whilst 
the difference in hydrodynamic sizes of the two complexes was significant, 
pCI.eGFP.DNAH5 containing complexes were not substantially larger. Being 
spherical and under 200nm both nanoparticles would have likely utilised the same 
uptake pathway (396) and so should have resulted in similar levels of vector and 
plasmid uptake, particularly when equimolar amounts of plasmid was transfected. 
It is unlikely then that differences in vector uptake could help explain the 
differences in transfection efficiency seen when comparing LPD complexes 
containing pCI.eGFP and pCI.eGFP.DNAH5 plasmids. However, further studies to 
test this hypothesis were not undertaken and should form the basis of future 
studies. This could be addressed with uptake studies utilising Cy5 labelled pCI.eGFP 
and pCI.eGFP.DNAH5.  
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Figure 3.12. Biophyscial characterisation of pCI.eGFP and pCI.eGFP.DNAH5 
containing LPD particles 
The morphology, size and zeta potential of LPD nanocomplexes formulated with the 
small pCI.eGFP and large pCI.eGFP.DNAH5 plasmid was assessed by (a-b) TEM and 
(c) DLS technqiues. NS, not significant; ***p<0.001; Student’s t-test used to assess 
significance. Values are mean ±SEM. Scale bars are 500nm. 
c 
a b 
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3.4. DISCUSSION 
In this chapter a non-viral vector system previously optimised for respiratory gene 
delivery (287) was investigated. This LPD complex contains a cationic liposome and 
cationic peptide which upon mixing with anionic DNA forms small cationic receptor-
targeted nanocomplexes. The receptor-targeting properties of the LPD complex is 
afforded by the peptide component which consists of a K16 DNA binding domain 
and a receptor-targeting domain consisting the SERSMNF motif found by phage 
display to target airway epithelial cells (288). Previous studies have shown that use 
of arginine-based peptides rather than lysine-based peptides result in enhanced 
transfection with polyplexes (390). However, in the LPD lipopolyplex, exchanging 
the 16 lysine residues in the K16E peptide for arginine residues produced an almost 
50% fall in transfection efficiency. Reducing the number of lysine residues to 8 
produced a larger drop in transgene expression which was likely due to inefficient 
DNA packaging resulting in unstable particles with poorer cellular uptake 
properties (390). The results therefore indicated that at least in the context of the 
LPD lipopolyplex, where the peptide is not a homopeptide, the use of arginine in 
place of lysine for DNA packaging dampens transgene expression. This difference 
was not further investigated but may be due to differences in DNA condensation 
and packaging, a key function of the cationic residues within the peptide, leading to 
differences in vector uptake and subsequently transgene expression. 
For the first time the optimal LPD complex, previously shown capable of efficiently 
transfecting the mouse (287, 289) and pig airway in vivo (290), was shown to 
efficiently transfect primary human airway epithelial cells obtained by nasal 
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brushing. The LPD vector consistently transfected around 20% of primary nasal cells 
irrespective of the donor from whom the cells were obtained. Gene delivery to 
around 20% of airway epithelial cells, at least in a mouse model of PCD, was 
sufficient to restore a low level of mucociliary clearance (283) which may offer 
some clinical benefit to PCD patients. 
The LPD lipopolyplex showed transgene expression levels substantially higher than 
binary LD lipoplexes or PD polyplexes thus showing a co-operation between the 
liposome and peptide components in the enhancement of transfection. This has 
been observed by others utilising different lipids and polymers (384, 386, 397). In 
an attempt to explain the synergy in transfection detailed functional and 
biophysical analysis of LPD, LD and PD complexes were undertaken. 
With respect to transfection, several key steps must take place to allow for efficient 
gene expression including, i) the formation of stable particles that can protect 
plasmid DNA from degradation, ii) attachment of vector to cells, iii) uptake of the 
vector into cells, iv) endosomal escape, v) nuclear entry and vi) release of plasmid 
DNA from the nanocomplex so that it is accessible to the transcription machinery. 
LPD and PD nanocomplexes by TEM produced discrete and roughly spherical 
particles while the LD lipoplexes appeared as stacked lamellar aggregates. The 
formation of small discrete particles is thus primarily a consequence of 
peptide/DNA interactions suggesting they more efficiently condense DNA than 
cationic liposomes as found in other studies (398). PD and LPD nanocomplexes 
were both cationic and the zeta potential of the latter was twice that of the former 
which could lead to differences in cell binding and internalisation (197). However, 
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cellular uptake studies showed that PD and LPD nanocomplexes were bound and 
internalised to very similar degrees. This implied the differences between the 
nanocomplexes lay in their ability to overcome intracellular barriers to transfection. 
Escape of nanocomplexes from the endosome compartment following cellular 
uptake is vital in evading lysosomal degradation of gene delivery nanocomplexes 
and therefore in the efficiency of transfection. The most common mechanisms by 
which vectors can undergo endosomal escape are i) destabilisation of the 
endosome bilayer through the use of fusogenic liposomes (399) or peptides (400) 
and ii) utilisation of the proton-sponge effect to burst the endosome (186). The 
presence of the fusogenic DOPE lipid within the LPD nanocomplex provides a 
mechanism of endosomal escape (401) for this nanocomplex. On the other hand, 
the PD complex has no obvious method of endosomal escape lacking both a 
fusogenic lipid/peptide component and, at physiological pH, free protonatable 
groups that would allow it to utilise the proton-sponge effect seen with PEI (186). 
Inefficient endosomal escape is thus most likely the major factor responsible for 
inefficient transgene expression following PD transfections. This is supported by the 
finding that removal of the DOPE lipid rendered LPD complexes no more efficient 
than PD complexes showing that the major difference between these two 
complexes is in their ability to escape lysosomal degradation. 
Cellular uptake of the nanocomplexes was the primary barrier to gene transfer to 
the lipoplex whilst inefficient intracellular trafficking hampered transgene 
expression by the polyplex. Having both peptide and liposome components in the 
lipopolyplex produced a cationic nanocomplex small and stable enough to give 
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efficient cellular uptake, a function of the peptide component, as well as efficient 
endosomal escape and subsequent release of plasmid DNA for transcription in the 
anionic environment of the cell, a function of the liposome component. This 
increased functionality afforded by having both the liposome and peptide in 
lipopolyplexes can help explain the synergy observed in transgene expression when 
comparing lipoplexes, polyplexes and lipopolyplexes. 
Moving towards PCD gene therapy, DNAH5 mRNA and protein expression was 
shown following transfection of a cloned DNAH5 cDNA construct. Importantly, it 
was shown that the large DNAH5 cDNA could be delivered to human bronchial 
epithelial (HBE) cells using the LPD vector. However, transfection of the large 
DNAH5 construct is likely to be less efficient than transfecting smaller transgenes as 
transfection of a GFP-DNAH5 fusion plasmid was found to give a significantly lower 
proportion of transgene positive cells than when a comparable eGFP only plasmid 
was transfected. The difference cannot be attributed simply to differences in the 
number of transgene constructs being delivered as even with equimolar amounts of 
both plasmids being transfected transgene expression from the large 
pCI.eGFP.DNAH5 (18.6kb) plasmid was lower than with the smaller pCI.eGFP 
plasmid (4.7kb). Whilst differences in the sizes of the two complexes were observed 
the values were not substantially different. That both complexes were under 
200nm, spherical and cationic having similar zeta potentials suggests that both 
complexes would have utilised similar uptake pathways (396) thus suggesting the 
differences seen in biophysical properties could not explain the significant 
reduction in transgene expression when transfecting the pCI.eGFP.DNAH5 plasmid. 
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However, vector uptake studies will help address whether uptake was the rate 
limiting step for efficient transfection with the large DNAH5 plasmid or if processes 
downstream are limiting. These answers will aid in overcoming the inefficient 
transgene expression currently observed. 
In summary, given that transfection of the large transgene was well below the 
target of 20% transfection efficiency required to recover some level of mucociliary 
clearance, at least in a Dnaic1 PCD mouse model (283), it was clear that further 
improvements to enhance transfection efficiency, particularly of the DNAH5 
transgene, were required.  
The liposome and receptor targeting peptide moieties of the LPD component have 
been optimised previously (287, 288) but the DNA component, which is responsible 
for initiating and maintaining transgene expression, has not. In the next chapter the 
use of minicircle DNA in LPD complexes is explored in the context of airway gene 
delivery. 
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MINICIRCLE DNA FOR AIRWAY GENE DELIVERY   
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4. MINICIRCLE DNA FOR AIRWAY GENE DELIVERY 
4.1. INTRODUCTION 
Plasmids have been engineered to carry the elements necessary for transgene 
expression in mammalian cells -namely a promoter element for the initiation of 
transcription, the transgene sequence and a polyadenylation signal to confer 
stability to the transcribed mRNA and enhance translation. Enhancer elements have 
also been included to improve transgene expression (304).  
Plasmids also contain elements necessary for stable replication in E. coli including 
an origin of replication and an antibiotic resistance gene under the control of a 
prokaryotic promoter but these are surplus in the context of mammalian gene 
transfer. In addition, bacterial sequences are typically rich in CpG dinucleotides 
which remain unmethylated in the E.coli host and unmethylated CpG dinucleotides 
have been shown to induce an immune response in vertebrates (298-301) via toll-
like receptor (TLR) - 9 (302).  
Minicircle DNA, like plasmids, are circular DNA molecules and have been developed 
through the use of site-specific recombination (309, 402, 403). Minicircle DNA lacks 
the prokaryotic elements required for replication in E. coli. Two methods are 
commonly used to derive minicircle DNA both starting with producer plasmids 
where the transgene expression cassette is flanked with recombination sequences, 
for example attB and attP sequences. In both systems producer plasmids are 
propagated in E. coli genetically modified to express recombinase under an 
inducible promoter. Following induction of the recombinase, recombination of the 
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producer plasmid yields minicircle and miniplasmid DNA. Minicircle is then purified 
either by use of affinity chromatography binding a specific recognition sequence 
found in the minicircle but not the miniplasmid (404), or by in vivo digestion of the 
miniplasmid resulting in its degradation thus allowing extraction of relatively pure 
minicircle DNA (405). The latter system is more convenient as both recombination 
and miniplasmid removal take place in E. coli thus allowing utilisation of standard 
plasmid extraction protocols and kits for purifying minicircle DNA. 
In the context of gene therapy, minicircles have been shown to exhibit sustained 
transgene expression to plasmids in a variety of organ systems in vivo including the 
liver (309, 310), heart (311, 312) and skeletal muscle (312). Whether the 
advantages of minicircle DNA are translatable to airway gene delivery have yet to 
be assessed. 
4.2. AIMS 
To assess if minicircle DNA would provide enhanced and prolonged transgene 
expression in the context of airway gene delivery in vitro and in vivo and to assess if 
minicircle DNA offers advantages over plasmid DNA when expressing large genes- 
namely DNAH5.  
To address these aims reporter genes and the DNAH5 cDNA were sub-cloned into a 
minicircle producer plasmid, minicircle DNA and plasmid DNA were extracted and 
transgene expression and persistence assessed in vitro and in vivo. Toxicity 
following minicircle and plasmid DNA administration was also assessed in vivo.  
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4.3. RESULTS 
4.3.1. PLASMID SUB-CLONING 
Figure 4.1 shows a schematic of the sub-cloning steps involved in the production of 
minicircle producer plasmids containing reporter genes and the DNAH5 cDNA under 
the control of an EF1α core promoter. A minicricle producer plasmid with a multiple 
cloning site (MCS) flanked with attB and attP sequences was purchased 
(pMC.BESPX-MCS2; System Biosciences) and promoter/enhancer elements together 
with a polyadenylation signal were sub-cloned into this plasmid to produce a 
cloning vector into which reporter genes and the DNAH5 cDNA could be sub-
cloned. An EF1α core promoter was chosen as previous studies have shown that 
this promoter provides high transgene persistence compared to CMV (296), the 
only other promoter available for use in the course of this thesis project. It was 
anticipated that this enhanced transgene persistence would beneficial when 
transfecting airway cells and then promoting mucociliary differentiation.  
All plasmid maps can be found in Appendix B. 
pMC.EF1α-MCS 
The CpG-free chimeric promoter from pCpGfree-LacZ (Invivogen), containing a CMV 
enhancer, EF1α core promoter and a downstream synthetic intron, was placed into 
the pMC.BESPX-MCS2 minicircle producer plasmid by digestion with NcoI and BglII 
respectively and overhangs filled in using large Klenow fragment. Both plasmids 
were further digested with EcoR1 and the liberated chimeric promoter then ligated 
into pMC.BESPX-MCS2 to produce the plasmid pMC.EF1α-MCS.  
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pMC.EF1α.MCS.SV40pA  
The CpG-free late SV40 polyadenylation signal from pCpGfree-LacZ (Invivogen) was 
PCR amplified and flanked with SalI and ApaI sites using the primers; 
Forward Primer; 5’ – CTGAGTCGACGCTAGCTGGCCAGACATGATA– 3’ 
Reverse Primer; 5’ – GACTGGGCCCGAATTCCATACCACATTTGTA– 3’ 
The PCR product was digested with SalI and ApaI and ligated into SalI-ApaI digested 
pMC.EF1α-MCS plasmid. 
pMC.eGFP 
pMC.EF1α.MCS.SV40pA and pEGFP-N1 were digested with SalI and NotI 
respectively and overhangs filled in using large Klenow fragment. SalI digested 
pMC.EF1α.MCS.SV40pA was then digested with BamHI and the eGFP gene isolated 
from NotI digested pEGFP-N1 by digestion with BamHI. eGFP was then ligated into 
the SalI-BamHI digested pMC.EF1α.MCS.SV40pA to produce pMC.eGFP. 
pMC.Luc2 
Firefly luciferase gene (luc2) and the late SV40 polyadenylation signal were isolated 
from pGL4.10 using NheI and SalI digestion and ligated into pMC.EF1α-MCS, 
digested with the same enzymes, to produce pMC.Luc2. 
pMC.NL1.3 
A secreted form of NanoLuc luciferase, i.e. with an N-terminal secretion signal and 
the late SV40 polyadenylation signal were isolated from pNL1.3 using NheI and SalI 
157 
 
digestion and ligated into pMC.EF1α-MCS, digested with the same enzymes, to 
produce pMC.NL1.3. 
pMC.DNAH5 
pCI.DNAH5 was digested with Acc65I and SalI to isolate the DNAH5 cDNA which was 
ligated into BsrGI-SalI digested pMC.EF1α.MCS.SV40pA to produce pMC.DNAH5. 
 
  
attB MCS attP pMC.BESPX-MCS2 
 attB MCS attP EF1α pMC.EF1α.MCS 
pMC.EF1α.MCS.SV40pA attB MCS attP  EF1α SV40 pA 
pMC.eGFP attB attP  EF1α SV40 pA eGFP 
pMC.DNAH5 attB attP  EF1α SV40 pA DNAH5 
pMC.Luc2 attB attP  EF1α SV40 pA Luc2 
pMC.NL1.3 attB attP  EF1α SV40 pA NL1.3 
 attB MCS attP EF1α pMC.EF1α.MCS 
Figure 4.1. Schematic of the plasmids described in this chapter 
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4.3.2. EFFICIENT PRODUCTION OF MINICIRCLE DNA 
Minicircle producer plasmids (pMC.xxxx) were transformed into the ZYCY10P3S2T E. 
coli bacterial strain and minicircle produced as described in Materials and Methods 
(Chapter 2.2.6; p87). ZYCY10P3S2T cells express φC31 integrase and the I-SceI 
endonuclease upon introduction of L-Arabinose to the bacterial culture. The φC31 
integrase causes recombination of attB and attP sites, which separate the transgene 
expression cassette from the bacterial backbone, to produce the minicircle DNA 
(MC.xxxx) and the plasmid backbone (miniplasmid). The I-SceI endonuclease digests 
I-SceI recognition sequences in the bacterial backbone thus linearizing the 
backbone resulting in its degradation within the E. coli host (406). The φC31 
integrase and the I-SceI endonuclease gene copy numbers in ZYCY10P3S2T strain E. 
coli were optimised by Kay et al., (405) to maximise minicircle DNA yield and purity. 
Minicircle DNA was then extracted and purified using conventional alkaline-lysis 
plasmid purification kits. Growth of E. coli for extraction and purification of the 
producer plasmid was no different to standard protocols for plasmid purification.  
Purified plasmid and minicircle DNA were digested by a relevant single cutting 
restriction enzyme and 500ng of the digest product was run on an ethidium 
bromide stained agarose gel and visualised under UV light. There was no visible 
producer plasmid contamination within minicircle DNA preparations (Figure 4.2) 
thus the DNA was considered sufficiently pure to be used for further studies. For 
DNAH5 coding DNA (pMC.DNAH5 and MC.DNAH5) the differences in size when 
comparing plasmid and minicircle DNA, whilst visible, was minimal given the 
resolution limits of agarose gels.  
159 
 
  
 
 
  
Figure 4.2. Purity of minicircle DNA produced in E. coli from plasmid constructs 
500ng of plasmid (pMC.xxxx) and minicircle (MC.xxxx) DNA were digested with 
single cutting restriction enzymes thus linearising the DNA. Minicircle preparations 
were considered relatively pure if only one band was observed as a second band 
running down to the same length of the producer plasmid DNA would be visible if 
significant producer plasmid contamination was present. 
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4.3.3. TRANSGENE EXPRESSION (IN VITRO) 
Varying amounts of minicircle DNA and plasmid DNA carrying either the firefly 
luciferase gene (MC.Luc2 and pMC.Luc2 respectively) or the eGFP gene (MC.eGFP 
and pMC.eGFP respectively) were transfected into 16HBE14o- cells using LPD 
nanocomplexes. Using firefly luciferase as the reporter gene, cells transfected with 
minicircle DNA showed 5-10-fold higher levels of luciferase activity than plasmid 
DNA transfected at equal mass (Figure 4.3a; minicircle vs plasmid p<0.001 at all 
mass quantities used; Student’s t-test) and equimolar amounts of DNA (Figure 4.3b; 
minicircle vs plasmid p<0.001 at all molar quantities used; Student’s t-test) 
indicating that minicircle DNA results in higher levels of transgene protein 
production.  
Transfection of cells with DNA carrying the eGFP gene confirmed that minicircles 
resulted in higher levels of protein production. By fluorescence microscopy, cells 
transfected with minicircle DNA were brighter than those transfected with an 
equimolar amount of plasmid DNA (i.e. expressed higher levels of eGFP protein; 
Figure 4.3c) and cells expressing eGFP also appeared to be more numerous when 
minicircle DNA was used. Flow cytometry (Figure 4.3d-g) revealed that cells 
transfected with minicircle DNA typically showed a 4-fold higher percentage of cells 
expressing eGFP when compared to cells transfected with plasmid DNA at equal 
mass (Figure 4.3d; minicircle vs plasmid p<0.001 at all mass quantities used; 
Student’s t-test) and equimolar amounts of DNA (Figure 4.3e; minicircle vs plasmid 
p<0.001 at all molar quantities used; Student’s t-test). Supporting the microscopy 
images further, the mean fluorescent intensity of cells transfected with eGFP coding 
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minicircle DNA were 2.5-3-fold higher than cells transfected with plasmid DNA at 
equal mass (Figure 4.3f; minicircle vs plasmid p<0.001 at all mass quantities used; 
Student’s t-test) and equimolar amounts of DNA (Figure 4.3g; minicircle vs plasmid 
p<0.001 at all molar quantities used; Student’s t-test).  
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Figure 4.3 Transgene expression following in vitro minicircle and plasmid DNA 
transfections 
16HBE14o- cells were transfected with minicircle DNA (green line) or plasmid DNA 
(red line) carrying the firefly luciferase gene (a-b) or the eGFP gene (c-g). Either 
equal mass amounts of DNA was used (a, d, f) or equimolar amounts (b, c, e, g). For 
eGFP transfections both the percentage of positive cells (d-e) and the MFI (f-g) 
were assessed. Scale bars are 100µm. Values are background subtracted and 
displayed as mean ±SEM. 
a b 
d e 
f g 
c OptiMEM pMC.EGFP (77.91 fmol) MC.eGFP (77.91 fmol) 
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4.3.4. LPD BIOPHYSICAL CHARACTERISATION 
pCI.eGFP.DNAH5, an 18.6kb plasmid, produced larger LPD complexes than 
complexes formed with pCI.eGFP, a 4.7kb plasmid (Chapter 3.3.3; p144). Plasmid 
size therefore affected the biophysical properties of LPD complexes, at least when 
the plasmid sizes are significantly different. Alteration of the biophysical properties 
could in turn impact on transgene expression and so the size and charge properties 
of LPD complexes formulated with 2µg of pMC.Luc2 were compared to complexes 
formulated with 2µg of MC.Luc2. pMC.Luc2 produced LPD complexes of 111.1 
±0.6nm which were slightly larger than MC.Luc2 containing LPD complexes of 103.2 
±1.1nm (Figure 4.4a; p<0.001; Student’s t-test). There was also a significant 
difference in zeta potential with pMC.Luc2 containing complexes exhibiting a zeta 
potential of 35.0 ±1.6mV compared to 18.2 ±3.4mV for MC.Luc2 containing 
complexes (Figure 4.4a; p<0.01; Student’s t-test). However, there were no 
significant differences in hydrodynamic size or zeta potential of LPD complexes 
formulated with pMC.eGFP and MC.eGFP (Figure 4.4b). As such, differences in the 
size and charge properties when comparing LPD complexes formulated with 
plasmid and minicircle plasmids were minimal and so unlikely to have affected 
transgene expression. 
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Figure 4.4. Biophysical characterisation of LPD complexes 
The hydrodynamic sizes (nm) and zeta potential (mV) of LPD complexes formulated 
with 2µg of (a) pMC.Luc2 or MC.Luc2 DNA and (b) pMC.eGFP and MC.eGFP DNA 
were assessed. NS, not significant; **P<0.01; ***P<0.001; Student’s t-test used to 
assess significance. Values are mean ±SEM. 
a 
b 
165 
 
4.3.5. Persistence of Transgene Expression (In Vitro) 
Persistence of transgene expression is one of the main benefits of minicircle DNA 
over plasmid DNA (309, 312). To assess transgene persistence in vitro NHBE BMI-1 
cells (described in Chapter 5; p183) were transfected at equimolar amounts with 
either plasmid DNA or minicircle DNA encoding a secreted luciferase gene 
(NanoLuc; Promega) derived from the deep sea shrimp Oplophorus gracilirostris. 
The cells were transfected 48 hours after seeding on permeable transwell supports 
with equal amounts of plasmid being added to both apical and basolateral sides for 
4 hours before the basolateral surface was replaced with ALI media and the apical 
surface aspirated to maintain an ALI. The basolateral media was collected and 
replaced daily thus ensuring that only new luciferase expression was being 
measured as opposed to accumulated luciferase expression. As the NHBE cells were 
at an ALI, had formed tight junctions and were no longer dividing but rather 
differentiating issues of plasmid dilution due to cell division were minimal. 
Consistent with earlier data using firefly luciferase and eGFP transfections, 
minicircle DNA resulted in significantly higher levels of NanoLuc expression (Figure 
4.5a; p<0.05; Student’s t-test). NanoLuc expression was followed for 10 days and 
the decay in new NanoLuc expression shown with day 1 luciferase activity displayed 
as 100% (Figure 4.5b). In doing this it was clear that the decay curve for minicircle 
DNA was shifted to the right of that for plasmid DNA indicating slower decay of 
NanoLuc expression (Figure 4.5b). Natural log transformed RLU values plotted 
against days post-transfection showed that the decay was exponential thus 
following first-order decay kinetics (Figure 4.5c; curves were transformed to a 
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straight line) and so half-life (t1/2) was measured for the 10-day period using 
equation (1) where k is the decay constant (slope of linear regression line). 
(1)    ⁄  
   
 
 
 
The levels of gene expression fell to half on average every 1.02±0.05 days (24.5 
hours) for plasmid DNA transfections but 1.78±0.12 days (42.7 hours) for minicircle 
DNA transfections implying greater persistence of transgene expression from 
minicircle DNA in this in vitro ALI model (Figure 4.5d; p<0.01; Student’s t-test). 
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Figure 4.5. Persistence of transgene expression following in vitro minicircle and 
plasmid DNA transfections  
NHBE BMI-1 cells were transfected with minicircle or plasmid DNA encoding a 
secreted luciferase (NanoLuc) and (a) luciferase activity 24 hours following 
transfection compared. (b) Transgene expression was followed for 10 days 
following transfection and luciferase activity displayed relative to day 1 levels. (c) Ln 
transformed luciferase activity values (RLU/100µL of supernatant) were used to 
determine the decay kinetics and (d) mean half-life of gene expression over the 10 
day period calculated. *P<0.05; **P<0.01; Student’s t-test used to assess 
significance. Values are background subtracted and displayed as mean ±SEM. 
a b 
c d 
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4.3.6. DNAH5 transfections (In Vitro) 
Having assessed the advantages of minicircle DNA when transfecting airway 
epithelial cells with standard reporter genes it was important to validate whether 
minicircle DNA would result in enhanced expression of the large DNAH5 transgene 
by transfection of equimolar amounts of pMC.DNAH5 or MC.DNAH5 into 
16HBE14o- cells. 48 hours following transfection RNA and DNA was extracted and 
DNAH5 expression and the amount of plasmid present quantified. As expected 
there was no significant difference in the levels of DNAH5 DNA in transfected cells 
(Figure 4.6a) but at the mRNA level cells transfected with minicircle DNA expressed 
66% more DNAH5 mRNA than cells transfected with pMC.DNAH5 plasmid (Figure 
4.6b; p<0.01; Student’s t-test) thus highlighting the value of using minicircle DNA 
for DNAH5 transfections in vitro. 
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Figure 4.6. DNAH5 expression following in vitro minicircle and plasmid DNA 
transfections 
16HBE14o- cells were transfected with pMC.DNAH5 or MC.DNAH5 complexed into 
LPD particles and the relative amounts of DNAH5 (a) DNA and (b) mRNA quantified 
using qPCR and the 2- ΔΔCt method. NS, not significant; **P<0.01; Student’s t-test 
used to assess significance. Values are mean ±SEM. 
 
a b 
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4.3.7. TRANSGENE EXPRESSION (IN VIVO) 
Whether the superiority of minicircle DNA when transfecting airway epithelial cells 
in vitro was translatable in vivo was assessed by transfection of CD1 mice with LPD 
complexes formulated with plasmid DNA (pMC.Luc2) or minicircle DNA (MC.Luc2). 
Luciferase assay of lung extracts 24 hours following luciferase gene delivery showed 
that minicircle DNA gave a 6.5-fold higher median level of transgene expression 
compared to plasmid DNA when 16.7µg of DNA packaged into LPD complexes was 
administered via the oropharyngeal route (Figure 4.7; median value of 8115.9 
RLU/mg of protein for 16.7µg of minicircle DNA and 1249 RLU/mg of protein for 
16.7µg plasmid DNA; p<0.01; Kruskal-Wallis test followed by Dunn’s post-test 
analysis). There was no significant difference in luciferase activity between plasmid 
DNA and minicircle DNA when equimolar amounts of DNA were transfected in vivo. 
Persistence of transgene expression was also assessed in vivo by assessing 
transgene expression 7 days following transfection. Luciferase activity was not 
detectable in mice transfected with plasmid DNA and in 3 out of 6 mice transfected 
with an equimolar amount of minicircle DNA (Figure 4.7). The median RLU value 
following an equimolar amount of minicircle DNA transfection fell over 190-fold 
from 1823 RLU/mg of protein on day 1 to 9.5 RLU/mg of protein on day 7 (Figure 
4.7; p<0.01; Mann-Whitney U test). Following transfection of 16.7µg minicircle DNA 
(equal weight) luciferase activity fell 2.5-fold from 6565 RLU/mg of protein on day 1 
to 2613.2 RLU/mg of protein on day 7 (Figure 4.7; p<0.01; Mann-Whitney U test). 
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Figure 4.7. Transgene expression following in vivo minicircle and plasmid DNA 
transfections 
Luciferase activity following oropharyngeal instillation of CD1 mice with LPD 
complexes containing pMC.Luc2 plasmid DNA or MC.Luc2 minicircle DNA at either 
equimolar or equal mass quantities. *P<0.05; **P<0.01; Kruskal-Wallis test 
followed by Dunn’s post-test analysis to assess significance. Values are background 
subtracted and bar represents median RLU/mg of protein. 
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4.3.8. TOXICITY (IN VIVO) 
In vivo equimolar amounts of minicircle DNA did not enhance transgene expression 
compared to plasmid DNA, instead providing similar transfection efficiencies. 
However, LPD nanocomplexes formulated with equimolar amounts of minicircle 
DNA contain less liposome, peptide and DNA which could potentially translate to 
reduced toxicity in vivo. Toxicity was therefore assessed in vivo.  
24 hours after LPD transfections, with luciferase encoding pMC.Luc2 plasmid or 
MC.Luc2 minicircle DNA, lungs were fixed by perfusion with 4% PFA and processed 
for H&E staining as described in materials and methods. PEI complexed pMC.Luc2 
was used as a positive control and MilliQ water as the vehicle control. Lungs of mice 
receiving the vehicle control showed no signs of inflammation or cellular infiltration 
by histology (Figure 4.8a). In contrast, the lungs of mice transfected with plasmid or 
minicircle DNA showed varied levels of alveolar, peribronchiolar and perivascular 
inflammation with predominantly monocyte and macrophage infiltration (Figure 
4.8b-e). Mice transfected with pMC.Luc2 complexed with 25kDa PEI (Figure 4.8e) 
showed more extensive inflammation and cellular infiltration than mice treated 
with LPD complexes containing pMC.Luc2 (Figure 4.8b) or MC.Luc2 (Figure 4.8c and 
d). In all LPD treatment group’s only foci of cellular infiltration and inflammation 
were observed rather than extensive inflammation but there were no clear 
differences when comparing pMC.Luc2 and MC.Luc2 transfections (Figure 4.8b-d). 
It is not possible to determine from this data whether the mild inflammation 
observed with LPD transfections was acute or represented chronic changes.  
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Figure 4.8. H&E staining of mouse lungs following in vivo minicircle and plasmid 
DNA transfections 
H&E stained CD1 mice lung sections following oropharyngeal instillations of (a) 
water as a vehicle control, LPD vectors containing (b) pMC.Luc2, (c) MC.Luc2 at an 
equal mass to pMC.Luc2, (d) MC.Luc2 equimolar to pMC.Luc2 and (e) PEI 
complexed with pMC.Luc2. 
a b 
c d 
e 
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Toxicity was further assessed by quantification of cytokine release. BALF was 
obtained 24 hours following transfections with pMC.Luc2 plasmid or MC.Luc2 
minicircles. Cytokine concentrations within the BALF were then assessed using the 
Cytokine Mouse 10-plex panel. PEI complexed pMC.Luc2 was again used as a 
positive control and MilliQ water as the vehicle control.  
Of the cytokines assessed (mouse granulocyte-macrophage colony-stimulating 
factor (GM-CSF), IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 and TNF-α) only IFN-γ, 
IL-12 and TNF-α were detectable. Levels of IL-12 in BALF were similar in mice 
receiving LPD vectors containing pMC.Luc2 and MC.Luc2 when the same mass of 
each DNA was transfected (Figure 4.9a). There was also no significant difference in 
the levels of IFN-γ when transfecting the same mass of pMC.Luc2 and MC.Luc2 
complexed into LPD vectors (Figure 4.9b). pMC.Luc2 transfections using LPD 
nanocomplexes yielded no detectable TNF-α expression which contrasted with a 
median of 67.22pg/mL of TNF-α in BALF following an equal mass of MC.Luc2 
transfections (Figure 4.9c; p<0.05; Kruskal-Wallis test followed by Dunn’s post-test). 
Transfections of an equimolar amount of MC.Luc2 plasmid complexed in LPD 
complexes yielded no detectable GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-
12 and TNF-α cytokines in BALF (data not shown). 
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Figure 4.9. Cytokine response in BALF following in vivo minicircle and plasmid 
DNA transfections 
Concentration of (a) IL-12, (b) IFN-γ and (c) TNF-α cytokines in BALF following 
instillation of LPD vectors containing luciferase encoding minicircle or plasmid DNA. 
Water was used as a vehicle control and PEI complexed with pMC.Luc2 used as a 
positive control. *P<0.05; Kruskal-Wallis test followed by Dunn’s post-test used to 
assess significance. Bar represents median. 
a 
b 
c 
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4.4. DISCUSSION 
Efficient airway gene delivery has been a goal for CF researchers for over two 
decades. Non-viral vectors received significant attention in this field due to the 
need for repeated delivery and scalability of vector production. A major focus for 
the enhancement of gene delivery has been to find molecules capable of efficiently 
packaging and delivering plasmid DNA. More recently attention has been focussed 
on optimising the plasmid DNA itself in order to improve transgene expression and 
persistence and so maintain therapeutic levels of gene expression.  
In this chapter it was shown that minicircle DNA enhanced transgene expression 
and persistence in airway cells in vitro regardless of whether an equimolar or equal 
mass amount of minicircle DNA was transfected relative to plasmid DNA. GFP 
expression studies showed that both the percentage of cells expressing eGFP and 
the amount of eGFP protein produced in each transfected cell was higher when 
using minicircle DNA. Importantly for PCD gene therapy enhanced transgene 
expression with minicircle DNA was also seen when transfecting DNAH5.  
The mechanisms behind the enhanced gene expression with minicircle DNA was not 
fully investigated as the primary aim was to assess whether minicircle DNA could 
enhance transgene expression and persistence in the context of airway gene 
therapy. Nevertheless, it is highly likely that the enhancement in transgene 
expression when transfecting an equal mass of plasmid and minicircle DNA is at 
least in part due to the increased molar amounts of minicircle DNA delivered 
relative to plasmid DNA. 
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LPD complexes formulated with minicircle DNA were slightly smaller (~10nm 
smaller) than their counterparts formulated with plasmid DNA when luciferase 
coding DNA was used but no differences were seen when using eGFP coding DNA. 
Regardless of whether minicircle or plasmid DNA was used all LPD particles were 
around 100nm so the same uptake pathway would have been utilised, namely via 
clathrin-mediated endocytosis (396). As such, it would be expected that 
transfection of equimolar amounts of plasmid and minicircle DNA would result in 
equimolar amounts of DNA being found within transfected cells. This was not 
assessed for luciferase and eGFP coding DNA but held true following equimolar 
amounts of DNAH5 plasmid and minicircle DNA transfections. Despite equimolar 
amounts of DNAH5 plasmid and minicircle DNA being found in transfected cells 
greater mRNA expression resulted from minicircle DNA. This phenomenon has been 
observed in other studies where enhanced transgene expression with minicircle 
DNA has been associated with greater transcriptional silencing of plasmid 
DNA (309, 404, 407). 
Along with enhanced initial transgene expression levels transgene persistence was 
also higher with minicircle DNA in vitro where an ALI culture system was used to 
minimise the effect of cell division on plasmid loss. In this system basolateral media 
was replaced daily so only new and not cumulative protein production was 
assessed. Given that equimolar amounts of DNA were transfected, that protein 
production declined faster with plasmid DNA supports the notion that 
transcriptional silencing occurred more rapidly with plasmid DNA in line with 
previous observations (309, 404, 407). 
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In contrast to in vitro studies, in vivo no significant differences in the initial levels of 
transgene expression were seen when comparing equimolar amounts of plasmid 
and minicircle DNA transfections. Nevertheless, when an equal mass of minicircle 
was transfected an ~8-fold increase in transfection efficiency was observed. 
Transgene expression following minicircle delivery persisted for at least 7 days but 
was not detectable at this time point after transfection of an equal mass of plasmid 
DNA. The MC.Luc2 minicircle used in this study was almost half (42.8%) the size of 
the pMC.Luc2 plasmid so an equal mass transfection of the two would result in 2.3-
times more copies of minicircle DNA being transfected. The enhancement and 
persistence of transgene expression following an equal mass transfection of 
minicircle DNA, at least in part, thus likely resulted from more copies of transgene 
being transfected. 
Whilst equimolar transfections of minicircle and plasmid DNA showed no 
differences in transgene expression, the former being smaller in size resulted in less 
liposome, peptide and DNA being delivered given that LPD complexes are 
formulated based on a mass ratio. Histological analysis of mice lungs following 
transfections showed mild inflammation in mice transfected with the LPD vector, as 
seen previously (287), with no obvious differences in severity when comparing 
minicircle and plasmid DNA transfections. However, analysis of BALF for a number 
of inflammatory mediators showed no detectable levels of a panel of common 
inflammatory cytokines and chemokines when minicircle was transfected at an 
equimolar amount relative to plasmid DNA. In contrast, IFN-γ and IL-12 levels were 
elevated in BALF following plasmid DNA transfections. The lower dose therefore 
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manifested as a reduced inflammatory response. There were no significant 
differences in IFN-γ and IL-12 expression following transfection of an equal mass of 
minicricle and plasmid DNA although TNF-α was found to be elevated following 
transfection of 16.6µg of minicircle DNA but not plasmid DNA. The levels of 
liposome and peptide delivered were the same when delivering an equal mass of 
minicircle and plasmid DNA so this would not have contributed to the elevated TNF-
α levels. Unmethylated CpG-dinucleotides, typically rich in plasmid DNA backbones, 
have been shown to induce an immune response in vertebrates (298-301) via toll-
like receptor 9 (302). However, the minicircle, containing CpG-free 
promoter/enhancer elements with no plasmid backbone, has fewer unmethylated 
CpG-motifs than the plasmid DNA used. Instead, it is more likely that the elevated 
cytokine release with minicircle DNA was due to the significantly increased amount 
of luciferase expressed. The development of an immune response to transgene 
products has been reported previously following airway gene delivery (408) and 
greater transgene expression would be expected to lead to a more robust immune 
response. This hypothesis requires further investigation. 
Despite the minicircle being CpG reduced the role that unmethylated CpG-motifs 
may have had on transgene expression and persistence in vivo was not assessed 
here. The removal of CpG dinucleotides has been implicated in enhancing 
transgene expression and persistence as well as minimising inflammatory responses 
following airway gene delivery (297, 303-306). However, in these studies control 
CpG containing plasmids were not directly comparable to the CpG-free plasmids for 
a number of reasons.  
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In the studies from the Rudolph lab (303, 306) the CpG-free plasmid contained a 
CpG-free chimeric promoter with a CMV enhancer and EF1α core promoter whilst 
in the CpG containing plasmid transgene expression was driven by a CMV promoter. 
As such, this variable rather than removal of CpG motifs may have produced the 
results obtained particularly given that the use of different promoters is known to 
affect both the initial levels of transgene expression (293-295) as well as transgene 
persistence (295). In addition the backbones of the two plasmids contained 
different elements with the CpG-free plasmids containing scaffold/matrix 
attachment region sequences known to prolong transgene expression by promoting 
extra-chromosomal stability through attachment of the plasmid to components of 
the nuclear matrix (409-411). 
In the studies from the Gill lab (297, 304, 305) the CpG-free plasmids had shorter 
backbone lengths compared to CpG containing or CpG-reduced plasmids, a variable 
recently shown to affect persistence of transgene expression (308). As such, in 
these studies it is difficult to isolate the specific effects of removing CpG motifs. 
Indeed Chen et al., (307) showed that transgene silencing in the mouse liver at least 
is independent of CpG methylation status and that removal of CpG motifs 
altogether did not abolish transgene silencing. Furthermore, Lu et al., (308) found 
that the plasmid backbone sequence, typically rich in CpG motifs, was not crucial in 
transgene silencing as when it was placed within the 3’ untranslated region of the 
eukaryotic expression cassette persistent transgene expression resulted at levels 
similar to minicircle DNA completely devoid of a bacterial backbone. Lu et al., went 
on to show that the size and not the sequence of the backbone outside of the 
181 
 
transgene cassette is what produced a potent negative effect on transgene 
persistence. 
In summary, the advantages of using minicircle DNA in the airways include 
enhanced transgene expression when using an equal mass of minicircle DNA with 
reduced toxicity using an equimolar amount of minicircle DNA without diminishing 
transfection efficiency. This enhanced gene expression is also seen when delivering 
the DNAH5 transgene having clear implications for PCD gene therapy. Minicircles 
were therefore to be used in further studies assessing efficacy of gene therapy for 
PCD. However, a suitable model for assessing PCD gene therapy was required and 
its development is described in the following chapter. 
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5. IN VITRO MODEL OF PCD 
5.1. INTRODUCTION 
To assess the efficacy of gene therapy for PCD caused by DNAH5 mutations a 
suitable disease model is required. Dnahc5 mutant mouse models have been 
produced but these develop severe developmental defects including cardiac 
abnormalities and severe hydrocephalus causing high levels of neonatal death (35, 
375). The models are therefore difficult to work with when assessing efficacy of 
respiratory gene therapy for PCD. Use of conditional knockout mouse models could 
potentially alleviate the severe developmental defects as was observed with the 
conditional Dnaic1 conditional knockout mouse (316). However producing a 
conditional knockout Dnahc5 mouse would be both time consuming and expensive 
so was not attempted here.  
In vitro models of disease, such as tissue samples obtained from patients, offer a 
cheaper and convenient alternative however the rarity of PCD and a lack of 
genotyping in the UK makes obtaining suitable samples difficult. One way around 
this is to use shRNA technology to produce a PCD phenotype in airway cells capable 
of undergoing differentiation to a ciliated phenotype. Primary nasal and bronchial 
epithelial cells when placed on ALI are capable of undergoing mucociliary 
differentiation but have a very limited life-span and diminished differentiation 
capacity following 2-4 passages. Manipulating primary nasal and bronchial epithelial 
cells to produce a model of disease and attempt correction whilst not exceeding the 
cell doubling threshold for mucociliary differentiation is difficult to achieve. In 
addition high donor-to-donor variability combined with the expense of obtaining 
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commercial primary human airway epithelial cells restricts their use and has 
stimulated the production of immortalised cell lines. 
Immortalised airway epithelial cell lines have been isolated from human lung 
cancers (412) and produced by using viral oncogenes with (413, 414) and 
without (376, 415, 416) hTERT to overcome the limited replication of primary cells 
thus enabling extensive manipulation. These cell lines have been shown to polarise 
and form tight junctions when placed on ALI but do not differentiate to a pseudo-
stratified and well ciliated airway epithelium on ALI. 
The viral oncogene products used for immortalisation act by inhibiting the pRB and 
p53 tumour suppressor genes so forcing cells through the G1/S checkpoint of the 
cell cycle and initiating cell division. Centrioles, which are essential for cell division, 
also function as basal bodies that nucleate cilia assembly in quiescent and 
differentiated cells (417) and cells also resorb their cilia during cell division (418). 
Controls for limiting the function of centrioles to either cell division or cilia 
assembly must therefore exist and work is taking place to elucidate the 
mechanisms involved (419). In the context of human airway epithelial cell lines cell 
division is promoted by inducing entry into the cell cycle. Cell division must 
therefore occur at the expense of ciliary differentiation- a possible explanation for 
why these cell lines have a limited differentiation capacity.  
Whilst production of cell lines typically relies on promoting entry into the cell cycle, 
preventing senescence should enhance the number of replications a cell undergoes. 
BMI-1 is an anti-senescence protein that is known to function in the self-renewal 
and maintenance of the multipotency of stem cells (416, 420-422). By using mouse 
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BMI-1 in combination with hTERT Fulcher et al., (423) have been able to extend the 
growth capacity of primary HBE cells, although not as potently as viral oncogenes 
and show that unlike cells transformed with viral oncogenes these cell lines had no 
chromosomal abnormalities and recapitulated most of the structure and function of 
primary cells when placed on ALI. However, the BMI-1-hTERT transduced cells, 
whilst showing a pseudo-stratified epithelium, gave only sparse ciliogenesis. The 
limited differentiation capacity may be explained by reports that hTERT, following 
long-term growth in culture, up-regulates expression of the potent mitogen c-Myc, 
so promoting entry into the cell cycle and that c-Myc itself up-regulates hTERT in a 
positive feedback loop that eventually results in apoptosis (424). In addition, the 
combination of BMI-1 and hTERT in fibroblasts resulted in loss of both hTERT 
telomerase activity and BMI-1 inhibition of p16Ink4a thus negating the anti-senescent 
and stem cell maintenance effects of BMI-1 (425). Using BMI-1 alone may 
overcome the issues of c-Myc up-regulation and the inhibition of both hTERT and 
BMI-1 activities and so potentially provide a cell model capable of extensive 
passaging and mucociliary differentiation. 
5.2. AIMS 
To produce an in vitro model of PCD caused by DNAH5 mutations.  
To achieve this aim BMI-1 transduction of NHBE cells was used and the 
differentiation capacity of the cells lines assessed. shRNA knockdown of DNAH5 was 
subsequently used to model PCD with cilia motility, DNAH5 protein localisation and 
cilia ultrastructure studies undertaken to determine whether this in vitro model 
recapitulated PCD phenotypes. 
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5.3. RESULTS 
5.3.1. CHARACTERISATION OF BMI-1 TRANSDUCED CELLS IN SUBMERGED CULTURE 
NHBE cells in submerged cultures showed a typical cobblestone appearance at a 
low passage (Figure 5.1a; passage 1) but further passaging resulted in a change in 
cell morphology where elongated cells were present (Figure 5.1b; passage 3; white 
arrow) and squamous differentiation was evident (Figure 5.1b; passage 3; black 
arrow). To produce BMI-1 expressing NHBE cells lentivirus containing the human 
BMI-1 cDNA was added to the culture media, incubated with passage 2 NHBE cells 
in submerged culture and incubated at 37oC for 48 hours. In contrast to passage 3 
untransduced NHBE cells, BMI-1 transduced NHBE cells (NHBE BMI-1) maintained a 
characteristic cobblestone appearance following extensive passaging (Figure 5.1c, 
passage 11; Figure 5.1d, passage 17) but began showing squamous differentiation 
following 25 passages (Figure 5.1e) after which the cells senesced (defined as 10 
days with no observable cell division). Encouragingly, the cells maintained a normal 
diploid karyotype despite extensive passaging (Figure 5.1f, passage 23).  
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e f 
Figure 5.1. Morphology and Karyotype of NHBE BMI-1 cells 
The morphology of (a) NHBE cells at passage 1 and (b) passage 3 was observed 
under light microscopy and compared to NHBE BMI-1 cells after passages (c) 11, (d) 
17 and (e) 25. (f) Karyotype of NHBE BMI-1 cells at passage 23 was also assessed. 
Examples of squamous cells are indicated by the black arrows and white arrows 
highlight examples of elongated cells. Scale bars are 100µm. 
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Next, the doubling times of NHBE BMI-1 cells was assessed and compared to NHBE 
cells at passage 2 (Figure 5.2a). Untransduced cells at passage 2 had a doubling time 
of 1.18 days which was not too dissimilar to BMI-1 transduced cells at passages 12 
and 15 (doubling times of 1.25 and 1.21 days respectively). Given that BMI-1 
transduced cells had senesced following 25 passages it is not surprising that the 
doubling time increased to 1.49 days after 23 passages.  
BMI-1 is known to function by down-regulating expression of the anti-senescent 
protein p16Ink4A. NHBE cells transduced with BMI-1 had low levels of p16Ink4A protein 
and high levels of BMI-1 (Figure 5.2b). Levels of BMI-1 in untransduced NHBE cells 
declined with an increase in passaging whilst levels of p16Ink4A increased and were 
highest in senesced passage 6 untransduced NHBE cells. In senesced cells BMI-1 
expression was not evident by western blot (Figure 5.2b). 
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Figure 5.2. Growth Kinetics and BMI-1 expression of NHBE cells 
Cell counting was used to determine the replication kinetics of NHBE and NHBE 
BMI-1 cells at varying passages and (b) a Western blot was used to assess the levels 
of BMI-1 and p16Ink4A in untransduced NHBE cells and NHBE BMI-1 cells. Values are 
mean ±SEM 
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5.3.2. CHARACTERISATION OF BMI-1 TRANSDUCED CELLS ON ALI CULTURE 
Having established that NHBE BMI-1 cells could be passaged more than 
untransduced NHBE cells in submerged culture, the differentiation potential of 
NHBE BMI-1 cells was investigated. Culture of NHBE BMI-1 cells at an ALI resulted in 
mucociliary differentiation with motile cilia evident (Video 1a and b). 
Immunostaining showed the presence of the tight junction marker occludin (Figure 
5.3a), Muc5aC producing cells (Figure 5.3b), Muc5b producing cells (Figure 5.3c), 
p63+ basal cells (Figure 5.3d) and ciliated cells (cilia was stained for using anti-
acetylated α-tubulin; Figure 5.3e). BMI-1 protein was also found to be localised in 
all nuclei (Figure 5.3f). TEM sowed that the cilia had a normal 9+2 ultrastructure 
with both inner and outer dynein arms present (Figure 5.3g). Video microscopy 
followed by CBF analysis with CiliaFA ImageJ plugin (383) showed a mean CBF of 
15.28 ±0.19 Hz- within the normal range for respiratory cilia of 9-17Hz (383, 426). 
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Figure 5.3. Mucociliary differentiation of NHBE BMI-1 cell line. 
Once placed at an ALI the extensively passaged NHBE cells (passage 15) maintain 
their ability to differentiate into a pseudostratified columnar airway epithelium 
with immunostaining showing tight junction formation (occludin; a), mucus 
production (MUC5AC and MUC5B; b and c respectively), extensive ciliation 
(acetylated α-tubulin; d), the presence of basal cells (p63+; e) and widespread BMI-
1 expression (BMI-1; f). TEM also revealed a normal ciliary ultrastructure (g). 
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5.3.3. SHRNA KNOCKDOWN OF DNAH5 
The development of NHBE cell lines capable of extended passaging yet still capable 
of differentiation to a mucociliary phenotype allows for further manipulation of 
these cells such as the production of PCD disease models through the use of gene 
modification technologies. Mutations in DNAH5 are the most common cause of PCD 
resulting in loss of protein function. As such, reducing DNAH5 expression 
sufficiently should have the same phenotypic effect on cells as mutations in the 
DNAH5 gene that result in PCD. This reduction in DNAH5 expression can be 
achieved through the use of shRNA. In order to provide a stable reduction of 
DNAH5 expression an shRNA lentivirus construct was used to enable integration of 
shRNA into the host chromosome. Commercial shRNA library vectors exist and the 
pGIPZ library developed by Open Biosystems is a library of lentiviral vectors 
containing shRNA targeted against human genes. The pGIPZ library was utilised in 
this study because of low cost. Along with the shRNA to the gene of interest the 
pGIPZ vectors also contain a GFP and puromycin selection cassette (Appendix B; 
p298). These markers allow the user to identify which cells are expressing the 
shRNA. 
An issue with the pGIPZ plasmids is their size. The pGIPZ plasmids are around 
11.7kb thus relatively large in comparison to typical plasmids. The provirus derived 
from the plasmid is also larger than typical lentivirus vectors and provirus length is 
inversely proportional to viral titre (427). It is unsurprising then that pGIPZ plasmids 
gave viral titres of 1-5 x107 TU/mL making their use impractical for efficient 
transduction of NHBE cells. To improve viral titres a 3.5kb cassette consisting of 
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zeocin resistance gene-CMV promoter-turbo GFP- Internal ribosome entry site 
(IRES)-puromycin resistance gene was excised from the pGIPZ plasmids using SanDI 
and XhoI restriction sites and replaced with a 1.6kb cassette consisting of eGFP 
under the control of the spleen focus-forming virus (SFFV) promoter obtained from 
the pHRsincpptSEClaI plasmid also using SanDI and XhoI restriction sites. This 
reduced the pGIPZ plasmids from a size of 11.7kb to 9.8kb and increased viral titres 
to 5-10 x108 TU/mL. 
To achieve efficient knockdown of DNAH5 three different shRNA constructs 
targeting DNAH5 were assessed (DNAH5 1, clone Id: V2LHS_263786; DNAH5 2, 
clone Id: V2LHS_225844; DNAH5 3, clone Id: V2LHS_113470). 16HBE14o- cells were 
transfected with DNAH5 shRNA plasmids using the LPD vector system. 48 hours 
following transfection total RNA was extracted and qRT-PCR performed to assess 
the relative amounts of DNAH5 mRNA remaining. The most efficient construct was 
DNAH5 3 which resulted in ~70% knockdown of DNAH5 mRNA relative to cells 
transfected with a scrambled shRNA construct (Figure 5.4). Relative to OptiMEM 
treated cells the DNAH5 3 construct showed 87.7 ±0.6% knockdown of DNAH5 
expression (Figure 5.4; p<0.01; one-way ANOVA with Bonferroni post-test used to 
assess significance.). The scrambled shRNA construct gave a 50.8 ±8.2% knockdown 
of DNAH5 relative to OptiMEM treated cells whilst DNAH5 1 and 2 constructs gave 
57 ±14.3% and 43.8 ±18.0% knockdown respectively (Figure 5.4). Providing the 
most efficient knockdown of DNAH5 the DNAH5 3 shRNA construct was therefore 
used for further studies. 
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Figure 5.4. DNAH5 knockdown in 16HBE14o- cells 
16HBE14o- cells were transfected with difference shRNA constructs and DNAH5 
mRNA expression was quantified and presented relative to DNAH5 expression in 
OptiMEM treated cells. NS, not significant;**P<0.01; one-way ANOVA with 
Bonferroni post-test used to assess significance. Values are mean ±SEM. 
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Lentivirus containing the DNAH5 3 shRNA construct was to be used to produce a 
DNAH5 deficient PCD model. The multiplicity of infection (MOI) required to give 
efficient transduction of NHBE BMI-1 cells was determined by transduction of 
submerged cultures with varying MOIs of scrambled shRNA lentivirus titrated on 
HEK293T cells. An MOI of 75 was found to transduce almost 100% of cells and so 
used for further studies. It is of note that at all MOIs assessed there were two 
populations of GFP positive cells, GFPlow and GFPhigh (Figure 5.5).  
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Having optimised the MOI required for efficient transduction NHBE BMI-1 cells 
were transduced at an MOI of 75 using lentivirus containing the DNAH5 3 construct 
and DNAH5 expression was assessed by qRT-PCR. In these DNAH5 knockdown cells 
DNAH5 expression was reduced by around 75% relative to untransduced cells 
(Figure 5.6; p<0.01; one-way ANOVA with Bonferroni post-test analysis). When cells 
were transduced with a scrambled shRNA no knockdown of DNAH5 expression was 
observed relative to untransduced cells showing that DNAH5 knockdown using 
DNAH5 3 construct was sequence specific in NHBE BMI-1 cells (Figure 5.6).  
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Figure 5.6. Knockdown of DNAH5 in NHBE BMI-1 cells 
DNAH5 mRNA expression was assessed following transduction of NHBE BMI-1 cells 
with scrambled or DNAH5-targeted shRNA. DNAH5 expression is presented relative 
to untreated NHBE BMI-1 cells. **P<0.01; one-way ANOVA with Bonferroni post-
test analysis used to assess significance. Values are mean ±SEM. 
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To assess if the levels of DNAH5 knockdown achieved in NHBE BMI-1 cells was 
sufficient to produce a PCD phenotype DNAH5 3 and scrambled shRNA transduced 
NHBE BMI-1 cells were cultured on ALI to induce mucociliary differentiation and 
cilia function and ultrastructure assessed.  
Following mucociliary differentiation NHBE BMI-1 cells transduced with the 
scrambled shRNA had motile cilia in ciliated cells where the shRNA was expressed 
(GFP positive; Video 2a and b). In contrast, DNAH5 knockdown cells grown on ALI 
had immotile cilia when the ciliated cells were expressing the shRNA (GFP positive; 
Video 2a and b) but motile cilia was observed in cells not expressing the shRNA 
(GFP negative; Video 2c).  
To quantify the numbers of motile and immotile cilia present high-speed videos of 
untransduced and transduced NHBE BMI-1 cells grown on ALI were taken and the 
percent active area, used as a surrogate for the proportion of beating cilia in a given 
area, together with the CBF were determined using CiliaFA ImageJ plugin (383). In 
untransduced and scrambled shRNA transduced NHBE BMI-1 cells percent active 
area was 20% and this value dropped to 11.6 ±2.0% in DNAH5 knockdown cells 
(Figure 5.7a; p<0.05; one-way ANOVA with Tukey’s post-test). CBF was 14.15 
±0.28Hz in DNAH5 knockdown cells which was slightly higher than that seen for 
untransduced or scrambled shRNA transduced cells which had CBF values of 12.96 
±0.28Hz and 13.21 ±0.15Hz respectively (Figure 5.7b; p<0.05; one-way ANOVA with 
Tukey’s post-test). Nevertheless the CBF were all within the normal range for 
respiratory cilia (9-17Hz) (383, 426).  
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The reduction in the percent active area seen when cells were transduced with the 
DNAH5-targeted shRNA (Figure 5.7a) could have resulted from either i) a greater 
proportion of immotile cilia being present or ii) a reduction in the levels of 
ciliogenesis. To assess whether ciliogenesis was disrupted following DNAH5 
knockdown, the same cells which were used to determine the percent active area 
and cilia CBF where fixed and immunostained for acetylated tubulin and DAPI. Next, 
confocal images of at least 25 fields of view were obtained at x40 magnification and 
the number of ciliated cells counted. There were no significant differences in the 
number of ciliated cells when comparing untreated NHBE BMI-1 cells with 
scrambled shRNA or DNAH5-targeted shRNA treated cells with the number of 
ciliated cells per field found to be 18.6 ± 1.0, 21.2 ±1.0 and 19.9 ±1.4 respectively 
(Figure 5.7c; one-way ANOVA). As such, the fall in percent active area in cells 
transduced with the DNAH5-targeted shRNA resulted from a greater proportion of 
immotile cilia being present.  
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Figure 5.7. Cilia beating analysis 
Videos of shRNA transduced and untreated NHBE BMI-1 cells grown at an ALI were 
taken and the proportion of the field of view containing actively beating cilia was 
determined (a) along with the CBF (b) using CiliaFA plugin. (c) The average number 
of cilia in at least 5 fields of view per well was counted to determine the level of 
ciliation obtained.*P<0.05; **P<0.01; one-way ANOVA with Bonferroni post-test 
used to assess significance. Values are mean ±SEM. 
a b 
c 
202 
 
PCD patients with DNAH5 mutations typically lack the DNAH5 protein in the ciliary 
axoneme and have missing ODAs (116). To assess this in the knockdown model 
produced, immunostaining followed by confocal microscopy was used to assess if 
the DNAH5 knockdown model recapitulated the lack of DNAH5 protein within the 
axoneme of ciliated cells. In shRNA transduced cells only cells that were GFP 
positive and so expressing the shRNA, were counted. Untransduced NHBE BMI-1 
cells and those transduced with the scrambled shRNA were found to have DNAH5 
localising to the ciliary axoneme in all the ciliated cells assessed. In contrast, only 
2.9% of ciliated cells had DNAH5 localised to the ciliary axoneme in DNAH5 
knockdown cells (Figure 5.8; p<0.001; Fisher’s exact test).  
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Figure 5.8. DNAH5 localisation 
Immunostaining of shRNA transduced and untreated NHBE BMI-1 cells grown at an 
ALI was used to quantify the number of ciliated cells with DNAH5 in the ciliary 
axoneme. Only eGFP positive cells were counted in NHBE BMI-1 cells transduced 
with scrambled or DNAH5-targeted shRNA to ensure only shRNA expressing cells 
were counted. ***P<0.001; Fisher’s exact test. 
*** 
*** 
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With DNAH5 not localising to the ciliary axoneme in DNAH5 knockdown cells it was 
predicted that the ODA would also be absent, as it is in patients, so axoneme 
ultrastructure was assessed in these cells. However, utilising standard PCD 
diagnostic methodology and criteria TEM showed no abnormalities in cilia 
ultrastructure outside of normal ranges in cilia from untransduced, scrambled 
shRNA and DNAH5-targeted shRNA transduced NHBE BMI-1 cells grown on ALI 
(Figure 5.9). In these studies over 200 individual cilia per condition were assessed 
for ultrastructural defects. Loss of ODA was therefore not detected in these studies, 
however, it is important to note that in the TEM studies, in contrast to the DNAH5 
localisation studies described above, there was no way to differentiate between 
cilia from cells expressing the shRNA and those not expressing the shRNA. 
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Scrambled shRNA No shRNA DNAH5 shRNA 
Figure 5.9. Cilia ultrastructure 
TEM was used to determine microtubule organisation and the presence of absence 
of dynein arms following mucociliary differentiation of shRNA transduced and 
untreated NHBE BMI-1 cells. Values are percent of total. Defects in microtubule 
organisation were assessed in at least 200 individual cilia cross-sections (n=202, 294 
and 323 for untransduced, scrambled shRNA transduced and DNAH5 shRNA 
transduced cells respectively). The presence/absence of dynein arms was assessed 
in at least 70 individual cilia cross-sections (n=71, 94 and 104 individual cilia from 
untransduced, scrambled shRNA transduced and DNAH5 shRNA transduced cells 
respectively). 
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 Despite cells pre-ALI showing an almost 100% transduction efficiency it has been 
observed that following differentiation of lentivirus transduced cells transgene 
silencing can occur (428). Given that PCD is a recessive disease a reduction in 
efficiency of DNAH5 knockdown could help explain the lack of a missing ODA 
phenotype using typical diagnostic TEM methodology designed for detecting 
defects in samples were all cells display a complete lack of protein. To address if 
silencing of shRNA expression had occurred the level of DNAH5 knockdown was 
assessed at the basal cell stage (pre-ALI) and following mucociliary differentiation 
(>4 weeks on ALI; post-ALI). DNAH5 knockdown was 91.67 ±0.88% pre-ALI but only 
62.00 ±6.66% post-ALI (Figure 5.10a; p<0.01; Students t-test). An over 600-fold up-
regulation in DNAH5 expression in cells post-ALI (Figure 5.10b; p<0.01; Students t-
test) may have contributed to the reduction in the percentage knockdown observed 
post-ALI. DNAH5 is an axonemal protein with no known cytoplasmic function so it is 
unsurprising that extensive gene expression only occurs in multi-ciliated cells. 
Supporting this, DNAI1 expression, a gene that codes for another axonemal protein, 
was also significantly up-regulated post-ALI (Figure 5.10b; p<0.01; Students t-test). 
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Figure 5.10. DNAH5 expression pre- and post-ALI 
DNAH5 expression was quantified using qRT-PCR and (a) DNAH5 knockdown pre- 
and post-ALI in cells transduced with a DNAH5-targeted shRNA was determined 
relative to DNAH5 expression in cells transduced with scrambled shRNA. (b) DNAI1 
and DNAH5 expression in NHBE BMI-1 cells post-ALI was also quantified and 
expression shown relative to NHBE BMI-1 cells pre-ALI. **P<0.01; ***P<0.001; 
Students t-test. Values are mean ±SEM. 
a 
b 
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To further assess if transgene silencing was occurring whilst removing the 
confounding effect that up-regulation of DNAH5 expression post-ALI could have the 
percentage of GFP positive cells (a reporter gene introduced together with the 
shRNA construct) was assessed pre-ALI and post-ALI. Manual counting showed that 
the percentage of GFP positive cells post-ALI was 71.2 ±1.24% (Figure 5.11a) whilst 
pre-ALI almost 100% of transduced cells were GFP positive (Figure 5.11b). This 
indicates that the transgene and so the shRNA, was being silenced after cells 
underwent mucociliary differentiation. Around 28.8% of cells were GFP negative 
post-ALI, as assessed by manual counting, which is similar to the proportion of cells 
found by FACS to express only low levels of GFP pre-ALI (32.7%; Figure 5.11b). 
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Figure 5.11. Transgene silencing post-ALI 
DNAH5 knockdown NHBE BMI-1 cells were (a) stained with DAPI following 
mucociliary differentiation and the percentage of eGFP positive cells post-ALI was 
determined. (b) The percentage of eGFP positive cells pre-ALI was determined by 
flow cytometry with the top panel showing gating such that all eGFP positive and 
GFP negative populations are differentiated. The bottom panel shows gating such 
that high and low eGFP expressing cells are differentiated. Values are mean ±SEM. 
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5.4. DISCUSSION 
Suitable models for studying gene therapy approaches for PCD are lacking. In this 
chapter studies aimed at the production of a suitable cell model from NHBE cells 
have been described. In the first instance it was vital to produce NHBE cells capable 
to long-term growth and differentiation to a mucociliary phenotype. Transduction 
of NHBE cells with BMI-1 resulted in significant extension of the growth potential of 
these cells without diminishing their differentiation capacity. Whilst greatly 
improving the number of population doublings NHBE cells could undergo, BMI-1 
transduction did not immortalise the NHBE cells in contrast to viral antigens such as 
the SV40 large T-antigen used to produce the 16HBE14o- cell line (376). 
Nevertheless the combined properties of extended growth capacity and 
maintenance of mucociliary differentiation potential of HBE cells is something not 
previously described and of importance in the production of a PCD disease model. 
Whilst Fulcher et al., (423) previously described the transformation of NHBE cells 
with BMI-1 alone no attempts at mucociliary differentiation of these cells has been 
described and the data in this chapter provides evidence that transformation of 
NHBE cells with BMI-1 alone allows for extensive ciliogenesis following ALI culture.  
Transduction with BMI-1 of HBE cells from PCD patients could potentially provide 
semi-immortalised cell lines that could be used to model PCD in vitro however in 
the course of this thesis project no such samples could be obtained. shRNA 
knockdown of DNAH5 in BMI-1 transduced NHBE cells was therefore used to 
attempt to model the PCD phenotype. Knockdown of DNAH5 at the mRNA level was 
observed as was immotile cilia and loss of axonemal localisation of DNAH5 protein 
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all faithfully recapitulating a PCD phenotype. However, TEM analysis, in which it 
was impossible to determine whether the cilia being observed were protruding 
from cells expressing DNAH5-targeted shRNA, failed to show missing ODA -a 
phenotype seen in PCD patients. The methodology for analysing cilia ultrastructure 
was the same as that used clinically for the diagnosis of PCD. In brief this involved 
characterising at least 200 individual cilia, not ciliated cells. Given that each ciliated 
cell has a few hundred cilia the count could therefore be biased to a few cells in 
which the vast majority of cilia were well aligned to the plane being observed. This 
is not an issue in the clinical diagnosis of PCD as all cells from a single patient should 
display a PCD phenotype. However, in the context of a heterogeneous population 
of knockdown cells where it was found that some shRNA expression was silenced in 
cells expressing low levels of transgene and potentially dampened in cells 
expressing high levels of transgene, a phenomenon also seen in the course of 
differentiating induced pluripotent stem cells (iPSCs) (428-430), such a counting 
method may not be sensitive enough to detect a PCD phenotype and a larger 
sample size should be used with only a single cilium per cell being characterised.  
The data in this chapter provide evidence that knockdown of DNAH5 could be used 
to recapitulate at least some aspects of a PCD phenotype. However, a number of 
improvements could be made. Firstly, a homogenous population of shRNA 
expressing cells would be desirable to ensure that all cells within a given culture 
behaved similarly and had similar levels of DNAH5 knockdown. Given the extended 
growth capacity of NHBE BMI-1 cells it is now plausible to establish and expand 
single cell clones expressing high levels of shRNA. However, even with a 
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homogenous population of cells transgene silencing following differentiation on ALI 
would remain an issue. Transgene silencing following lentivirus transduction 
typically involves DNA methylation or histone modification of the promoter 
element (428). The use of an alternative promoter more resistant to DNA 
methylation, such as a ubiquitous chromatin opening element (UCOE) (431), may 
offer a solution. Use of UCOE has been shown to prevent transgene silencing in 
iPSCs and importantly their differentiated progeny (432). Alternatively, cell specific 
promoters could prevent silencing in certain cell types. To this end the human 
FOXJ1 promoter, expressed in multi-ciliated cells (433), would help maintain shRNA 
expression in multi-ciliated cells. An alternative option to the use of shRNA 
knockdown of DNAH5 is the use of gene modification technologies, such as 
CRISPR/Cas9 systems, to introduce frameshift mutations, or patient specific 
mutations, that prevent wild-type DNAH5 expression. 
In summary, this chapter describes the generation of an airway epithelial cell line 
capable of mucociliary differentiation and with an extended growth potential. This 
advance paves the way to modelling PCD in vitro by direct transformation of patient 
cells with BMI-1, or the use of gene modification technologies in healthy cells to 
mutate DNAH5. The shRNA studies described here provide proof-of-principle that 
knockdown of DNAH5 faithfully reproduces the immotile cilia and lack of axonemal 
DNAH5 expression seen in PCD patients. As such, correcting these phenotypes 
would still provide proof-of-principle that gene therapy could restore cilia beating in 
PCD caused by DNAH5 mutations. This model was therefore moved forward to 
experiments testing this hypothesis.  
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6. CORRECTION OF IN VITRO PCD MODELS 
6.1. INTRODUCTION 
Two proof-of-principle studies have demonstrated that cilia beating can be restored 
in PCD cells by introduction of a functional copy of the mutated gene. In these 
studies PCD resulted from mutations in DNAI1 (283) or its mouse homolog 
Dnaic1 (314), the second most common cause of PCD. No study has yet determined 
whether cilia beating can be restored in PCD caused by mutations in DNAH5, the 
most common cause of PCD and so of highest potential benefit to PCD patients. 
Previous chapters in this thesis have described the cloning of wild-type DNAH5 
cDNA into a mammalian expression plasmid, enhancement of transgene expression 
using minicircle vectors and the production of a model in which to assess PCD gene 
therapy. This provided the tools required for assessing the hypothesis that gene 
therapy could be used to restore cilia beating in PCD caused by DNAH5 mutations. 
6.2. AIMS 
To test the hypothesis that gene therapy would restore cilia beating in PCD caused 
by DNAH5 mutations. 
To achieve this aim, reporter genes were used to optimise transfection of well 
differentiated ALI cultures and a reverse transfection protocol, previously optimised 
for siRNA transfections, was assessed for DNA transfections. The latter approach 
relied on transfecting de-differentiated cells and so the persistence of transgene 
expression was also assessed. Finally, correction of the PCD model previously 
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described was attempted by transfection of DNAH5 cDNA using the method of 
transfection found to be optimal. 
6.3. RESULTS 
6.3.1. PCI-DNAH5 MUTAGENESIS 
The DNAH5 cDNA cloned earlier (Chapter 3.3.3; p137) was of a wild-type sequence 
and so would be silenced by the shRNA used to produce the PCD model described 
earlier (Chapter 5; p183). To avoid this knockdown 6bp spaced along the 21bp 
shRNA recognition sequence were mutated. The recognition sequence of the 
DNAH5-targeted shRNA was; 
5’ – GGACTGACTTTCTAATTCAAA – 3’  
A codon optimised DNAH5 cDNA sequence was obtained from Blue Heron Bio 
(https://wwws.blueheronbio.com) and the wild-type shRNA recognition sequence 
was mutated to the codon optimised sequence (red denotes the mutated 
nucleotides); 
5’ – GAACGGACTTCCTTATCCAGA – 3’ 
The overlapping primers used for this mutagenesis were; 
Forward primer; 5'-
GGTGCCAAATGTTGACAATGTGAGAACGGACTTCCTTATCCAGACCATTGCTAAACAGGG
CAAGGCT-3' 
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Reverse primer; 5'-
AGCCTTGCCCTGTTTAGCAATGGTCTGGATAAGGAAGTCCGTTCTCACATTGTCAACATTTG
GCACC-3' 
Site-directed mutagenesis using QuickChange II XL Site-Directed Mutagenesis kit 
was unsuccessful yielding no PCR product or colonies. The primers used had a high 
melting temperature (Tm) of 79.6
oC whose sequences had the potential for hairpin 
formation, self-annealing and primer dimerization. In addition, that the 
amplification temperature for the DNA polymerase used was 68oC, below the 
recommended annealing temperature of primer Tm-5
oC, secondary annealing would 
have been a problem and all of this could have contributed to the lack of a PCR 
product and so lack of colonies. 
To overcome these issues the mutagenic primers were used with a high-fidelity 
polymerase whose maximal activity was achieved at 72oC. In addition both 
annealing and extension steps were performed at this temperature (Table 6.1) thus 
reducing the potential for hairpin formation, self-annealing, primer dimerization 
and secondary annealing. Following this PCR reaction the PCR product was purified 
and a SLIC reaction performed as described in materials and methods (Chapter 
2.2.22; p93). The mutated portion of the DNAH5 cDNA was sub-cloned into 
pMC.DNAH5 using AfeI and SexAI restriction sites to yield the plasmid pMC.DNAH5 
(shRNA). MC.DNAH5 (shRNA) minicircle DNA was produced from the pMC.DNAH5 
(shRNA) producer plasmid. 
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Step Temperature (oC) Duration Number of Cycles 
Initial denaturation 95 3 minutes 1 
Denaturation 98 20 seconds  
17 Annealing 72 15 seconds 
Extension 72 1 minute/kb 
Final extension 72 1 minute/kb 1 
Table 6.1. Cycling conditions for 6bp mutagenesis 
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To assess if the mutations introduced to the DNAH5 cDNA were sufficient to allow 
escape of the resultant transcripts from shRNA-mediated degradation HEK293T cell 
clones stably expressing either a scrambled shRNA (HEK293T Scrambled KD) or the 
DNAH5-targeted shRNA (HEK293T DNAH5 KD) were produced by transducing 
HEK293T cells with lentivirus carrying either a scrambled shRNA or the DNAH5-
targeted shRNA used to produce the PCD model described earlier (Chapter 5; 
p183). HEK293T Scrambled KD and HEK293T DNAH5 KD cells were then transfected 
using L2K with either MC.DNAH5 or MC.DNAH5 (shRNA) minicircle DNA and DNAH5 
expression was quantified by qRT-PCR. When wild-type DNAH5 was transfected 
DNAH5 expression was knocked down in HEK293T DNAH5 KD cells by 44.0 ±2.3% 
relative to HEK293T Scrambled KD cells (Figure 6.1; p<0.01; Students t-test). No 
significant knockdown was seen in HEK293T DNAH5 KD cells when MC.DNAH5 
(shRNA) was transfected (Figure 6.1) indicating that mRNA transcribed from this 
DNA evaded knockdown by the DNAH5-targeted shRNA used to model PCD. 
Therefore MC.DNAH5 (shRNA) DNA was to be used in studies attempting to correct 
the PCD model described earlier. 
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Figure 6.1. MC.DNAH5 mutagenesis 
Wild-type (MC.DNAH5) and mutated (MC.DNAH5 (shRNA)) were transfected into 
HEK293T cells stably transduced with a scrambled or DNAH5-targeted shRNA and 
DNAH5 expression assessed by qRT-PCR. NS; not significant; **P<0.01; Student’s t-
test used to assess significance. Values are mean ±SEM. 
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6.3.2. TRANSFECTIONS OF CILIATED ALI CULTURES 
To assess whether gene therapy could restore cilia beating in PCD caused by DNAH5 
mutations it was vital that the DNAH5 transgene could be efficiently transfected 
and expressed in ciliated cells. The human airway contains ciliated and mucus 
producing cells connected together by tight junctions and overlaid with a mucus 
barrier all of which act to restrict cell entry of external agents. The in vivo barriers 
are best recapitulated in vitro by mucociliary differentiation of human airway 
epithelial cells induced by use of an ALI culture system. The ALI culture system was 
therefore considered to be the most relevant system for assessing the potential 
efficacy of PCD gene therapy.  
Prior to attempting correction of in vitro PCD models on ALI systems the 
transfection efficiency of this approach was optimised using reporter genes to 
assess the likelihood of successes when transfecting the DNAH5 cDNA. Transfection 
efficiency of ciliated ALI cultures using the LPD vector was assessed by transfecting 
DNA encoding a secreted luciferase gene (NanoLuc) to enable easy quantification.  
First the site of application of nanocomplexes was assessed comparing apical, 
basolateral and apical+basolateral (both) applications. A total of 2µg of MC.NL1.3 
DNA was transfected per well with 1µg apical application and 1µg basolateral 
application used when both sides were transfected simultaneously. To assess 
transgene expression 700µL of ALI media was added to the apical surface and 
incubated for 30 minutes at 37oC and 5% CO2 to allow the secreted luciferase 
protein to diffuse into the media. Luciferase activity within this media was assessed 
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along with luciferase activity in the 700µL basolateral media which the cells were 
cultured with.  
Basolateral application of nanocomplexes was found to provide no detectable 
transgene expression above background levels (untransfected cells). There was no 
significant difference in transgene expression following application of 
nanocomplexes to the apical surface alone or both the apical and basolateral 
surface (Figure 6.2a) although both gave transgene expression above background 
levels. That transgene expression was only present following apical delivery of the 
LPD vector highlights that the LPD vector preferentially transfects the apical surface 
of ALI cultured cells.  
Whilst there was no significant difference in transfection efficiency with apical or 
apical and basolateral application of nanocomplexes, the latter was chosen for 
future studies as it allowed efficient transfection via the apical surface and would 
allow basolateral surface transfection events if later treatments assessing the use of 
tight junction modulators permitted this route of gene delivery.  
Having optimised the route of delivery the amount of DNA required for ALI 
transfections was optimised by transfecting well-ciliated ALI cultures with a total of 
1, 2 or 4µg of DNA per well. No significant differences between the different 
treatment groups were detected likely due to the high variability in transfection 
efficiencies within groups combined with the low sample sizes per group (Figure 
6.2b; n=3 for each group).  
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It was clear that to be successful for the assessment of gene therapy treatment the 
methodology used to transfect ALI cultures would need to be further optimised to 
enhance efficiency and the use of 4µg of DNA per well was used in these further 
studies as at this dose all treated wells produced RLU values above that of 
background levels (untreated wells) which contrasted with when 1 and 2µg of DNA 
were transfected where 1/3 and 2/3 of treated wells respectively did not display 
RLU values above background.  
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Figure 6.2. Transfections of differentiated ALI cultures 
LPD transfections were optimised using a secreted luciferase and both the (a) route 
and (b) dose for efficient transfection determined. Values in (a) are background 
subtracted and displayed as mean ±SEM. Values in (b) are mean ±SEM. 
 
a 
b 
224 
 
ALI cultures are known to be difficult to transfect and transduce so a number of 
methods have been developed to enhance gene delivery with the most common 
being the use of LPC (261, 434), EGTA (435-437) and sodium decanoate (also known 
as sodium caprate) (244, 438). Treatment of ALI cultures with these compounds has 
the effect of reversibly disrupting the integrity of tight junctions. How this 
disruption translates to enhanced transgene expression for non-viral vectors is not 
clear. In contrast, access to receptors on the basolateral surface is thought to be the 
mechanism by which disruption of tight junctions enhances viral transduction (263, 
439).  
To enhance transfection of ALI cultures by LPD complexes EGTA, sodium decanoate 
and ethanol treatments were assessed. The latter has not previously been assessed 
for enhancement of airway gene delivery but was included due to evidence that 
ethanol increased the permeability of ALI cultures formed from NHBE cells (440). In 
brief, five different treatment conditions were tested i) 2 hour treatment with LPD 
alone, ii) 24 hour pre-treatment of ALI cultures with 0.6% (v/v) ethanol followed by 
2 hour treatment with LPD, iii) 2 hour treatment with LPD together with 0.6% (v/v) 
ethanol, iv) 2 hour treatment with LPD together with 10mM EGTA and v) 3 minute 
pre-treatment of ALI cultures with 30mM sodium decanoate followed by 2 hour 
treatment with LPD. All incubations were performed at 37oC and 5% CO2 and apical 
washes and basolateral media were collected for luciferase assays 48 hours 
following transfection. These treatment conditions and concentrations were used 
as they were previously shown to be optimal for enhancing transgene expression 
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with viral and non-viral vectors (244, 435-438) or enhancing the permeability of ALI 
cultures in the case of ethanol pre-treatment (440). 
Treatment of ALI cultures with LPD together with EGTA produced a 145-fold 
enhancement in transgene expression compared to treatment with LPD alone as 
assessed by luciferase activity from basolateral media (Figure 6.3a; p<0.01; one-way 
ANOVA with Tukey’s post-test analysis). Pre-treatment of ALI cultures with sodium 
decanoate similarly enhanced transfection with a 115-fold increase in luciferase 
activity (Figure 6.3a; p<0.01; one-way ANOVA with Tukey’s post-test analysis) whilst 
ethanol did not significantly enhance transgene expression. Assessing luciferase 
activity in the apical washes of the same cells 48 hours following transfections there 
were no significant differences between the different treatment groups (Figure 
6.3b). 
Whilst toxicity was not quantified in this study it was of note that sodium 
decanoate pre-treatment of ALI cultures resulted in significant toxicity with cell 
monolayer integrity being compromised most likely due to significant cell death 
given that a confluent monolayer was no longer present (Figure 6.3c). Whether this 
toxicity resulted from the sodium decanoate treatment alone, or the combination 
of sodium decanoate treatment followed by LPD application was not assessed but 
given that the toxicity has not been reported in previous studies employing the 
same conditions used here (438) it is likely that the latter produced the toxicity 
observed.   
226 
 
b 
a 
 
 
 
  
227 
 
c 
OptiMEM 
EtOH pre-treatment 
EtOH + LPD 
LPD alone 
EGTA + LPD 
Sodium decanoate pre-treatment 
Figure 6.3. Tight junction disruption for enhanced gene delivery 
Luciferase activity in (a) basolateral media and (b) apical wash was assessed 48 
hours following transfections of ALI cultures with LPD and a variety of tight junction 
disruption treatment protocols. (c) Light microscopy of these transfected ALI 
cultures. *P<0.05; **P<0.01; one-way ANOVA with Bonferroni post-test analysis 
used to assess significance. Values are background subtracted and displayed as 
mean ±SEM. 
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As secreted luciferase was used to optimise transfections in differentiated ALI 
cultures, no data was available on the percentage of cells transfected, an important 
consideration for PCD gene therapy. To assess this MC.eGFP was transfected using 
2.0µg of DNA on each the apical and basolateral surfaces (4µg total per well) and 
the different tight junction modulation strategies tested above were also used. It 
was evident that regardless of what treatment option was used far less than 1% of 
cells were transfected (fewer than 5 out of 500,000 cells seeded) highlighting the 
futility of using ALI culture transfections to provide proof-of-principle of PCD gene 
therapy. In attempting to quantify the percentage of cells transfected cells were 
fixed, the nucleus stained with DAPI and over 15 random fields of view per 
treatment were assessed for GFP positive cells but none were detected. Rather 
than proceeding with the approach of transfecting well differentiated ALI cultures a 
different strategy of transfecting cells prior to ALI culture was investigated. 
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6.3.3. REVERSE TRANSFECTION 
Transfecting primary airway epithelial cells 24 hours following seeding onto tissue 
culture plates, the standard method for transfecting cells, resulted in significant 
toxicity as was described when transfecting primary nasal epithelial cells (Chapter 
3.3.1.3; p121) and so was not utilised. Ramachandran et al., (441) have shown that 
transfecting primary human or porcine airway epithelial cells in suspension 
followed by seeding the cells on ALI culture did not affect cell viability and resulted 
in both enhanced transfection efficiency relative to differentiated cells and 
differentiation of the cells to a mucociliary phenotype. The authors were 
transfecting siRNA and gene silencing persisted for at least 2 weeks. This “reverse 
transfection” (441) method was utilised here in the context of DNA delivery. 
Submerged NHBE BMI-1 cells were transfected for 30 minutes at room temperature 
with varying concentrations of MC.eGFP DNA packaged into LPD nanocomplexes. 
The percentage of cells transfected varied from 4.2 ±1.7% with a DNA 
concentration 2µg/mL/5x105 cells to 17.7 ±0.6% at 8µg /mL/5x105 cells (Figure 6.4a; 
p<0.001; one-way ANOVA with Bonferroni’s post-test analysis). DNA concentrations 
above 8µg /mL/5x105 cells were found to be toxic resulting in significant cell death 
and so were considered unsuitable for further studies (Figure 6.4f and g). There was 
no significant difference in transfection efficiency at a dose of 4 and 6µg /mL/5x105 
cells (Figure 6.4a). Given the desire to minimise potential toxicity that may impact 
on the ability of cells to undergo mucociliary differentiation 4µg /mL/5x105 cells 
was selected as the optimal dose that balanced efficient transfection with minimal 
toxicity and so was used in further studies. 
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Figure 6.4. Reverse transfection protocol DNA dose optimisation 
Following MC.eGFP transfection at a variety of doses (a) the percentage of cells 
transfected was assessed by flow cytometry. (b-g) Light microscopy images showing 
cell morphology following reverse transfection with (b) 0-, (c) 2-, (d) 4-, (e) 6-, (f)  8- 
and (g) 10µg/mL/5x105 cells. NS; not significant; **P<0.01; one-way ANOVA with 
Bonferroni post-test analysis used to assess significance. Values are background 
subtracted and displayed as mean ±SEM. 
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Having optimised the DNA concentration for transfection transgene persistence 
was assessed by transfecting cells pre-ALI with MC.eGFP, seeding the cells on ALI 
and obtaining whole well scans using a fluorescent microscope (Figure 6.5a) 
followed by quantification of the percentage of eGFP positive cells using ImageJ 
software. An aliquot of the same cells seeded on ALI were also seeded on standard 
tissue culture plates to allow more sensitive determination of initial levels of 
transgene expression by flow cytometry. 
Transfection efficiency assessed by flow cytometry was 2.6 fold higher than that 
calculated using ImageJ (14.7±2.4% for flow cytometry and 5.6±0.8% for ImageJ; 
Figure 6.5b) thus highlighting the differences in sensitivity between the two 
approaches. Interestingly the percentage of GFP positive cells almost doubled 6 and 
8 days post transfection from 5.6±0.8% at day 2 to 9.6±0.9% and 9.4±0.8% on day 6 
and 8 respectively using the ImageJ calculation method (Figure 6.5b; p<0.01; one-
way ANOVA with Bonferroni’s post-test analysis). Transgene expression declined to 
day 2 levels at 15 days post-transfection and fell further at 29 days post-
transfection. As cells on ALI typically produced cilia at around 14-21 days on ALI, 
that transgene expression was still present at these time point indicates that the 
reverse transfection method has the potential to allow proof-of-principle studies 
assessing PCD gene therapy in vitro.  
232 
 
 
 
 
   
2 days 6 days 8 days 
a 
b 
Figure 6.5. Persistence of transgene expression using reverse transfection 
NHBE BMI-1 cells reverse transfected with MC.eGFP were placed on ALI and (a) 
whole well scan images taken and (b) GFP fluorescence quantified up to 29-days 
post transfection. *P<0.05; one-way ANOVA with Bonferroni post-test analysis 
used to assess significance. Values are background subtracted and displayed as 
mean ±SEM. 
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Having established that the reverse transfection protocol allowed efficient and 
persistent transgene expression, its effects on cilia formation and function were 
determined by assessing the levels of ciliogenesis and CBF 32 days following 
transfection. This time-point was chosen so as to minimise the potential effects of 
eGFP overexpression on cilia formation and function. Cells transfected using the 
reverse transfection method were found to undergo mucociliary differentiation as 
assessed by light microscopy (data not shown) and encouragingly no differences in 
the percentage active area (Figure 6.6a) and CBF (Figure 6.6b) were found when 
comparing transfected and untransfected cells so indicating that the reverse 
transfection method did not adversely affect cilia formation or function. This 
method was therefore considered suitable for assessing PCD gene therapy in vitro.  
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Figure 6.6. Cilia characterisation following reverse transfection 
NHBE BMI-1 cells reverse transfected with MC.eGFP were placed on ALI and 32 days 
following transfection videos captured and the (a) percent active area and (b) CBF 
determined using CiliaFA ImageJ plugin. NS; not significant; Student’s t-test used to 
assess significance. Values are mean ±SEM. 
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Having optimised the conditions for transfecting NHBE BMI-1 cells whilst retaining 
efficient transgene expression until at least the time point at which mucociliary 
differentiation takes place it was feasible to assess whether gene transfer of a 
functional DNAH5 cDNA would restore cilia beating in in vitro PCD disease models.  
The cell model developed and described in this thesis - NHBE BMI-1 cells stably 
expressing DNAH5-targeted shRNA (Chapter 5; p183)- was transfected with 
MC.DNAH5 (shRNA) using the reverse transfection method and cells then seeded 
on to standard tissue culture plates. No significant difference in DNAH5 expression 
was found by qRT-PCR 48 hours following transfection when comparing transfected 
with untransfected cells (Figure 6.7a). As such, it was unsurprising that the PCD 
phenotypes observed from the NHBE BMI-1 DNAH5 knockdown cells were not 
corrected with immunostaining of cells 30 days post-transfection (28 days post-ALI) 
failing to show any DNAH5 expression. Due to the lack of DNAH5 expression no 
further phenotyping studies of transfected cells were pursued. 
To provide a guide as to the number of cells that could be expected to have been 
transfected in these correction studies NHBE BMI-1 cells were transfected with the 
eGFP-DNAH5 fusion plasmid pCI.eGFP.DNAH5. The fusion protein was expressed in 
around 0.35% of cells when accounting for auto-fluorescence detected in 
untransfected cells, this difference whilst small was significant (Figure 6.7b; p<0.01; 
Students t-test). This low transfection efficiency helps explain why no DNAH5 
expression was seen in MC.DNAH5 (shRNA) transfected NHBE BMI-1 DNAH5 
knockdown cells. The biophysical properties of the LPD vector carrying MC.DNAH5 
(shRNA) was compared to MC.eGFP containing LPD vectors to assess if any 
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differences here could explain the different transfection efficiencies observed when 
transfecting NHBE BMI-1 cells. With regards to zeta potential, a factor that impacts 
on vector binding to the cell surface, there was no significant difference between 
MC.DNAH5 (shRNA) and MC.eGFP containing LPD complexes which had a zeta 
potential of 35.4 ±0.5mV and 36.5 ±1.5mV respectively (Figure 6.7c). There was a 
small but significant difference of around 10nm to the hydrodynamic sizes of LPD 
complexes formulated with MC.DNAH5 (shRNA) and MC.eGFP DNA with the mean 
values being 110.5 ±1.1nm and 102.5 ±2.0nm respectively (Figure 6.7c; p<0.01; 
Student’s t-test). However, it is unlikely that this small difference impacted 
significantly on transfection efficiency.   
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Figure 6.7. DNAH5 transfections 
(a) DNAH5 expression was assessed by qRT-PCR following MC.DNAH5 (shRNA) 
transfection into DNAH5 knockdown NHBE BMI-1 cells. (b) GFP expression was 
assessed by flow cytometry following transfection of NHBE BMI-1 cells with 
pCI.eGFP.DNAH5 and (c) hydrodynamic size and zeta potential of LPD complexes 
containing MC.DNAH5 (shRNA) and MC.eGFP DNA was also assessed. NS, not 
significant; **P<0.01; Student’s t-test used to assess significance. Values are mean 
±SEM. 
a b 
c 
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6.4. DISCUSSION 
To assess whether gene therapy can correct PCD caused by DNAH5 mutations it is 
imperative that the functional gene can be delivered and expressed in ciliated cells. 
In this chapter studies aimed at optimising gene delivery to ciliated cells are 
described. In vitro two culture methods have been used to differentiate primary 
airway epithelial cells to a ciliated phenotype, namely ALI cultures and the Jorissen 
culture method (315). The Jorissen culture method allows differentiation of airway 
epithelial cells to a ciliated phenotype under submerged conditions with cells grown 
in suspension. Airway cells in suspension, once in contact with neighbouring cells, 
form spheroids thus inducing differentiation with cilia protruding into the lumen of 
the spheroid structure. In contrast, ALI cultures present a more native system in 
that the basolateral surface of cells are exposed to culture media whilst the apical 
surface is exposed to air. Growing airway epithelia cells at this ALI induces 
mucociliary differentiation so this system has the added potential of allowing 
assessment of mucociliary clearance, a vital outcome measure in assessing 
potential clinical efficacy of a gene therapy treatment. However, transfections of 
differentiated ALI cultures are notoriously difficult presenting a number of 
challenges to vector uptake including polarisation of the cell epithelium, formation 
of tight junctions, production of mucus and cilia beating. In PCD, cilia are immotile 
but their presence may still hinder transfection given the presence of a periciliary 
bush preventing particles above 40nm from reaching the cell surface (442). In light 
of this it is unsurprising that the gene transfer was inefficient.  
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EGTA and sodium decanoate enhances gene transfer by LPD vectors to 
differentiated ALI cultures, as observed in other studies with different viral and 
non-viral vectors (244, 435-438). However, these treatments still resulted in less 
than 1% of cells showing transgene expression. Transfection of differentiated ALI 
cultures by the optimised LPD vector is thus too inefficient to allow correction to be 
observed in vitro given that the LPD vectors do not exclusively transfect ciliated 
cells and that the proportion of ciliated cells in ALI cultures are typically under a 
third of the cells present.  
Transfection of ALI cultures with siRNA is also inefficient and a reverse transfection 
protocol was devised to overcome this (441). In this chapter, for the first time, the 
reverse transfection method was shown to also allow more efficient DNA 
transfection relative to transfection of fully differentiated ALI cultures. Using this 
protocol transgene expression persisted long enough for ciliogenesis to take place, 
a crucial requirement for the method to be utilised in gene therapy proof-of-
principle studies in vitro. The percentage of cells expressing eGFP following the 
reverse transfection protocol peaked at around 6-8 days post-transfection whereas 
peak expression is typically 48-72 hours in dividing cells (443, 444). Native GFP has a 
relatively long half-life of ~26hours (445) (compared with native firefly luciferase 
with a half-life of ~2 hours (446)) and this stability combined with a lack of cell 
division would have contributed to the delayed peak in eGFP expression seen. The 
lack of cell division would have also contributed to the persistence of transgene 
expression where eGFP expression was still present 28-days post-transfection. 
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Whether the cells transfected by the reverse transfection protocol had a bias 
towards differentiation to a specific lineage, for example ciliated cells, was not 
assessed and this will be an important consideration in PCD gene therapy proof-of-
principle studies, particularly if any potential bias was against differentiation to a 
ciliated cell phenotype. However, in these studies, of greater concern was the low 
transfection efficiency of the DNAH5 transgene. Correction studies of the DNAH5 
knockdown NHBE BMI-1 cells were unsuccessful most likely due to the size of the 
transgene being delivered, a phenomenon observed in previous studies (395, 447). 
As the 4µg/mL/5x105 cells dose was used in this correction study far fewer 
MC.DNA5 (shRNA) DNA molecules and so transgene constructs, would have been 
delivered compared to MC.eGFP DNA which was used to optimise the reverse 
transfection protocol for DNA transfections. Equimolar amounts of the larger 
MC.DNAH5 (shRNA) DNA (31.2µg/mL/5x105 cells) was not delivered in these studies 
due to toxicity concerns given the need to then induce mucociliary differentiation. 
Nevertheless when equimolar amounts of DNA were used in earlier studies in cell 
lines (Chapter 3.3.3; p144) transfection efficiency was not significantly enhanced as 
assessed by using the pCI.eGFP.DNAH5 construct.  
The principle aim of this chapter was to assess the hypothesis that gene therapy 
could restore cilia beating in PCD caused by DNAH5 mutations. Experiments 
described in this chapter highlight the need to improve expression of large 
transgenes as delivery of the smaller eGFP transgene was found to be more 
efficient than the larger DNAH5 coding cDNA. There are several barriers to the 
process of transfection and it will be important to assess where the bottleneck lies 
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when transfecting DNAH5 cDNA. One of the first steps in transfection is binding of 
the gene delivery vector and its uptake into cells. Low uptake of gene delivery 
vectors will invariably result in inefficient transfection. Cell uptake is determined by 
the biophysical properties of a gene delivery vector. That zeta potential did not 
differ when comparing MC.DNAH5 (shRNA) and MC.eGFP containing LPD 
nanocomplexes suggests that vector binding to the cell surface would have 
remained constant between the two complexes. Whilst a small but significant 
difference in particle size was seen when comparing complexes containing the small 
MC.eGFP DNA with the larger MC.DNAH5 transgene, as both complexes were 
around 100nm it is likely that both would have utilised the same uptake 
mechanism- namely clathrin-mediated endocytosis (396). As such poor cell uptake 
is unlikely to have been the cause of the poor expression of DNAH5 but this 
hypothesis should be assessed directly by fluorescence labelling of the MC.DNAH5 
(shRNA) and MC.eGFP DNA delivered.  
Following cell binding gene delivery vectors are taken up into endosomes which 
then go on to form lysosomes that degrade the contents within. It is vital that gene 
delivery vectors, or at least the DNA cargo, escapes the endosome prior to this 
occurring if transgene expression is to be successful. Given that the DOPE liposome 
within the LPD vector has been shown to aid in endosomal escape (401) and was 
present in the same quantity when transfecting with MC.eGFP and MC.DNAH5 
(shRNA), poor endosomal escape when transfecting MC.DNAH5 (shRNA) is unlikely 
to be the explanation for poor transgene expression.  
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Downstream of endosomal escape nuclear entry is vital to allow transgene 
transcription and subsequent translation in the cytoplasm. The precise mechanisms 
by which nuclear entry is achieved is unclear but given that cells transfected by the 
reverse transfection method would have been dividing, even if only briefly, nuclear 
entry is unlikely to have been a significant barrier. Nevertheless, quantification of 
transfected DNA in cytoplasmic and nuclear fractions of cells would provide a 
method for addressing whether poor nuclear entry was involved in the differences 
in transfection efficiency when comparing MC.eGFP and MC.DNAH5 (shRNA) 
transfections. 
Once inside the nucleus transfected DNA is transcribed and, as discussed, given that 
vector uptake, endosomal escape and nuclear entry are unlikely to sufficiently 
explain the poor transgene expression when transfecting MC.DNAH5 (shRNA) DNA, 
poor transcription of the large transgene may as long transcripts are invariably 
more prone to early termination. Hyper-phosphorylation of RNA polymerase is 
known to be important in preventing early transcription termination although the 
identity of the phosphatases involved remains elusive and the regulation of this 
mechanism is poorly understood (448). RNA viruses such as HIV-1 (around 9kb RNA 
genome) utilise cellular transcription factors, including RNA polymerase II, for 
replication of its RNA genome and employs the trans-activator of transcription (Tat) 
protein to prevent early termination by hyper-phosphorylation of RNA polymerase 
II (449, 450). Given the need for HIV-1 to employ the transactivator of transcription 
(Tat) protein for efficient replication of its 9kb genome by RNA polymerase II it is 
not inconceivable that early termination of DNAH5 transcription from MC.DNAH5 
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(shRNA) could be occurring given that no mechanism has been introduced to help 
prevent this. It will be important to assess if the limiting step in DNAH5 expression 
following MC.DNAH5 (shRNA) transfection is indeed at the transcription level. If so, 
studies aimed at elucidating the mechanisms involved in the transcription of 
DNAH5 and other large genes, from chromosomal DNA would provide clues on how 
DNAH5 expression from cDNA could be enhanced. 
In conclusion, in this chapter a reverse transfection protocol was optimised for DNA 
delivery and found to be a more efficient way of obtaining transgene expression in 
differentiated airway epithelial cells when compared to transfection of well-
differentiated ALI cultures. In attempting to correct a PCD disease model generated 
by shRNA knockdown of DNAH5 it was found that transfection of the DNAH5 
transgene was too inefficient to allow assessment of the hypothesis that gene 
therapy could be used to restore cilia beating in PCD. In the interests of testing this 
hypothesis and providing proof-of-principle it is worth pursuing the use of viral 
vectors capable of delivering large transgenes. Adenovirus could be used in proof-
of-principle studies given its large packaging capacity of ~30kb and the fact that it is 
an established airway gene delivery vector with protocols described for ALI culture 
transduction (451, 452). 
Given the difficulty of transfecting and transducing ciliated cells, the target for PCD 
gene therapy studies, human RSV should also be considered a potential candidate 
vector for proof-of-principle studies given its preference towards transducing 
ciliated cells (453). With a genome of around 15kb the virus could package DNAH5 
cDNA. A replication competent RSV vector should also be used in proof-of-principle 
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studies as this would allow for a 100% transduction efficiency removing poor gene 
delivery efficiency as a limiting step to determining whether recovery of cilia 
beating is feasible following gene therapy for PCD caused by DNAH5 mutations. Of 
course, a replicating virus vector would not gain approval for clinical use and so 
would be unsuitable for gene therapy in patients.  
Whilst currently inefficient when used to transfect the DNAH5 cDNA in vitro, the 
LPD vector is more suitable for clinical use and shown to be efficient for airway 
gene transfer of smaller transgenes. As such, efforts should be made to enhance 
DNAH5 expression using the LPD vector described in this thesis by addressing the 
issues behind why expression of large transgenes is inefficient. 
245 
 
 
 
 
 
 
 
 
 
CHAPTER SEVEN 
GENERAL DISCUSSION AND 
CONCLUSION 
 
  
246 
 
7. GENERAL DISCUSSION AND CONCLUSION 
PCD is a multi-systemic genetic disease resulting from ciliary dyskinesia. Chronic 
respiratory infections are the major cause of morbidity leading to bronchiectasis 
and potentially the need for lung transplantation (1). Current treatments are aimed 
at slowing this deterioration but none addresses the underlying ciliary defects. 
Gene therapy offers the potential to treat the primary defects in PCD. To date two 
proof-of-principle studies have been published both focussing on the DNAI1 gene 
and both utilising a lentivirus vector (283, 314). However, the most common cause 
of PCD involves mutations in DNAH5 (117), a large gene that cannot be packaged 
into a lentivirus vector. In this thesis advances have been made towards the 
development of gene therapy for PCD caused by mutations in DNAH5. 
A non-viral vector previously optimised for respiratory gene delivery (287) was 
utilised to transfect DNAH5 cDNA, cloned into a mammalian expression vector and 
both mRNA and protein expression were shown. However, transfection of this large 
construct was found to be inefficient as assessed by the transfection of a GFP-
DNAH5 fusion construct. To maximise the probability of observing gene correction 
it was important that transgene expression was optimised. To this end, minicircle 
DNA previously shown to enhance transgene expression in a number of organ 
systems (309, 311, 312, 404) was shown, for the first time, to enhance transgene 
expression in the airways. Importantly, expression of the DNAH5 transgene was 
increased by 50% at the mRNA level in airway epithelial cells. Next, a model in 
which to assess whether gene therapy could recover cilia beating in PCD patients 
was developed. 
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Transduction of cells with the proto-oncogene BMI-1 produced a semi-immortalised 
cell line capable of extended passaging whilst maintaining its mucociliary 
differentiation capacity. shRNA knockdown of DNAH5 in these cells was then used 
to provide an in vitro PCD model that recapitulated most of the phenotypes 
observed in PCD patients. Finally, correction of this model was attempted utilising a 
reverse transfection protocol (441) that minimised cell toxicity observed when 
utilising a standard transfection protocol and also overcame the barriers of 
transfecting differentiated cells. In attempting to correct this in vitro PCD model it 
was clear that the transfection efficiency of the large DNAH5 cDNA was too low. 
Transfection efficiency was quantified using the GFP-DNAH5 fusion construct and 
protein expression was detected in less than 1% of cells. Significant improvements 
to delivering the large DNAH5 transgene are therefore required to allow 
assessment of the hypothesis that gene therapy could recover cilia beating in PCD 
resulting from DNAH5 mutations. 
Whilst recovery of cilia beating following DNAH5 transfection was not shown a 
number of key advances were made towards the development of a gene therapy 
treatment for PCD. The finding that minicircle DNA enhances airway gene delivery is 
novel and has implications for PCD gene therapy and gene therapy of other airway 
disorders such as CF where plasmid DNA transfections have so far proven inefficient 
in clinical trials (454). Also, whilst minicircle DNA provided enhanced DNAH5 
expression, the enhancement in expression of smaller transgenes, such as eGFP and 
luciferase, was far greater. The majority of PCD causing genes, including DNAI1, the 
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second most common cause of PCD (122), have short ORFs and so would likely 
benefit more from minicircle based gene delivery.  
To further enhance transgene expression the use of novel mini-intronic plasmids 
(MIPs) for airway gene delivery should be assessed as these have been found to be 
superior to minicircle DNA, at least in the liver (455). Also, the use of stronger 
promoter and enhancer elements, such as the use of CMV and SV40 viral promoters 
could be used to boost transgene expression (296). A short EF1α promoter with a 
CMV enhancer was utilised in this thesis due to previous studies showing greater 
transgene persistence with an EF1α promoter than with the stronger CMV 
promoter (296, 297), a beneficial feature in a clinical setting and one required with 
the reverse transfection protocol utilised. 
In the context of airway gene delivery non-DNA constituents have been optimised 
with GL67A lipid found to be one of the most efficient to date (292). The LPD vector 
system shows similar transfection efficiencies to GL67A (287) but yet was still 
inefficient when transfecting DNAH5 cDNA. To assess the hypothesis that PCD 
caused by DNAH5 mutations could be corrected by gene therapy viral vector 
systems should be considered, particularly replication competent vectors that 
would remove transfection efficiency as a limiting factor to addressing the 
hypothesis. Translating any success to a clinical setting will however prove 
challenging given that replicating vectors are unlikely to meet the safety criteria 
required for clinical approval.  
With regards to clinical efficacy Ostrowski et al., (283) have shown, using a Dnaic1 
mouse model of PCD, that at least 40% of normal Dnaic1 mRNA expression is 
249 
 
required to provide normal mucociliary clearance. This represents a significant 
challenge as to date no vector optimised for airway gene delivery and capable of 
packaging the large DNAH5 cDNA achieves this level of efficiency with a single dose. 
Whether repeated administration would provide accumulation of transgene 
expression and increase the percentage of cells transfected needs to be tested with 
the LPD vector. This approach may prove fruitful given the low turnover of 
differentiated airway epithelial cells, at least 6 months in the mouse (456, 457). It 
would be important to optimise the timing between doses to obtain accumulation 
of transgene expression but avoid accumulation of toxicity. 
A repeated dosing strategy similar to that described above was undertaken in 
mice (278) and sheep (279) using the GL67A vector to deliver the CFTR transgene 
and found no accumulation of toxicity when using a dosing regimen of once per 
week and once per month in mice and sheep respectively. Whilst in mice repeated 
dosing did produce an accumulation of CFTR expression when transfecting a low 
dose of DNA (~1.2mg/kg), this was not seen when a medium (~4.8mg/kg) or high 
dose (~14.4mg/kg) was used (278). In addition, accumulation of CFTR expression 
was not observed in the sheep (279). In both studies the percentage of cells 
transfected was not quantified. It is important to note that these studies were 
undertaken as part of safety assessment of a repeat dosing strategy being 
investigated in man for CF gene therapy and so the goal was not to optimise 
transgene expression with the dosing regimen used but rather to show that 
repeated dosing does not lead to accumulated toxicity and that transgene 
expression was not diminished following repeated administration. 
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The development of a semi-immortalised cell line capable of undergoing 
mucociliary differentiation represents another significant novel development with 
the potential to impact the broader airway research field. Whilst in this thesis a PCD 
model was produced by shRNA knockdown of BMI-1 transformed NHBE cells, BMI-1 
transduction of HBE cells obtained from patients could potentially be used to 
produce patient specific cell lines capable of undergoing mucociliary differentiation. 
In addition to utilising these cell models for gene therapy research they would also 
allow detailed study of disease mechanisms which would be particularly useful 
when studying rare genetic defects where the supply of patient tissue is limited. 
Patient specific models would be superior to models produced by shRNA 
knockdown as they are mutation specific and so potentially more relevant for 
study. Such models would allow for mutation specific therapeutics to be assessed, 
for example the use of small molecule drug screens targeted at common disease 
causing mutations. The ability to extensively expand BMI-1 transduced cells makes 
high-throughput drug screening approaches feasible. 
Along with HBE cells, nasal brushing samples can also be used in mucociliary 
differentiation protocols in vitro and are less invasive to obtain than bronchial 
biopsies. Assessment of BMI-1 transduction of nasal brushing samples should be 
undertaken to see if this less invasive source of patient material could be utilised to 
generate cell models that could undergo mucociliary differentiation. This will be of 
particular advantage in the case of PCD where bronchial biopsies are not routinely 
taken for clinical purposes and obtaining samples for the sole purpose of research is 
unethical given the invasiveness of the procedure. 
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Recently the use of Rho-kinase inhibitor along with co-culture of NHBE cells with 
irradiated fibroblasts has been described to allow indefinite passage of NHBE cells 
whilst retaining the cells differentiation capacity by removal of the Rho-kinase 
inhibitor and feeder cells and placing the cells at an ALI (458). Being able to culture 
these “conditionally reprogrammed cells (CRC)” (458) indefinitely provides an 
obvious advantage over NHBE BMI-1 cells which senesce at around 25 passages. 
However, the need for cells to be co-cultured with freshly irradiated feeder cells 
limits the utility of the CRC approach to facilities equipped with irradiators and 
researchers with appropriate training and monitoring. With the CRC approach 
freshly irradiated feeder cells and the Y-27632 Rho-kinase inhibitor also represent 
recurring costs that are in addition to the media required to maintain NHBE cells. 
Together these issues impact on the potential for sharing CRC cell lines with 
different research groups. In contrast, NHBE BMI-1 cells are treated no differently 
to untransduced NHBE cells with only standard tissue culture techniques employed 
for cell maintenance. As such, BMI-1 transformed NHBE cells produced by one 
group can be disseminated to other groups who have standard tissue culture 
facilities. Only the producer of the BMI-1 transformed cells would require access to 
facilities allowing the production of lentivirus vectors. The transduction of NHBE 
cells with BMI-1 therefore represents a simpler and cheaper option for producing 
cells with an extended growth capacity that retain a mucociliary differentiation 
potential. 
In conclusion a number of advances towards PCD gene therapy have been 
described in this thesis including the cloning of the DNAH5 cDNA, enhancement of 
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transgene expression, the development of an in vitro PCD model and optimisation 
of a transfection protocol that provides efficient transfection of NHBE cells and 
where transgene expression persists until at least after mucociliary differentiation 
takes place. The technologies developed in this thesis project also have broader 
applications beyond PCD gene therapy. 
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9. APPENDICES 
9.1. APPENDIX A – NANOCOMPLEX FORMULATION 
In Vitro Transfection with LPD complexes  
Day 1 
 Seed cells at 2x104 cells/well in complete medium in a 96-well plate 
Day 2 
 Make up LPD complexes in Optimem 
Example for 0.75:4:1 L:P:D weight ratio for 8 wells of 96 well plate. 
1) 0.75 µL of L at 2mg/ml + 49.25 µL Optimem mixed well in eppendorf 1 
(e.g. DHDTMA:DOPE) 
2) 40 µL of P at 0.2 mg/ml + 60 µL Optimem mixed well in eppendorf 2 (e.g. 
K16E) 
3) 2 µL of D at 1mg/ml + 48 µL Optimem mixed well in eppendorf 3 (e.g. 
pCI.Luc) 
Then, using pipette, add content of eppendorf 2 into 1 and mix 5 times, then add 
contents of eppendorf 3 into 1 and mix 5 times and incubate at room temperature 
for 30 minutes. (ORDER OF MIXING IS IMPORTANT) 
 Add 25 µL of formed complexes to each well 
 Centrifuge cells at 1500rpm for 5min (VITAL, IF SKIPPED THEN 
TRANSFECTION EFFICIENCY DRAMATICALLY FALLS) 
 Put plate in Incubator for 24h 
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Day 3 (Luciferase and Protein Assays) 
 Prepare enough 1x Reporter Lysis Buffer (dilute 5x in MilliQ water) to give 
20µL per well 
e.g. for one 96 well plate will need to prepare 20µL x 100 wells = 2mL of 1x RLB 
 After 24h incubation, remove media from wells 
 Wash with 100µL 1x PBS and add 20µL 1x RLB 
 Wrap plate in cling film and place at 4oC for 20minutes 
 Transfer plate to -80oC and leave for at least 30mins (can leave overnight if 
you wish to perform luciferase assay following day). 
Day 3 or 4 (Luciferase and Protein Assays) 
 Thaw Luciferase Buffer and Substrate at RT approx 1h (1 pair of bottles per 
96-well plate) 
 Thaw plate from -80oC, approx 0.5-1h 
 Mix Luciferase Buffer and Substrate to make reagent 
 Perform luciferase and protein assay using Optima (100µL of reagent added 
by Optima) 
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In Vivo Transfection with LPD complexes 
 Make up complexes in sterile ddH2O 
Example for 0.75:4:1 L:P:D weight ratio for 3 mice each receiving 16.7µg of DNA. 
1) 18.75 µL of L at 2mg/ml + 31.25 µL ddH2O mixed well in eppendorf 1 
(e.g. DHDTMA:DOPE) 
2) 20 µL of P at 10 mg/ml + 30 µL ddH2O mixed well in eppendorf 2 (e.g. 
K16E) 
3) 10 µL of D at 5mg/ml + 40 µL ddH2O mixed well in eppendorf 3 (e.g. 
pCI.Luc) 
Then, using pipette, add content of eppendorf 2 into 1 and mix 5 times, then add 
contents of eppendorf 3 into 1 and mix 5 times and incubate at room temperature 
for 30 minutes. (ORDER OF MIXING IS IMPORTANT) 
 Deliver 50µL of formed complexes per mouse via oropharyngeal instillation. 
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9.2. APPENDIX B – PLASMID MAPS 
Plasmid maps are displayed in alphabetical order and were obtained directly from 
the supplier’s websites or produced in Vector NTI (v.11.5) 
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Nucleotides that differ from the NCBI reference sequence NM_001369.2 are 
highlighted and their effect on translation, if any, is also shown. 
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